Differential DNA methylation profiles modulating phenotypes : Regions of tissue-specific DNA methylation and their relation to gene expression, their evolutionary conservation and their application as molecular biomarkers by Cortese, Rene Gabriel
 Differential DNA methylation profiles modulating phenotypes. 
Regions of tissue-specific DNA methylation and their relation to gene 
expression, their evolutionary conservation and their application as 
molecular biomarkers  
 
 
Dissertation 
zur 
Erlangung des Doktorgrades (Dr. rer. nat) 
der 
Mathematisch-Naturwissenchaftlichen Fakultät 
der 
Rheinischen Friedrich-Wilheims-Universität Bonn 
 
 
vorgelegt von 
 
Rene Gabriel Cortese 
aus 
Mercedes (BA) Argentinien 
 
Bonn 2007 
 

  
Angefertigt mit Genehmigung der Mathematisch-Naturwissenschaftlichen Fakultät 
der Rheinischen Friedrich-Wilhelms-Universität Bonn 
 
 
 
 
 
 
 
Wissenchaftliche Betreeung 
Dr.  Florian Eckhardt   Brahms AG 
      Neuendorfs. 25 
      D-16761 Hennigsdorf 
 
1. Referent: 
Prof. Dr. Klaus Olek   Labor für Abstammungsbegutachtungen 
      Marie-Curie-Straße 1 
      D-53359 Rheinbach 
 
2. Referent: 
Prof. Dr. Karl-Heinz Scheidtmann Institut für Genetik 
      Universität Bonn 
      Abt. Molekulargenetik 
      Römerstr. 164 
      D-53117 Bonn 
 
Tag der mündlichen Prüfung: 17.03.2008 
 
Diese Dissertation ist auf dem Hochschulsschriftenserver der ULB Bonn 
http://hss.ulb.uni-bonn.de/diss_online elektronish publiziert. 
Erscheinungsjahr: 2008 
  
 
 i
Acknowledgments 
 
 
This work was performed under the direction of Prof. Dr. Klaus Olek (University of 
Bonn) and the supervision of Dr. Florian Eckhardt at Epigenomics AG, Berlin.  
The practical work was carried out at Epigenomics AG, which also founded the vast 
majority of the experimental work. 
Some sections of this thesis were partially founded by the European Union: 
Conservation of DNA methylation patterns in human/mouse orthologues (HEROIC 
program) and Conservation of DNA methylation upon gene duplications (MolPAGE 
program). 
 
After so many years and so much interaction with so many people, it is quite difficult 
to thank all without being unfair and forgetting someone. However, I would like to 
acknowledge very special people, who contributed to make this possible. 
In first place, I would like to thank Prof. Dr. Klaus Olek for accepting and directing 
the work and his constant support.  Furthermore, I am very grateful to my 
supervisor at Epigenomics, Dr. Florian Eckhardt, for supporting, guiding and 
encouraging me in all my projects.  
Moreover, I would like to thank the whole staff of Epigenomics AG (actual and 
former directors, managers and colleagues) for sharing this time with me, for their 
support and valuable discussions. Very especially, I would like to thank Dr. 
Alexander Olek for giving me the chance to work in the Company and for 
introducing me in the fascinating world of Epigenetics. In addition, I would like to 
thank Dr. Ralf Lesche for guiding my first steps. 
I would like to express as well my gratitude to Dr. Thomas Brune (University of 
Magdeburg) and to the Human Epigenome Project team, especially to Dr. Stephan 
Beck (Cambridge University, UK), for the very exciting collaborations in the 
Laminopathies and HEP projects, respectively. 
 
Becoming more emotional, I would like to thank very especially my family (Mamá, 
Papá, Karina, Rodrigo, Ramiro, Gabriel, Cecilia, Malena and Tobias) and friends in 
  ii
Argentina (I should mention everyone, but it is hard due to the number and quality 
of friends I have been blessed, I hope you understand) for being so close, no matter 
the distances. Without them and their unconditional support, nothing of this dream 
had been possible.  
Finally, I would like to thank my very good friends in Germany, Hong, Marco and 
Manuel, and my pretty nice “Family in Europe” (Carolina, Joaquin and Vicky) for 
their tireless support and being always at my side all along the road. 
 
I dedicate this work to my family and friends with all my heart.  
Thanks a lot, vielen Dank, muchas gracias, to all of them... 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  iii
Contents 
 
 
Abstract................................................................................................................ 1 
 
 
1. Introduction ................................................................................................. 3 
 
1.1. Generalities about epigenetic and DNA methylation .................................... 3 
1.1.1. The concept of epigenetics ............................................................................. 3 
1.1.2. DNA methylation. Principles and definitions ............................................ 3 
1.1.3. DNA methyltransferases................................................................................ 4 
1.2. Epigenetic models of gene expression regulation ........................................... 6 
1.3. Methods to detect and measure DNA methylation......................................... 9 
1.4. The Human Epigenome Project......................................................................... 13 
1.5. DNA methylation role in biological processes in healthy tissues ............. 14 
1.5.1. Gene silencing................................................................................................ 14 
1.5.2. De novo DNA methylation of integrated foreign DNAs.......................... 15 
1.5.3. Gene duplications and tissue- specific DNA methylation profiles........ 16 
1.5.4. Development.................................................................................................. 18 
1.5.5. Coexpression in “head-to-head” genes...................................................... 20 
1.5.6. Imprinting ...................................................................................................... 20 
1.6. Impact of DNA methylation in cancer ............................................................. 22 
1.6.1. General considerations ................................................................................. 22 
1.6.2. Hyper- and hypomethylation in cancer..................................................... 23 
1.6.3. Loss of imprinting in cancer ........................................................................ 24 
1.6.4. Potential applications for DNA methylation in clinical practice ........... 25 
1.6.5. DNA methylation in Lung Cancer.............................................................. 25 
1.7. Impact of DNA methylation in non-oncogenic diseases.............................. 28 
1.7.1. DNA methylation in complex non- oncogenic diseases.......................... 28 
1.7.2. Interaction of genetic and epigenetic alterations in monogenic diseases
 28 
1.7.3. Interaction of genetic and epigenetic alterations in non-oncogenic 
complex diseases ........................................................................................................... 29 
  iv 
1.8. Structure of the thesis.......................................................................................... 31 
1.8.1. Topics .............................................................................................................. 31 
1.8.2. Hypothesis...................................................................................................... 31 
1.8.3. Objectives........................................................................................................ 32 
1.8.4. Relevance of the presented results.............................................................. 32 
 
 
2. Results......................................................................................................... 35 
 
2.1. Tissue specific DNA methylation and expression profiles ......................... 35 
2.1.1. Candidate gene approach ............................................................................ 35 
2.1.2. Case of study: Are SLC22A1 and PLG genes imprinted in healthy adult 
tissues? 39 
2.2. Determination of differential transcriptional and DNA methylation 
profiles in fetal and healthy adult lung....................................................................... 44 
2.2.1. Experimental design ..................................................................................... 44 
2.2.2. Determination of expression profiles in Fetal and Healthy Adult Lung
 47 
2.2.3. Validation of expression profiles by qRT-PCR ......................................... 52 
2.2.4. Pathway analysis ........................................................................................... 54 
2.2.5. Correlation between DNA methylation and gene silencing in fetal and 
adult lung ....................................................................................................................... 56 
2.2.6. DNA methylation and expression profiling of bi-directional promoters
 57 
2.2.7. Differentially expressed genes in lung development as methylation 
marker in lung cancer ................................................................................................... 62 
2.3. Conservation of tissue-specific DNA methylation profiles throughout the 
evolution ............................................................................................................................ 67 
2.3.1. Conservation of tissue-specific DNA methylation patterns  in human / 
mouse orthologues ........................................................................................................ 67 
2.3.2. Case of study: Methylation and expression in the IGF2R locus in human 
and murine orthologous loci ....................................................................................... 71 
2.3.3. Conservation of DNA methylation upon gene duplications.................. 75 
  v
2.4. Interaction of Genetic and Epigenetic variations in disease ....................... 96 
2.4.1. Case of study: DNA Methylation profiles in Progeria and FPLD 
patients 96 
 
 
3. Discussion................................................................................................ 103 
 
3.1. General considerations...................................................................................... 103 
3.2. Relations between DNA methylation and gene expression – Theory and 
experimental approaches .............................................................................................. 103 
3.3. RNA expression related to tissue- specific differentially methylated 
regions .............................................................................................................................. 105 
3.4. DNA methylation and transcriptional profiles in lung development..... 106 
3.5. DNA methylation and regulation of bi-directional promoters................. 108 
3.6. DNA methylation profiles in lung development and lung tumorigenesis
 109 
3.7. Conservation of DNA methylation between human and mouse ............. 110 
3.8. Methylation of the IGF2R cluster but not imprinting status is conserved 
in mouse and human orthologues............................................................................... 111 
3.9. Conservation of DNA methylation upon genome duplications............... 112 
3.10. DNA methylation in non-cancer diseases. Modulating the phenotypic 
features upon similar genetic backgrounds.............................................................. 114 
3.11. DNA methylation markers found in blood. A feature enabling low-
invasive diagnostic procedures and screening ......................................................... 116 
3.12. Concluding remarks ...................................................................................... 117 
 
 
4. Materials and methods .......................................................................... 119 
 
4.1. Samples and Patients......................................................................................... 119 
4.1.1. Tissue samples and primary cells from healthy human individuals .. 119 
4.1.2. Tissue samples from mouse....................................................................... 120 
4.1.3. Patients and controls for the study of DNA methylation profiles in 
Progeria and FPLD syndromes ................................................................................. 120 
  vi 
4.1.4. Fetal and Healthy Adult Lung tissue samples........................................ 123 
4.1.5. Patients and controls for the study of DNA methylation profiles in 
Lung Cancer ................................................................................................................. 124 
4.2. DNA isolation ..................................................................................................... 124 
4.3. RNA isolation...................................................................................................... 124 
4.4. PCR amplification .............................................................................................. 125 
4.4.1. Amplification of bisulfite-treated DNA ................................................... 125 
4.4.2. Amplification of genomic DNA ................................................................ 125 
4.5. Reverse transcription PCR................................................................................ 125 
4.5.1. Semiquantitative reverse transcription PCR ........................................... 125 
4.5.2. Quantitative reverse transcription PCR................................................... 126 
4.6. Bisulfite sequencing .......................................................................................... 126 
4.6.1. Direct sequencing strategy......................................................................... 126 
4.6.2. Sequencing of subcloned fragments......................................................... 127 
4.7. Expression profiling using Affymetrix GeneChipTM microarrays ........... 127 
4.8. Analysis and statistical methods..................................................................... 129 
4.8.1. DNA methylation studies .......................................................................... 129 
4.8.2. DNA distance matrices and radial trees .................................................. 130 
4.8.3. Microarray expression profiling................................................................ 131 
4.8.4. q-RT-PCR expression analysis................................................................... 131 
4.8.5. Pathway analysis ......................................................................................... 132 
 
 
5. References ................................................................................................ 133 
 
 
 
 
 
 
 
 
  1
Abstract 
 
Tissue- specific DNA methylation plays a major regulatory role. The association of 
increased tissue-specific DNA methylation and gene silencing is widely accepted 
despite the lack of experimental evidence. I have approached this topic in two 
complementary directions. First, using direct sequencing of bisulfite-converted DNA 
and semiquantitative RT-PCR, I show that increased methylation correlates with 
decreased expression of the cognate transcript in healthy adult tissues and primary 
cells in 16 out of 43 (39%) tissue-specific differentially methylated regions (T-DMRs) 
located at the 5’-UTR of annotated genes. In the second approach, I have first 
determined the genome-wide expression profiles of fetal and healthy adult human 
lung and then studied the methylation status of 43 differentially expressed genes. 
Among them, highly methylated 5’-UTR regions correlate with decreased expression 
levels in 19% of the cases. Furthermore, this approach allowed the discovery of four 
differentially expressed genes in fetal lung (MEOX2, MDK, LAPTM5 and FGFR3), 
whose differential methylation arise as potential biomarker for lung cancer.  
Next, I have studied the conservation of T-DMRs throughout the evolution. First, 
using direct sequencing of bisulfite-converted DNA, I show that the majority (69.4%) 
out of 61 orthologous regions in human and mouse differ by less than 20% in their 
methylation, indicating significant conservation. Additionally, by comparative DNA 
methylation analysis of three different gene duplication events leading to functional 
gene families, unprocessed and processed pseudogenes, I show that for genes that 
evolved recently and for some unprocessed pseudogenes, tissue-specific DNA 
methylation and RNA expression are conserved upon duplication.  
Finally, I have studied the interaction of genetic and epigenetic alterations in 
modulating phenotypes in non-oncogenic diseases. The RARB gene appears highly 
methylated in patients with familial partial lipodystrophy (FPLD) compared to 
progeria patients and healthy controls. This differential methylation might explain 
the different phenotypes observed despite similar genetic backgrounds. 
Altogether, this work presents vast experimental evidence supporting the hypothesis 
of differential DNA methylation patterns influencing, and in may cases determining, 
phenotypes in healthy and diseased tissues. 
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1. Introduction 
 
1.1. Generalities about epigenetic and DNA methylation 
 
1.1.1. The concept of epigenetics 
 
Epigenetics refers to the study of heritable changes in genome function that occur 
without a change in DNA sequence. From a functional point of view, research on this 
field approaches issues such how patterns of gene expression are passed from one 
cell to its descendants, how gene expression changes during cell differentiation, and 
how environmental factors can change the way genes are expressed. 
Epigenetics studies focus on three related molecular mechanisms: DNA methylation, 
histone code changes and RNA interference. Among them, DNA methylation 
represents the most stable epigenetic modification. DNA methylation marks are 
copied after DNA synthesis resulting in heritable changes in chromatin structure [1]. 
 
1.1.2. DNA methylation. Principles and definitions 
 
DNA methylation is the biochemical addition of a methyl group (CH3) to a 
nucleotide molecule. In mammalian DNA, this addition occurs predominantly to 
cytosines, especially in the context of a cytosine-guanosine (CpG) dinucleotides. In 
healthy cells, the modified methyl cytosine (mC) is present at a 2%-5% level of all 
cytosines [2]. CpG sites are present very significantly less than expected (5-10 fold) 
from the overall base composition of the DNA and unevenly distributed throughout 
the genome. While the vast majority of the genome is CpG poor, about 1% consists of 
CpG rich areas, typically related to the transcription start sites (TSS) of the genes. 
These CpG regions are referred as “CpG islands” and are mainly unmethylated 
when located nearby the TSS of expressed genes, in clear contrast to the mainly, but 
not exclusively, hypermethylated rest of the genome [3].  
As the annotation of the human genome was completed, a clear definition of the 
criteria for naming a CpG dense region as “CpG island” became indispensable. The 
generally accepted definition of what constitutes a CpG island was proposed in 1987 
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by Gardiner-Garden and Frommer as being a 200-bp stretch of DNA with a C+G 
content of 50% and an observed/expected CpG ratio of 0.6 [4]. However, different 
authors and annotation databases may add their own small variations to this 
definition. For example, current version of the Ensembl database (release 42, as 
February 2007) CpG island definition requires a minimum length of 1000 bp, a 
minimal observed/expected ratio of 0.6 and a minimal GC content of 50%. In the 
present work, I took this definition and only CpG islands annotated in Ensembl 
database are named as such. All other CpG dense regions not fulfilling these 
requirements are called “CpG rich regions” accordingly. 
 
1.1.3. DNA methyltransferases  
 
Various methyltransferase enzymes (DNMT) catalyze cytosine methylation. In 
eukaryotes, there are three DNMT families (1, 2 and 3). DNMT1 and DNMT3 
proteins comprise two domains: the N-terminal “regulatory” domain and C-terminal 
“catalytic” domain; in contrast DNMT2 has only the “catalytic” domain. Four 
DNMTs have been identified so far: DNMT1, DNMT2, DNMT3A and DNMT3B. In 
addition, DNMT3L has been found as a stimulator of the DNMT3A and DNMT3B 
enzymes, reviewed in [5].  
DNMT1 enzyme showed a 5-10 fold preference for hemimethylated DNA [6]. This 
property suggests that DNMT1 reproduces parental DNA methylation pattern into 
the daughter DNA strand, therefore this enzyme is referred as responsible for 
“maintenance methylation”. Functional experiments in mammalian cells also 
assigned a role for DNMT1 in the overall genome methylation, X- chromosome 
inactivation, allelic silencing of imprinted genes and silencing of incorporated 
transposons, reviewed in [7]. Function and roles for DNMT2 are not completely 
elucidated. Okano and colleagues showed that Dnmt2 is not essential for global de 
novo or maintenance methylation of DNA in embryonic stem (ES) cells [8]. In 
addition, purified mouse Dnmt2 protein has weak DNA methyltransferase activity 
and probably related to a loose ttnCGga(g/a) consensus sequence, suggesting that 
DNMT2 has a more specialized role than other mammalian DNA methyltransferases 
[9]. DNMT3a and DNMT3b are generally regarded as de novo DNA 
1. Introduction 
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methyltransferases. During early development (when most of the de novo 
methylation occurs), both enzymes are highly expressed and essential for the 
establishment of new methylation patterns and subsequent proper development [10]. 
All methyltransferases share the catalytic mechanism. The AdoMet cofactor (S-
adenosylmethionine) contributes the methyl groups to the reaction [11]. The reaction 
starts when cytosine is flipped out of DNA and inserted into the binding pocket of a 
methyltransferase enzyme (Figure 1.1.1). In the active site, the catalytic cysteine 
thiolate forms a transition state intermediate with the carbon-6 of the cytosine’s ring. 
This creates a reactive 4–5 enamine, which attacks the methyl group provided by the 
cofactor. After the methyl group transfer to the C-5 position of the cytosine ring, 
proton abstraction from this position causes reformation of the 5,6 double bond and 
the release of the enzyme by β-elimination [12], [13]. 
 
 
Figure 1.1.1: Reaction catalyzed by DNA methyltransferases. The reaction starts with a thiolate 
attack at position C6 and subsequent formation of a covalent intermediate. This intermediate will 
gain the CH3 group at the C5 position from the donor, AdoMet, by an enamine attack. Finally 
enzyme is released by ß-elimination. Reproduced from Siedlecki and Zielenkiewicz [7] 
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1.2. Epigenetic models of gene expression regulation 
 
Several models describe the way DNA methylation directs gene silencing. The 
simplest model states that methylation at particular CpGs within the promoter 
region of a gene avoids the binding of transcription factor and further assembly of 
the transcription machinery [14] (Figure 1.2.1).  
 
 
Figure 1.2.1: DNA methylation blocks transcription by avoiding the binding of transcription 
factors. Schematic representation showing the simplest model of transcriptional regulation by DNA 
methylation. Cytosines are depicted as orange circles, while all other nucleotides are blue. 
Transcription factors can bind to unmethylated DNA at the promoter region promoting the 
expression of the cognate gene (Upper graphic).  Methyl groups (represented as lollipops at the 
corresponding cytosine position) avoid the binding of transcription factors and the gene expression is 
blocked (Lower graphic). 
 
Although this model may explain gene silencing in several genes where target 
sequences contain single CpG position that become methylated [15], [16], [17], [18], 
more complex molecular interactions drive this process. In the vast majority, proteins 
containing domains that bind methylated CpGs appear to recognize methyl cytosines 
enabling interactions with protein complexes that drive transcription and chromatin 
packing. Currently, five methyl-CpG binding proteins are recognized in mammals, 
reviewed in [19]. Four of these proteins, MeCP2, MBD1, MBD2 and MBD4 bind 
methylated CpGs through a conserved protein motif called the methyl-CpG binding 
domain (MBD). Unlike, Kaiso binds methylated DNA through a zinc finger motif. 
Four of the methyl-CpG binding proteins, MBD1, MBD2, MeCP2 and Kaiso, 
displayed transcription repression activity in vitro by interacting with histone 
1. Introduction 
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deacetylase complexes [20], [21]. In contrast, MBD4 is implicated in DNA repair [22], 
[23]. 
Knockout mice for Mecp2 and Mbd2 did not show increased expression of 
endogenous genes or parasitic DNAs [24], [25]. However, the redundant functions 
among the methyl-CpG binding family may compensate the deficiency of one its 
members.  
Methyl-CpG binding proteins interact with histone deacetylases enzymes (HDACs) 
[26], [27], [28], [29]. Histones become acetylated in several residues leading to an 
open chromatin conformation [30]. HDACs remove the acetyl groups from these 
residues resulting on close chromatin packing, which makes DNA inaccessible to 
transcription factors and other elements enabling transcription. Futscher and 
colleagues [31] proposed a model of interaction between methylated DNA, methyl-
CpGs binding proteins, HDACs and other protein factors to explain the relation 
between DNA methylation status of the promoter of the SERPINB5 gene and its 
complete silencing in skin fibroblasts and expression in epithelial skin cells. In this 
model (Figure 1.2.2); epithelial cells in skin have an unmethylated promoter that is 
occupied by the transcriptional regulators Ap1 and p53. Surrounding histones are 
acetylated limiting histone-histone interactions and providing an open chromatin 
structure that enables transcription.  In contrast, the promoter in skin fibroblasts is 
fully methylated. Methylated DNA is associated to methyl-CpG binding proteins, 
which attract HDACs and chromatin remodeling complexes. Deacetylated histones 
result in local close chromatin packing and subsequent gene silencing.  
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Figure 1.2.2: Model of cell-type specific control of SERPINB5 expression by DNA methylation. The 
epithelial cells in skin have an unmethylated SERPINB5 that is occupied by transcriptional regulators. 
The histones (blue) are acetylated (Ac) and chromatin conformation is open, allowing SERPINB5 
expression.  In contrast, promoter in fibroblasts is methylated. MeCP2 binds to methylated DNA and 
attracts HDAC, leading to a local change in chromatin conformation and further gene silencing. 
Reproduced from Costello and Vertino [32] 
 
In agreement with this model, Harikrishnan and colleagues [33] demonstrated that 
MeCP2 interaction with methylated DNA results in the recruitment of the SWI/SNF 
complex. This complex would be responsible for chromatin remodeling in an ATP-
dependent manner.  
Methylation of lysine residues in histones represents another epigenetic mechanism 
for gene silencing. Similar to hypoacetylation, methylation at lysine position leads to 
transcriptional repression. Vire and colleagues demonstrated that a histone 
methyltransferase, EZH2, interacts -within the context of the Polycomb repressive 
complexes 2 and 3- with DNA methyltransferases and associates to further gene 
silencing [34]. 
Csankovszki and colleagues [35] added a new layer to the model, the role of an 
antisense transcript interacting with DNA methylation and histone modifications. 
They demonstrated in vitro a synergic effect of Xist RNA, DNA methylation and 
histone hypoacetylation in maintaining X chromosome inactivation. 
1. Introduction 
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In addition, methylation in silencer or insulator elements might block the binding of 
the cognate binding proteins, potentially abolishing their repressive activities in gene 
expression [36], [37], [38]. Figure 1.2.3 displays a model to explain how DNA 
methylation of these elements might influence the binding of proteins to DNAs, thus 
altering the expression of a gene. 
 
 
Figure 1.2.3: DNA methylation regulates expression by influencing factor binding to regulatory 
regions. (Top) The enhancer is functional because the silencer and insulator are methylated (filled 
lollipops) and, thus, not occupied by their respective cognate factors.  Methylation here is permissive 
for expression. Transcripts are not initiated at the potentially active LINE element because it is 
methylated. (Bottom) Lack of methylation (open lollipops) in a silencer and insulator can lead to the 
binding of the cognate protein (i.e. GCF2 and CTCF at the silencer and insulator, respectively), thus 
preventing the enhancer from functioning.  Reproduced from Jones and Takai [39] 
 
Models cited here represent only a part of a growing body of evidence towards the 
fully understanding of the epigenetic regulations. Taken together, these models 
suggest that probably there is no such universal mechanism for epigenetic gene 
silencing. In contrast, a group of several molecular interactions taking part 
coordinately at particular tissular, developmental or physiological stages appears as 
the most probably scenario.  
 
1.3. Methods to detect and measure DNA methylation  
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Epigenetic models drawn in the seventies were mainly theoretical. Continuous 
technological advances have allowed the development of methods and procedures to 
precisely determine the methylation status of a particular CpG position, a particular 
locus or even the genome-wide analysis of methylation content and variations (Table 
1.3.1) 
 
Table 1.3.1: Techniques for the detection of DNA methylation 
Application Technique Methylation detection Platform 
Key 
reference 
HPLC Enzymatic 
hydrolysis 
High performance 
separation 
[40] 
HPCE Enzymatic 
hydrolysis 
High performance 
separation 
[41] 
SsI acceptance assay Enzymatic 
methylation 
Blotting. 
Radioactive 
detection 
[42] 
Analysis of genome-
wide methylation 
content 
Immunochemical 
analysis 
Anti- methyl-
cytosine antibody 
Microscopy [43] 
MSRE-Southern Enzymatic 
digestion 
Blotting. 
Radioactive 
detection 
[44] 
MSRE-PCR Enzymatic 
digestion 
Electrophoresis [45] 
MSP Bisulfite treatment Electrophoresis [46] 
COBRA Bisulfite treatment 
and enzymatic 
digestion 
Electrophoresis [47] 
Direct /cloned 
bisulfite sequencing 
Bisulfite treatment Sequencing [48] 
MS-SNuPE Bisulfite treatment Electrophoresis [49] 
MethyLight Bisulfite treatment Real time PCR [50] 
MS-MCA Bisulfite treatment Real time PCR [51] 
MS-DGGE Bisulfite treatment Electrophoresis [52] 
MS-SSCA Bisulfite treatment Electrophoresis [53] 
Analysis of 
methylation status 
at a particular locus 
Methylation specific 
microarray 
Bisulfite treatment Microarray [54] 
Differential 
Methylation 
Hybridization 
Enzymatic 
digestion 
Microarray [55] 
RGLS Enzyme digestion 2D-electrophoresis [56] 
MCA-RDA Enzyme digestion Subtractive 
hybridization. 
Electrophoresis 
[57] 
MS-APPCR Enzyme digestion Electrophoresis [58] 
MBD-SPM Methyl binding 
protein 
Chromatography. 
Electrophoresis 
[59] 
ICEAMP Methyl binding 
protein 
Subtractive 
hybridization. 
Sequencing 
[60] 
Discovery of novel 
DNA methylation 
sites 
Chip on chip Methyl binding 
protein 
Microarray [61] 
1. Introduction 
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Besides differences in detection platforms and further applications, described 
methods in the literature share common features. Methods can be grouped according 
to their scope and applications. Hence, some methods are focused on a global scale to 
determine the overall content of cytosine methylation (i.e. HPLC, HPCE), while 
others are focused on detecting the methylation status of a particular locus (i.e. 
bisulfite sequencing, MSP). Interestingly, other methods have been developed to 
discover differences in methylation profiles at genome-wide scale (i.e. RGLS, MS-
APPCR, DMH). 
A second grouping category is the principle applied to detect methylation 
differences.  Methods to quantify the overall content of methylated cytosines require 
the initial complete hydrolysis of the genome either by chemical or enzymatic 
treatments (i.e. HPLC, HPCE). Methylated cytosines display different peaks to 
unmethylated ones, enabling therefore the calculation of overall ratio of 
methylated/unmethylated cytosines. Global methylation analyses do not allow 
determining the methylation status at a particular locus. In contrast, methods based 
on methylation–sensitive restriction enzymes (i.e. MSRE-PCR, DMH) and methyl-
cytosine binding proteins (i.e. MBD-SPM, ICEAMP, ChIP-Chip) take advantage of 
biological properties allowing the qualitative and quantitative methylation studies at 
particular locus. Isoschizomers of bacterial restriction endonucleases display 
different sensitivities to methylated cytosines. Despite sharing the same recognition 
site with the insensitive isoschizomer, sensitive restriction enzymes will cut only 
when cytosines are unmethylated. A popular isoschizomer pair for methylation 
analysis is HpaII/MspI. Both enzymes cleave CCGG sites, but HpaII is unable to 
cleave if the internal cytosine is methylated. On the other hand, proteins containing 
methyl-DNA binding domains bind specifically methylated CpG positions, as 
explained in section 1.2. Some methylation detection methods make use of this 
property and generally combines MBDs to chromatin immunoprecipitation (ChIP) or 
binding columns to obtain a fraction of the genome enriched in methylated- cytosines 
followed for the detection by quantitative PCR or microarray analysis. Methods 
based on methylation specific restriction enzymes and methyl-cytosine binding 
proteins suffer the limitation that they provide information only about CpGs within 
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the cleavage or binding site. Treatment of genomic DNA with sodium bisulfite 
overcomes this limitation and allows the analysis of virtually any CpG position 
within the genome. This method depends on the reaction of bisulfite with cytosines 
in single-stranded DNA, which are converted to uracil, whereas methyl-cytosines are 
unreactive [62] (Figure 1.3.1). Based on this chemical property, Frommer and 
colleagues developed a sequencing method that allows the detection of methylation 
positions at single-base resolution level [48]. The modified DNA strands are then 
amplified by PCR and further sequenced, directly or after subcloning of the 
amplified fragment. Direct sequencing gives information about the average 
methylation of a CpG position in a sample, while sequencing of cloned DNA allows 
the analysis of CpG sites on individual half-strand DNA molecules.  Other methods 
relies on the single nucleotide polymorphisms (SNPs) introduced by the bisulfite 
treatment to design PCR primers specific for methylated and unmethylated states 
(i.e. MSP) or methylation specific probes for real time PCR detection (i. e. 
MethyLight). The major limitation of bisulfite treatment based method arises from 
the possibility of incomplete conversion of unmethylated cytosines to uracil. 
Consequently, conversion rates must be calculated and results corrected accordingly. 
 
 
Figure 1.3.1: Conversion of unmethylated cytosine to uracil by bisulfite treatment. Unmethylated 
cytosines add a HSO3- to form cytosine sulfonate in alkaline medium, which after hydrolytic 
deamination is converted to uracil sulfonate. Final desulfonation in alkaline medium yields uracil. 
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Different platforms to detect differential methylation allow several applications at 
different levels of resolution. High performance separation methods are used for 
global methylation analysis (i.e. HPLC, HPCE). Originally, methods relying on 
restriction enzymes were resolved by Southern blotting. The combination of 
enzymatic restriction or bisulfite treatment and PCR allows the detection of 
differences by gel electrophoresis (i.e. MSRE-PCR, MSP, COBRA, etc). High 
quantitative methods, such real-time PCR (i.e. MethyLight) or microarrays (i.e. MSO, 
DMH), are currently the method of choice in the discovery, development and 
validation of methylation markers. In addition, microarray platforms allow the 
analysis of many genes in parallel (MSO) or even the genome-wide discovery of 
previously unknown methylation sites (DMH). Optimization and automation of 
sequencing platforms have allowed the sequencing of the whole genomes at single-
based nucleotide resolution [63]. In the same manner, such advances have allowed 
the realization of the Human Epigenome Project, a joint effort to unravel the tissue-
specific DNA methylation status in human beings, as detailed in the next section. 
 
1.4. The Human Epigenome Project 
 
The publishing of the complete sequence of the human genome [63] constituted a 
yardstick in biological research. The published data provided the background 
knowledge not only for further genomic research but also for the study of different 
layers of control of the encoded information.  
Epigenetics constitute one of the most important layers of control in the expression of 
the genes and it is unique in explaining how environmental stimuli might affect 
phenotypes. In this regard, the need for a human epigenome project has been long 
recognized [64], [65]. Recently, a workshop sponsored by the American Association 
of Cancer Research (AACR) attempted to coordinate the efforts towards an 
international collaboration. In this work, researchers stated the guiding principle for 
such collaboration: “The goal of the Human Epigenome Project is to identify all the 
chemical changes and relationships among chromatin constituent that provide 
function to the DNA code, which will allow a fuller understanding of normal 
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development, aging, abnormal gene control in cancer, and other diseases as well as 
the role of the environment in human health” [64]. 
As part of an European Consortium (www.epigenome.org), our group took part in 
the deciphering of DNA methylation profiles in normal tissues and primary cells. In 
a pilot phase, authors demonstrated the feasibility of the project by determining the 
methylation patterns in the Major Histocompatibility Complex (MHC) on human 
chromosome 6 [66]. Completing the first phase of the full-scale HEP, we have 
published the methylation profiles of human chromosomes 6, 20 and 22 [67].  
Similarly to the Human Genome Project data, HEP data require exhaustive 
interpretation to understand the phenotypic consequences of the established DNA 
methylation profiles. In some parts of this work, I have taken the produced data in 
HEP as baseline knowledge for further practical work in the laboratory. Accordingly, 
based on discovered individual T-DMRs, I have studied the expression of their 
associated genes by semiquantitative RT-PCR (section 2.1.1) and the methylation 
status of orthologous genes in mouse (section 2.3.1). The results of my experiments 
presented in these sections are included in the publication of the results of the first 
phase of HEP [67]. Furthermore I selected discovered T-DMRs corresponding to 
pseudogenes and determined the methylation status of their parental genes by direct 
sequencing of bisulfite-converted DNA (section 2.3.3.2). 
 
1.5. DNA methylation role in biological processes in healthy tissues 
 
1.5.1. Gene silencing 
 
Hypermethylation of CpG dense 5’ untranslated regions (5’-UTR) frequently 
correlates with the silencing of the cognate transcript. Some models relate this effect 
to a blocking of binding site for transcription factors, while other attributes the 
silencing effect to an tight chromatin condensation in which methylated DNA 
interacts with modified histones, reviewed in part 1.2. Besides the responsible 
mechanism, hypermethylation of particular 5’-UTR has a phenotypic effect and are 
frequently referred as “epimutations”. 
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Experimental approaches to investigate the functional consequences of DNA 
methylation are usually based on the utilization of analogous of deoxycytidine, 
which allow the pharmacological inhibition of DNMTs. Advantages and drawbacks 
for this experimental approach are discussed in section 3.2 in the Discussion chapter.  
The correlation between hypermethylation of the 5’- UTR is not so clear when tissue- 
specific DNA methylation profiles are taken in account. In section 2.1 of this work, I 
show in a group of 55 T-DMRs that methylation of 5’-UTR correlates with a 
decreased expression of the associated transcript in 37% of the cases.  
 
1.5.2. De novo DNA methylation of integrated foreign DNAs   
 
DNA methylation is associated to the silencing of mobile elements inserted into the 
genome. Transgenes very often become inactive upon insertion, despite they were 
artificially introduced to the cells (i.e. by genetic engineering procedures) [68] or in 
naturally occurring viral infections [69] and genome recombination [70]. Promoter 
methylation has been noted as one of the mechanisms responsible for the inactivation 
of mobile elements [71]. Accordingly, silenced transgenes can be subsequently 
reactivated by 5- azacytidine treatment [72]. 
Upon insertion, some viral genomes become de novo methylated in specific patterns 
related to their transcriptional activity in the transformed cells [73]. The site of 
initiation of this de novo methylation appears to be variable. Starting from this point, 
DNA methylation spreads subsequently in both directions [74]. 
In section 2.3.3, I have studied the dynamics of DNA methylation in three gene 
duplication events: functional gene families, unprocessed pseudogenes and 
processed pseudogenes. Differently to functional gene families and unprocessed 
pseudogenes, processed pseudogenes are thought to be evolutionary relics of 
transposon insertion [75]. By comparative analysis of 17 pseudogene-parental gene 
pairs, I determined that 76% displayed tissue- specific methylation in at least one of 
the tissues analyzed and 24% hypermethylation in all analyzed tissues. In contrast to 
the unprocessed pseudogenes, I did not find a conservation of tissue-specific 
methylation between any of the analyzed processed pseudogene - parental gene 
pairs. 
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1.5.3. Gene duplications and tissue- specific DNA methylation profiles 
 
Several recent reports have recognized the widespread occurrence of T-DMRs in 
healthy tissues [67] [76] [77] [78]. Extrapolating from these results, about 5 to 25% of 
all human genes might be tissue specifically methylated. T-DMRs frequently map to 
the 5’ regions of annotated genes, however many are located in exon, introns or 
intergenic regions. In addition, differential methylation is not limited to coding 
genes, but has been observed in pseudogenes as well [67] [79]. Currently, little is 
known how T-DMRs evolve and are maintained and the signals that regulate them. 
One possibility is that differentially methylated loci might bear an intrinsic genetic or 
epigenetic signature that triggers differential methylation. Another possibility, not 
mutually exclusive, is that differential methylation is the result of other cis- or trans-
acting factors or sequences that regulate the methylation profile of a particular locus. 
In this regard, gene duplication events represent a well-suited model to address the 
dynamics of (differential) methylation. 
Gene duplications are a source of genomic novelties leading to gene families and 
unprocessed pseudogenes. Using comparative analysis, Lynch and Conery [80] 
estimated that gene duplications arise at a high frequency of about 0.01 per gene per 
million years. The classical model by Ohno [81] predicts that upon gene duplication, 
one copy retains the original function under strong surveillance by negative selection 
while the other copy becomes free of selective constraints and evolves mainly in a 
neutral fashion.  
Two possible fates are therefore possible for the new duplicates. If the mutation is 
advantageous, it is fixed and the duplicate will develop a new function. In that way, 
functional divergence may lead to genes either with a reduced functional capacity 
(subfunctionalization) or a new function (neofunctionalization). Groups of 
functionally related genes are frequently recognized as gene families. On the other 
hand, if the mutation is disadvantageous, the duplicate will degenerate to an 
unprocessed pseudogene.  
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As most of the mutations are expected to be deleterious, pseudogenization 
constitutes the most likely fate of a new gene duplication event. However, little is 
known on the mechanisms that prevent degradation into a non-functional gene. 
I have selected two gene families that differ greatly in their evolutionary age, the 
ancient TBX family that exists in vertebrate and invertebrates and the more recently 
evolved PLG family that is only present in the hominoid lineage. The unifying 
feature of the TBX transcription factor family is the presence of the T-domain that 
confers DNA binding and dimerization. In mammals, 17 distinct genes have been 
identified that can be grouped into 5 subfamilies (the T, TBX1, TBX2, TBX6 and Tbr1 
subfamilies) based on their evolutionary distance [82]. TBX transcription factors are 
crucial in regulating a plethora of processes such as craniofacial development, limb 
outgrowth and patterning, as well as T-cell differentiation [82]. The second gene 
family I investigated is the plasminogen precursor, PLG, family consisting of three 
known members (PLG, PLGLA and PLGLB). While the PLG gene itself is located on 
chromosome 6q25.3 within the IGF2R imprinting cluster, the two plasminogen-
related genes, PLGLA and PLGLB map to chromosome 2q12.2 and 2q11-p11, 
respectively [83] [84]. PLG encodes plasminogen that circulates in the plasma as a 
pro-enzyme [85] and in the presence of a fibrin clot, is converted to plasmin by the 
tissue plasminogen activator (tPA). Upon this activation, the proteolytic plasmin 
digests the insoluble fibrin clot, playing a key role in tissue repair and wound 
healing. However, the functions of PLGA and PLGB remain largely elusive. 
In section 2.3.3.1, I have analyzed the conservation of T-DMRs in the PLG and TBX 
families in healthy human tissues. I found that methylation and sequence are more 
conserved in the more recently PLG family. 
Moreover, I have studied the conservation of T-DMRs in pseudogenes (section 
2.3.3.2). As mentioned above, pseudogenes are divided in two groups according to 
their origin [75]. Unprocessed pseudogenes derive from a gene duplication 
mechanism and generally maintain the exon/intron structure of their parental genes. 
In turn, processed pseudogenes arose due to the reverse transcription of the parental 
gene mRNA and typically lack both regulatory sequences and an exon/intron 
structure. While some unprocessed pseudogene display T-DMR conservation 
similarly to that observed in gene families, none of the processed pseudogenes do.  
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1.5.4. Development 
 
It is generally accepted that the developmental program from fertilized egg to adult 
is under epigenetic control.  Knockout mice for DNA methyltransferases undergo 
genome-wide DNA methylation alterations that lead to embryo lethality or 
developmental defects [86], [10].  
In mammals, methylation patterns are reprogrammed in vivo in germ cells and early 
embryos, reviewed in [87]. Experiments in mouse showed that primordial germinal 
cells (PGCs) are highly methylated in early development but undergo genome-wide 
demethylation before embryonic day 13-14. Remethylation takes place later, earlier in 
the male germ line (from day 15 onwards) and after birth in the female germ line 
(Figure 1.5.1, panel A). In preimplantation embryos (Figure 1.5.2, panel B) the 
paternal genome is demethylated by an active mechanism after fertilization while 
maternal genome is demethylated by a DNA replication-dependent passive 
mechanism. At the time of implantation both genomes are remethylated to different 
extents in embryonic and extraembryonic lineages. While reprogramming of germ 
line cell erases parental imprints and acquired epigenetic modifications, postzygotic 
reprogramming are thought to erase those acquired during gametogenesis and to be 
linked to first-lineage decisions during mammalian development. 
Pioneer models stated that specific DNA methylation patterns are imposed in the 
genome at defined developmental time points in precursor cells and maintained by 
DNMT1. This maintenance would lead to predetermined patterns of gene expression 
during development in descendants of precursor cells and specific demethylation 
events could reactivate genes in differentiated tissues [88], [89]. These models, 
however, are essentially theoretical. Experimental evidence is contradictory and how 
DNA methylation is related to gene expression during normal development remains 
to be elucidated [90], [91], [92].  
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Figure 1.5.1: DNA methylation reprogramming in the germ line and preimplantation embryos. 
Primordial germ cells (PGCs, panel A) become demethylated in early development. Remethylation 
begins at E16 in male mouse cells and after birth in growing oocytes. In preimplantation embryos 
(panel B) the paternal genome (blue) is demethylated by an active mechanism immediately after 
fertilization. The maternal genome (red) is demethylated by a passive mechanism depending on 
DNA replication. Both genomes are remetylated around the time of implantation to different extents 
in embryonic (EM) and extraembryonic (EX) lineages. Methylated imprinted genes and some repeat 
sequences (dashed lines) do not become demethylated. Unmethylated imprinted genes (dashed line) 
do no become methylated. Reproduced from Reik et al [87] 
 
In section 2.2 of the present work, I determined genome-wide expression profiles in 
fetal and healthy adult lung samples. 99 genes appeared as highly expressed in fetal 
lung and 354 as highly expressed in healthy adult lung.  Out of them, I selected 43 
genes displaying CG-rich 5’UTRs and studied their DNA methylation status by 
direct sequencing of bisulfite-converted DNA. Highly methylated 5’-UTR regions 
correlated with decreased expression levels in 19% of the cases.  
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1.5.5. Coexpression in “head-to-head” genes 
 
Noteworthy, CpG islands are frequently located in regions known as “bi-directional 
promoters”.  Genes in these regions, also denominated “head-to-head” genes, are 
transcribed in opposite directions and their transcription start sites (TSSs) are closely 
located. Little is known about the methylation status of these regions and how it 
might influence in the regulation of the associated genes. Recently, Ikeda and 
colleagues reported hypermethylation of the bi-directional promoter region of 
COL4A5/COL4A6 and subsequent loss of expression in colorectal cancer [93]. 
Moreover, Shu and colleagues showed that levels of mRNA were inversely 
correlated with the degree of methylation in three bi-directional promoters and 
reactivated by 5’-aza-2’-deoxycytidine treatment in several cell lines [94]. Whether 
differential methylation of “bi-directional“ promoters is a common feature in lung 
development remains to be determined. In section 2.2.5, I have determined the 
methylation profiles of 20 putative “bi-directional” promoters in fetal and healthy 
adult lung.  Expression profiles of the paired genes suggested co-expression when 
compared to random-pairs of genes in different chromosomes. In addition, the 
majority (17 bi-directional promoters) was unmethylated and their respective “head-
to-head” genes highly expressed. In contrast, 3 hypermethylated regions showed 
lower expression of the associated transcripts, giving experimental support for co-
regulation.  
 
1.5.6. Imprinting 
 
Genomic imprinting refers to the parent-of-origin-specific gene silencing. Since the 
discovery of this phenomenon more than 20 years ago, [95], [96], more than 80 
imprinted genes have been reported. Imprinting status of orthologous genes are 
frequently discordant between human and mouse. Furthermore, imprinted genes are 
frequently noncoding RNAs or genes derived from retrotransposition in many cases 
[97]. Among the most common examples of protein coding imprinted genes can be 
mentioned the insulin-like growth factor 2, IGF2, and the alpha unit of the Gs 
protein, GNAS1 [97]. In mammals, imprinted genes are especially implicated in the 
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regulation of fetal growth, development and function of the placenta, and postnatal 
behaviors, reviewed in [98].  
Most imprinted genes are clustered in large chromosomal domains [97]. Common 
regions referred as “Imprinting Controlling Regions” (ICRs) generally direct the 
expression in such clusters. ICRs are regulated epigenetically, being usually one of 
the parental alleles methylated. Parental DNA methylation imprints at ICRs are 
established during gametogenesis. After fertilization, imprints are maintained 
throughout the development (Figure 1.5.2). In addition to DNA methylation, 
monoallelic silencing of some genes require the interaction of histone modifications 
[99] or non-coding RNAs [100], [101]. 
 
 
Figure 1.5.2: Parental imprints are established during oogenesis or spermatogenesis at ICRs and 
maintained thereafter. After fertilization the imprints are maintained throughout development. 
DNA methylation (red lollipops) is the most consistent hallmark of imprints. Two examples are 
depicted: an ICR with paternally derived (ICR1), and one with maternally derived DNA methylation 
(ICR2). Reproduced from Delaval and Feil [102] 
 
Several developmental and behavioral disorders in human are associated to 
alterations in imprinted genes. In many of them, the origin of the disorder is the 
inheritance of two chromosomal copies of the locus from a parent, in an alteration 
denominated uniparental disomy (UPD). The best-characterized imprinting 
syndromes are the Beckwith-Wiedemann syndrome (BWS) and Prader-
Willi/Angelman syndrome (PWS and AS, respectively). In BWS, a paternal UPD of 
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chromosome 11p15.5 leads to the biallelic expression of the IGF2 gene and loss of 
expression of the CDKN1C gene. BWS phenotypic features are exomphalos, 
macroglossia, and gigantism in the neonate. Moreover, BWS patients show a 
predisposition to early tumors, reviewed in [103].  
PWS is caused by deletion or disruption of a gene or several genes on the 
chromosome 15p15.5 or maternal UPD, because the gene(s) on the maternal 
chromosome(s) 15 are virtually inactive through imprinting. Correspondingly, the 
paternal UPD in the same region causes AS. Phenotypic features of PWS patients 
include diminished fetal activity, obesity, muscular hypotonia, mental retardation, 
short stature, hypogonadotropic hypogonadism, and small hands and feet. AS 
features includes mental retardation, movement or balance disorder, characteristic 
abnormal behaviors, and severe limitations in speech and language, reviewed in 
[104].  
In this work, I have studied the role of DNA methylation in the imprinting in healthy 
adult tissues of the IGF2R cluster in human chromosome 6, as presented in sections 
2.1.2 and 2.3.2 
 
1.6. Impact of DNA methylation in cancer  
 
1.6.1. General considerations 
 
Alterations of DNA methylation profiles have been recognized as an important, and 
in many cases essential, component of cancer development.  When compared to 
normal cells with the same tissue of origin, transformed cells display aberrant 
profiles, which have an application in diagnosis and molecular classification of the 
tumor [105]. In this regard, it has been proposed that epigenetic alterations in stem 
cells might precede the differences that clearly distinguish tumor types [106]. 
Nowadays, aberrant methylation profiles constitute a widely accepted feature in 
cancer. Aberrant methylation profiles in more than 120 genes have been related to 
malignant phenotypes in cancer. Some of these epigenetic alterations were detected 
in a particular cancer or tumor type, while others appear as more universal. As an 
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example table 1.6.1 lists 20 genes, which are frequently reported as aberrantly 
methylated in cancer. 
 
Table 1.6.1: Examples of genes aberrantly methylated in cancer 
Gene 
name Gene Name Aberrant methylation 
Key 
reference 
CCNA1 Cyclin A1 Head and neck 
squamous cell carcinoma 
[107] 
CCND1 Cyclin D1 B-cell malignancy [108] 
CDH1 E-cadherin Cervical cancer [109] 
CDKN1A p21CIP1 Prostatic cancer [110] 
CDKN1B Cyclin-dependent kinase inhibitor 1B (p27, Kip1) Lymphoid malignancies [111] 
CDKN1C Cyclin-dependent kinase inhibitor 1C (p57, Kip2) Pancreatic ductal 
neoplasms / Imprinting 
[112] 
ESR1 Estrogen receptor 1 (alpha) Colorectal cancer [113] 
FHIT Fragile histidine triad gene Leukemia [114] 
GSTP1 Glutationine S-transferase Prostate cancer [115] 
H19 H19 Colorectal cancer [116] 
HIC1 Hypermethylated in cancer 1 Invasive ductal breast 
carcinoma 
[117] 
IGF2 Insulin-like growth factor 2 (somatomedin A) Hepatoblastoma [118] 
MLH1 mutL homologue 1, colon cancer, nonpolyposis 
type 2 (E. coli) 
Colorectal carcinoma [119] 
PTEN Phosphatase and tensin homologue (mutated in 
multiple advanced cancers 1) 
Breast Cancer [120] 
PTGS2 Prostaglandin-endoperoxide synthase 2 
(prostaglandin G/H synthase and 
cyclooxygenase) 
Prostate cancer [121] 
RARB Retinoic acid receptor, beta Uterus carcinoma [122] 
RASSF1 Ras association (RalGDS/AF-6) domain family 1 Lung Small Cell 
Carcinoma 
[123] 
S100A2 S100 calcium binding protein A2 Prostate cancer [124] 
TP53 Tumor protein p53 (Li-Fraumeni syndrome) Ductal carcinoma [125] 
VHL Von Hippel-Lindau tumor suppressor Renal carcinoma [126] 
 
1.6.2. Hyper- and hypomethylation in cancer 
 
At global level, the methyl-cytosine content was shown to be lower in transformed 
cells [127]. In normal cells, repetitive sequences originated by ancestral 
retrotransposon insertions (e.g. LINEs, SINEs) are mainly hypermethylated, as well 
as coding regions and intronic CpG positions. These non-promoter regions contain 
approximately 95 % of the methyl-cytosines of the human genome. Many of these 
regions became hypomethylated in cancer cells leading to the registered “global 
hypomethylation“ values [128]. In mouse models, the overall degree of 
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hypomethylation of satellite or LINE-1 sequences correlated with the frequency of 
chromosomal aberrations and increased tumor frequency [129]. 
In parallel to the observed global hypomethylation, cancer cells also display aberrant 
hypermethylation of normally unmethylated CpG islands [3]. Hypermethylation 
mainly occurs in tumor-suppressor genes and is often linked to silencing of the 
cognate gene. Promoter hypermethylation appears as an early event in 
tumorigenesis. Epigenetic alterations can produce the early losses of cell cycle 
control, altered regulation of gene transcription factors, disruption of cell-cell and 
cell-substratum interaction and even multiple types of genetic instability, 
characteristic of human cancer, reviewed in [130], [131]. Epigenetic silencing of tumor 
suppressor genes occurs at least as frequently as mutations or deletions in human 
cancers [3].  
According to the “Two-hits” hypothesis of carcinogenesis proposed by Knudson 
[132] loss of function of both alleles is required for malignant transformation. A 
mutation of a critical gene typically constitutes the first hit, followed by loss of the 
wild-type allele throughout deletion or loss of heterozygosity. Hypermethylation of 
tumor suppressor genes can constitute the initial hit in many somatic cancers, with 
subsequent alterations at DNA sequence level eliminating the second gene copy 
[133]. Furthermore, epigenetic alterations have also been reported to cause the 
second hit in familial cancers [134], [135]. 
In contrast, promoter hypomethylation affects frequently genes, known as 
“oncogenes”, whose products are known to have oncogenic properties that over-
expressed lead to the malignant transformation of the cell [128]. Several genes that 
are hypomethylated in cancer fall into the class of cancer-testis antigens (e.g. MAGE-
A, -B and –C) [136], [137]). In addition, other hypomethylated genes in cancer are 
related to cellular stress and immune response (e.g. S100P [138]), cell cycle (e.g. 
CDKN2A [139]) and homeobox genes (e.g. HOX11 [140]) 
 
1.6.3. Loss of imprinting in cancer  
 
Loss of imprinting (LOI) is the disruption of imprinted epigenetic marks through 
gain or loss of DNA methylation, or simply the loss of normal allele-specific gene 
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expression [141]. LOI of a growth-promoting imprinted gene leads to activation of 
the normally silent allele and results in abnormally high expression of the gene 
product, which gives cells a growth advantage.  LOI of the IGF2 locus is the most 
common LOI event across a wide range of tumor types, including colon, liver, lung 
and ovarian cancers as well as Wilms’ tumor [142]. 
 
1.6.4. Potential applications for DNA methylation in clinical practice 
 
DNA methylation has a great potential for translation into clinical practice. Aberrant 
methylation has been shown to have potential in risk-assessment, early detection, 
disease classification and prognosis prediction in a variety of cancers [143], [144]. In 
addition, some research in the field points towards the therapeutic application of 
targeting DNA methylation. As observed in early embryogenesis, DNA replication in 
absence of DNMTs leads to hypomethylation. Therefore, pharmacological inhibition 
of DNMTs could reactivate tumor-suppressor genes silenced by hypermethylation in 
cancer cells. Two of these inhibitors, 5-azacytidine (azacytidine) and 5-aza-2'-
deoxycytidine (decitabine), demonstrated encouraging antileukemic activity but little 
activity in solid tumors, reviewed in [145].  However, when the molecular action of 
these drugs is considered, the simple inhibition of DNMTs appears as an over-
simplification, as discussed in section 3.2. 
 
1.6.5. DNA methylation in Lung Cancer 
 
Lung Cancer is the second most common cancer and the most common cause of 
cancer-related death in both men and women in developed countries. The American 
Cancer Society estimates more than 213,000 new cases and 160,000 new deaths in the 
United States for 2007 [146].   
There are two main types of lung cancer, small lung cell cancer and non-small cell 
lung cancer. Classically, tumor types are identified by pathological examination of 
cell morphology from patients’ biopsies.  
 
Small cell lung cancer. Classification, prognosis and treatment alternatives 
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Small cell carcinoma is the most aggressive type of lung cancer. Without treatment, 
patients show a median survival of only 2 to 4 months. Because patients with small 
cell lung cancer tend to develop distant metastases, localized forms of treatment, 
such as surgical resection or radiation therapy, rarely produce long-term survival 
[147]. Chemotherapy regimens prolong the survival 4- to 5- fold, being the overall 
survival at 5 years 5-10 % [148]. 
Currently, the cellular classification of subtypes of small cell lung cancer comprises 
small cell carcinoma, mixed small cell/large cell carcinoma and combined small cell 
carcinoma [149]. 
Small cell cancer patients are separated in two groups, according to the extension of 
the location of the tumors at the time of diagnosis. Patients with “limited-stage” 
disease have tumors confined to the hemithorax, mediastinum or supraclavicular 
lymph nodes. Under current treatments, patients with limited stage disease have a 
median survival of 16 to 24 months [150]. Patients with tumors that have spread 
beyond the supraclavicular areas belong to the “extensive-stage” disease group and 
have a worse prognosis.  
Regardless of the stage, the current prognosis for patients with small cell lung cancer 
is unsatisfactory and the National Cancer Institute (U.S.A) recommends considering 
all patients for the inclusion in clinical trials at the time of diagnosis [151]  
 
Non-small cell lung cancer. Classification, prognosis and treatment alternatives 
 
Three main histological subtypes are differentiated in non-small cell lung cancer 
(NSCLC): squamous carcinoma (or epidermoid), adenocarcinoma and large cell 
carcinoma. Approaches to diagnosis, staging, prognosis and treatment are similar for 
these subtypes.  
Factors that have correlated with adverse prognosis include the following: presence 
of pulmonary symptoms, large tumor size (>3 cm), nonsquamous histology, 
metastases to multiple lymph nodes and vascular invasion [152]. 
Possibility to surgically remove the tumor correlates with its staging and will mark 
the treatment approach. The most frequent treatment for patients with resectable 
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disease in NSCLC is surgery. In many cases, surgery is complemented with adjuvant 
chemotherapy. Local control can be achieved with radiation therapy in a large 
number of patients with unresectable disease. Patients with locally advanced, 
unresectable disease may have long-term survival with radiation therapy combined 
with chemotherapy. Patients with advanced metastatic disease may achieve 
improved survival and palliation of symptoms with chemotherapy [149]. 
Because the treatment is not satisfactory for almost all patients with NSCLC, the 
National Cancer Institute (USA) recommends considering eligible patients for clinical 
trials [151].  
 
The need of a precise diagnosis for lung cancer – Application of DNA methylation markers 
 
The application of effective and specific therapies requires precise diagnosis and 
classification of tumors. Particularly in lung cancer, small cell carcinomas, which 
respond well to chemotherapy and are generally not treated surgically, can be 
confused on microscopic examination with non-small cell carcinoma [149]. 
Currently, several genomic and proteomic methods allow the molecular 
characterization of lung cancers based on physiological processes during oncogenic 
transformation, reviewed in [153]. Among those processes, epigenetic phenomena 
are widely recognized to play a fundamental role in carcinogenesis and tumor 
progression [154].  In particular, DNA methylation alterations (e.g. inappropriate 
gene silencing through promoter hypermethylation) affect the normal physiological 
and morphological state of the cell towards malignancy. Hence, changes in 
methylation patterns appear as very promising markers for lung cancer in tissue- 
based diagnosis [155], as well as screening in body fluids [156]. 
 
Similarities between tumor ontogeny and embryonic development. Potential role of embryonic 
biomarkers in cancer 
 
Reya and colleagues suggested that lung tumor ontogeny is determined by the 
consequences of gene transcription activation and/or repression events that 
recapitulate events important in embryonic development [157]. Several experimental 
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works in lung cancer support this hypothesis in terms of expression profiling [158], 
[159], [160] and sequence alterations [161]. Despite the accepted role of DNA 
methylation in oncogenesis and mammalian development, it is not known whether 
DNA methylation profiles in cancer cells also resemble those observed in fetal cells. 
To further investigate this possibility, in section 2.2.7 I have determined the 
expression profiles of fetal lung tissue samples relative to healthy adult lung tissue 
samples and explored the methylation status of differentially expressed genes in 
fetal, healthy adult and tumor lung. Using this approach, I have identified four genes 
(MEOX2, MDK, LAPTM5 and FGFR3) that are differentially methylated in lung 
cancer. MEOX2 is uniformly hypermethylated in lung cancer compared to healthy 
adult and fetal lung. Furthermore, I provide evidence that the methylation is not 
uniform in lung cancer but is rather correlated with either the differentiation state 
(MDK, LAPTM5) or the lung cancer type (FGFR3). The results presented in section 
2.2.7 indicate that some differentially methylated regions during lung morphogenesis 
may act as molecular markers in lung cancer. 
 
1.7. Impact of DNA methylation in non-oncogenic diseases 
 
1.7.1. DNA methylation in complex non- oncogenic diseases 
 
Besides the overwhelming evidence linking aberrant DNA methylation with cancer, 
DNA methylation is suspected to play a role in other non-oncogenic human 
pathologies as well. Among them, experimental work has related aberrant DNA 
methylation profiles to a wide range of complex diseases, such diabetes [162], 
arteriosclerosis [163], inflammatory bowel disease [164], inflammatory arthritis [165], 
schizophrenia [166] and autoimmune diseases [167]. 
 
1.7.2. Interaction of genetic and epigenetic alterations in monogenic diseases 
 
DNA methylation represents the cause in several monogenic diseases interacting 
with alterations at DNA sequence level. LOI in the GNAS1 locus was proposed as the 
molecular mechanism that underlies sporadic and familial types of 
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pseudohypoparathyroidism type Ib (PHP-Ib) [168]. Similarly, LOI in a CpG-island-
associated ICR leading to an increased expression of the PLAGL1 gene constitutes 
one of the mechanisms proposed to give rise to transient neonatal diabetes mellitus, 
TNDM [169].  
DNA methylation defects have also been linked to human diseases that are 
associated with repeat instability. For example, Fragile X syndrome (FRAXA), an X-
linked disorder, is a common cause of inherited mental retardation. The molecular 
basis of FRAXA lies in the highly polymorphic CGG repeat within the 5’-UTR of the 
FMR1 gene. Normally, 6-52 copies of the repeat are present, which increase to more 
than 200 copies in individuals with FRAXA. Affected individual show de novo 
methylation of the expanded CGG repeat and silencing of FMR1 [170]. Further 
evidence suggests that CGG repeat and hypermethylation in other folate-sensitive 
fragile sites across the genome [171]. Hypomethylation seems also to play a role in 
the development of non-oncogenic human diseases associated to repeat instability.  
In Fascioscapulohumeral muscular dystrophy (FSHD), some patients display the 
contraction of a repeat in the D4Z4 gene, whereas others do not such this alteration. 
Despite the presence of such a contraction, all FSHD display aberrant 
hypomethylation of the D4Z4 gene, suggesting that hypomethylation of D4Z4 is a 
key event in the cascade of epigenetic events causing FSHD [172]. 
 
1.7.3. Interaction of genetic and epigenetic alterations in non-oncogenic 
complex diseases 
 
Although it represents an inherent idea of epigenetic regulation, little is known about 
how the epigenetic layer of control interacts with the genetic background in the 
development of a diseased phenotype in a complex disease, discussed in [173] [174]. 
In this regard, progeroid syndromes represent an excellent model to study such 
interaction. 
Mutations within the LMNA gene cause many diseases with different phenotypes, 
such as different muscular dystrophies, progeroid syndromes, mandibuloacral 
dysplasia, dilated cardiomyopathies, restrictive dermopathy and lipodystrophy 
syndromes. Among laminopathies, the mutation position within the LMNA sequence 
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can partially predict the phenotype [175], but the underlying mechanisms for the 
development of these different phenotypes are still unclear. A combined effect of a 
mutation in the gene encoding the lamin protein and altered gene expression of 
genes encoding proteins that interact with the nuclear lamina might constitute one of 
the mechanisms leading to different phenotypes [176].  
Familial partial lipodystrophy type 2, FPLD2, (OMIM ID: 151660) is an autosomal 
dominant syndrome, whose phenotypic manifestations include gradual lack of 
subcutaneous adipose tissue in extremities and gluteal and troncal regions at the 
onset of puberty. Simultaneously, adipose tissue accumulates on face and neck. 
Affected patients are insulin-resistant and may develop glucose intolerance and 
diabetes mellitus after 20 years of age. Several mutations in the LMNA gene have 
been mapped in patients with FPLD2 [177], [178]. 
Progeroid syndromes are characterized by a premature ageing of the affected 
patients (OMIM ID: 176670). In particular, the Hutchison- Gilford progeria syndrome 
is a rare disorder characterized by precocious senility. Death from coronary artery 
disease is frequent and may occur before 10 years of age. As in FPLD2, mutations in 
the LMNA gene are mapped in Hutchison- Gilford syndrome patients [179]. 
Concordantly, variations in DNA methylation have been widely reported as 
correlating with age [180]. 
In section 2.4, I investigate of the methylation status of 10 candidate genes in patients 
affected with FPLD2 and Progeria bearing different mutations in the LMNA gene and 
healthy control individuals.  In general, genes displayed unmethylation. However, 
the RARB gene showed a significant higher methylation in all 6 FPLD2 patients when 
compared to the Progeria patients as well as the healthy control individuals. In 
addition, LMNA gene was clearly, though not significantly, differentially methylated 
in two different FPLD2 families bearing distinct LMNA mutations. The results 
presented in section 2.4 allow postulating that alterations at epigenetic level 
modulate the different phenotypes observed in progeroid syndromes upon a similar 
genetic background. 
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1.8. Structure of the thesis 
 
1.8.1. Topics 
 
The general focus of the present work is the study of differential DNA methylation 
influencing phenotypes in healthy and diseased tissues. It brings valuable 
information about several biological processes occurring in healthy tissues, such as 
tissue-specific gene silencing, imprinting and epigenetic control in human 
development. In addition, I applied the produced knowledge and the established 
methods to study DNA methylation biomarkers for an oncogenic disease, Lung 
Cancer, and a group of non-oncogenic complex diseases, Laminopathies. 
Specifically, the contained topics can be listed as it follows: 
- Correlation of DNA methylation and transcription profiles in healthy human 
tissues  
- Conservation of tissue-specific DNA methylation profiles throughout the 
evolution. 
- Interaction of genetic and epigenetic alterations in modulating phenotypes in 
laminopathies 
 
1.8.2. Hypothesis 
 
The main hypothesis under test in the present work is: 
- Patterns of differential methylation influence biological processes in tissues or 
cells where they were observed.  
 
Complementarily, secondary hypotheses are under test along the work: 
- Specific methylation in healthy tissues and primary cells correlates with the 
expression of the cognate transcript 
- DNA methylation at bi-directional promoters drives the co-expression of the 
corresponding “head-to-head” genes 
- Differentially expressed genes between fetal and adult lung tissue samples are 
candidates for differential methylation in lung cancer 
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- Tissue specific methylation observed in human genes is conserved in their 
murine orthologues 
- Tissue specific methylation is conserved upon genome duplications 
- Differential DNA methylation modulates phenotypic expression upon similar 
genetic backgrounds 
 
1.8.3. Objectives 
 
General objective: 
- To study the influence of differential methylation in biological processes 
occurring in healthy individuals as well as patients with oncogenic and non-
oncogenic diseases. 
 
Specific objectives: 
- To determine the degree of correlation between hypermethylation of the 5’-
UTR and gene silencing in healthy adult and fetal human tissues as well as in 
primary cells. 
- To estimate the degree of evolutionary conservation of tissue-specific DNA 
methylation profiles by studying orthologous and paralogous genes. 
- To study the interaction of DNA methylation and alterations at DNA 
sequence level in establishing the different phenotypes characteristic of 
laminopathies. 
 
1.8.4. Relevance of the presented results 
 
Results on correlation between hypermethylation and gene silencing in healthy 
human tissues bring experimental evidence supporting a long-standing theory of 
epigenetic regulation of gene expression, as discussed in [32]. The study of such 
correlation in human fetal tissues gives an insight on the role of DNA methylation in 
organogenesis during lung development. In addition, the establishment of high 
quality transcriptional profiles of fetal lung provides valuable information on 
functional genomics during lung development beyond epigenetics. 
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Results on conservation of tissue-specific DNA methylation profiles in human and 
murine orthologue genes provide very valuable base-line knowledge for further 
experimentation of the epigenetic phenomena using animal models. 
The discovery of differential methylation in four genes in Lung cancer, MEOX2, 
LAPTM5, MDK and FGFR3 nominate them as putative novel biomarkers for this 
disease. Evaluation of these markers in a larger sample panel would lead to a future 
application in diagnosis or screening. 
Finally, results the study of the synergetic effects of mutations and aberrant 
methylation help explaining the different phenotypes observed in distinct 
laminopathies. Additionally, their relevance goes beyond laminopathies and 
progeroid syndromes. It supports a role for DNA methylation in the modulation of 
different phenotypes upon similar genetic backgrounds. 
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2. Results 
 
2.1. Tissue specific DNA methylation and expression profiles 
 
2.1.1. Candidate gene approach 
 
It is widely accepted that methylation of the promoter region is related to gene 
silencing. However, the available experimental evidence supporting this concept is 
scarce.  
To further investigate the functional role of tissue-specific DNA methylation regions 
in human healthy adult tissues, I have selected 55 tissue-specific differentially 
methylated regions (T-DMRs) from the results of the Human Epigenome Project 
(HEP) [67] and studied the expression of their associated genes by semiquantitative 
RT-PCR. The results of my experiments presented in this section were published as 
part of the first phase of HEP [67] 
My experiments showed that hypermethylation of the 5’ region correlates with 
transcriptional silencing in 37 % of the investigated genes, but I did not find such 
correlation when the T-DMRs were located either in the coding region or 
downstream to the gene. 
I have studied the expression profiles of the selected genes in the same samples, 
where methylation profiles were determined. In that manner, I included in the study 
total RNA samples from three major human healthy tissues (Heart Muscle, Liver and 
Skeletal Muscle) and primary cells (CD4+ and CD8+ lymphocytes, keratinocytes, 
melanocytes and fibroblasts). Unlike established cell lines, studies using tissue and 
primary cells samples avoid changes in DNA methylation and expression profiles 
introduced by culture and repeated cell passage [181]  
Figure 2.1.1 shows the results of single gene semiquantitative RT-PCR and bisulfite 
sequencing results for some example genes in the studied tissues. Expression levels 
were compared to the expression of a housekeeping gene, ACTB1, which displayed 
high levels of expression in all studied tissues and cells.   
MYO18B, SLC22A1 and OSM are examples of genes where hypermethylation of the 
5’ region correlates with gene silencing. In that manner, MYO18B was expressed only 
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in heart and skeletal muscle (50 % methylation), SLC22A1 only in liver (50% 
methylation) and OSM in CD4+/CD8+ lymphocytes (0% methylation). These three 
genes were silenced in the rest of studied tissues and primary cells showing 100 % 
methylation.  
TBX18, GRIK2 and CELSR1 are examples of genes whose methylation status does not 
correlate with the expression profiles. TBX18 was highly expressed in fibroblasts 
despite hypermethylation, while cells showing no methylation (CD4+/CD8+ 
lymphocytes, keratinocytes) did not express the gene. Fibroblasts, melanocytes and 
keratinocytes displayed hypermethylation of GRIK2, however this gene was highly, 
slightly and no expressed in these cells, respectively. CELSR1 was unmethylated and 
slightly expressed in CD4+/CD8+ lymphocytes, however it was highly expressed in 
keratinocytes, melanocytes, heart and liver, which showed 100% methylation. 
Furthermore, I analyzed the expression of SERPINB5 in the included tissues and 
cells. In agreement with that reported in the literature [31], I found the gene being 
expressed only in keratinocytes, which showed no methylation, but not in any other 
tissue (all showing 100% methylation).  
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Figure 2.1.1:  Examples of DNA methylation and expression profiles. A) DNA methylation profiles 
for six example genes and the positive control SERPINB5 in primary cells and healthy adult tissues. 
Samples are displayed column wise with rows representing individual CpGs of the PCR fragment. 
Quantitative methylation analysis results are shown in a color scale ranging from yellow (~0% 
methylation), green (~50% methylation) to dark blue (~100% methylation). B) Correlation between 5’-
UTR methylation and mRNA expression. RT-PCR results for genes in A) are shown as well as the 
housekeeping gene ACTINB1. While MYO18B, SLC22A1 and OSM displayed a correlation between 
hypermethylation and gene silencing, TBX18, GRIK2 and CELSR1 did not show any correlation. I 
have used SERPINB5 as positive control, as correlation was reported for this gene [31]. Mean of 
methylation at the 5’UTR are displayed as a colored bar above each gene. Color code corresponds to 
that in panel A). Shown RT-PCR results are representative of three independent samples per tissue 
type. Pool of adult and fetal RNAs was used as positive control for the RT-PCR (+ control) 
 
Table 2.1.1 lists the studied genes, the position of the found T-DMR and the relation 
to the expression of the cognate transcript.  
 
 
 
 
 
 
Differential DNA methylation profiles modulating phenotypes 
________________________________________________________________ 
 38 
Table 2.1.1: Studied genes, position of T-DMR and relation to expression 
Gene Name Ensembl ID T-DMR Position T-DMR / Expression 
Group 1 
CTA-299D3.6-005 OTTHUMG00000030140 5'-UTR Inverse correlation 
OSM ENSG00000099985 5'-UTR Inverse correlation 
SOX10 ENSG00000100146 5'-UTR Inverse correlation 
SLC22A1 ENSG00000175003 5'-UTR Inverse correlation 
MYOD18B ENSG00000133454 5'-UTR Inverse correlation 
IHPK3 ENSG00000161896 5'-UTR Inverse correlation 
PARVG ENSG00000138964 5'-UTR Inverse correlation 
A4GALT ENSG00000128274 5'-UTR Inverse correlation 
AP006358.2-002 OTTHUMG00000030241 5'-UTR Inverse correlation 
MDFI OTTHUMG00000014681 5'-UTR Inverse correlation 
TGM3 ENSG00000125780 5'-UTR Inverse correlation 
PLG ENSG00000122194 5'-UTR Inverse correlation 
PRAME ENSG00000185686 5'-UTR Inverse correlation 
PIB5PA  ENSG00000185133 5'-UTR Inverse correlation 
Q8N7A7 ENSG00000183964 5'-UTR Inverse correlation 
FILIP1 ENSG00000118407 5'-UTR Inverse correlation 
SLC7A4 OTTHUMG00000030129 5'-UTR No correlation 
CTA-243E7.3  OTTHUMG00000030167 5'-UTR No correlation 
TBX18 ENSG00000112837 5'-UTR No correlation 
SSTR3 ENSG00000183473 5'-UTR No correlation 
RP4-756G23.1   OTTHUMG00000030852 5'-UTR No correlation 
RP3-398D13.4-001 OTTHUMG00000014188 5'-UTR No correlation 
RP11-174C7.4-001 OTTHUMG00000015553 5'-UTR No correlation 
RP3-43804.2-002 OTTHUMG00000030922 5'-UTR No correlation 
SUSD2 ENSG00000099994 5'-UTR No correlation 
TFAP2A OTTHUMG00000014235 5'-UTR No correlation 
RIN2 ENSG00000132669 5'-UTR No correlation 
RP1-47A17.8 OTTHUMG00000030878 5'-UTR No correlation 
RP1-32B1.4-001 OTTHUMG00000015628 5'-UTR No correlation 
ENSESTG00000027621 ENSESTG00000027621 5'-UTR No correlation 
CMAH ENSG00000168405 5'-UTR No correlation 
GRAP2 ENSG00000100351 5'-UTR No correlation 
GAR22/GAS2L1 ENSG00000185340 5'-UTR No correlation 
GABRR1 ENSG00000146276 5'-UTR No correlation 
PACSIN1 ENSG00000124507 5'-UTR No correlation 
PLA2G3 ENSG00000100078 5'-UTR No correlation 
PKHD1 ENSG00000170927 5'-UTR No correlation 
HMGA1 ENSG00000137309 5'-UTR No correlation 
GRIK2 ENSG00000164418 5'-UTR No correlation 
SEPT5 ENSG00000184702 5'-UTR No correlation 
RAET1E ENSG00000164520 5'-UTR No correlation 
RASSF2 ENSG00000101265 5'-UTR No correlation 
VNN1 ENSG00000112299 5'-UTR No correlation 
Group 2 
RP1-165D5.4-004 OTTHUMG00000030772 Coding region No correlation 
GAR22/GAS2L1 ENSG00000185340 Coding region No correlation 
RP3-355C18.2 OTTHUMG00000030072 Coding region No correlation 
NP_955377 ENSG00000183506 Coding region No correlation 
HMG2L1 ENSG00000100281 Coding region No correlation 
CELSR1 ENSG00000075275 Coding region No correlation 
SMTN ENSG00000183963 Coding region No correlation 
PIPPI ENSG00000172346 Coding region No correlation 
FER1L4 OTTHUMG00000032354 Coding region No correlation 
CECR1 ENSG00000093072 Coding region No correlation 
Group 3 
PMM1 ENSG00000100417 Intergenic No correlation 
SA50 ENSG00000100347 Intergenic No correlation 
 
2. Results 
_____________________________________ 
 39
Studied genes can be separate in three groups. The first group consisted of 43 genes 
displaying tissue-specific DNA methylation in the 5’ region. I defined this 5’ region 
as the area between 2 kB upstream and 1 kB downstream of the Transcription Start 
Site (TSS). Within this group, 16 genes (37.21 %) showed a correlation between the 
DNA methylation status and gene silencing. Among the remaining 27 genes 
(62.79%), I did not found DNA methylation correlating neither with decreased nor 
with increased expression. 
The second group consisted of 10 genes containing T-DMRs within their coding 
regions. T-DMRs in these genes were located in both, exons and introns. In no case, I 
found this differential methylation correlating with the expression profiles of the 
genes, neither positive nor inverse. 
The third group consisted of 2 genes that showed T-DMRs located downstream of 
their coding regions. Investigated regions were located in intergenic areas and 
displayed a clear tissue-specific DNA methylation. Although there is no examples in 
the literature linking functionally these two T-DMRs to the investigated genes, I have 
chosen these genes because they are the ones located immediately upstream of the T-
DMRs. In none of the two genes, the observed hypermethylation of the upstream 
region correlated with the transcriptional silencing of the gene. 
 
2.1.2. Case of study: Are SLC22A1 and PLG genes imprinted in healthy adult 
tissues? 
 
Among those genes showing a correlation between hypermethylation of their 5’ 
region and gene silencing, SLC22A1 and PLG were worth noting. Both genes are 
located in chromosome 6q25.3 in a cluster containing also the IGF2R gene, which is a 
well-studied locus for imprinting in mouse [182]. By analyzing the allelic profiles for 
DNA methylation and expression in these two genes, I concluded that SLC22A1 and 
PLG are not imprinted in healthy adult human liver. 
First, I directly sequenced the bisulfite-converted DNA PCR products and analyzed 
the expression by semiquantitative RT-PCR in matched DNA/RNA samples derived 
from human liver, skeletal muscle and heart muscle. SLC22A1 and PLG showed 50% 
methylation and expression in liver, while 100% methylation and silencing in all the 
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other studied tissues and cells. Figure 2.1.2 shows the methylation and expression 
values observed in these genes.  
 
 
 
Figure 2.1.2: SLC22A1 and PLG are expressed only in tissues showing 50% methylation. Direct 
bisulfite sequencing (A) and RT-PCR (B) results for the methylation and expression profiles of 
SLC22A1 and PLG in healthy adult heart, liver and skeletal muscle.  Three matched RNA/DNA 
samples from the same individuals were used. Methylation results in A) are shown as in figure 2.1.1. 
Expression results of only one representative sample are shown in B). The housekeeping gene ACTB1 
was used as a RNA integrity control. A pool of adult and fetal RNAs was used as positive control for 
the RT-PCR (+ control) 
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The observed 50% methylation in liver might constitute a hint for allelic specific 
methylation. When taken together, fully methylated alleles (i.e. maternal allele) and 
unmethylated alleles (i.e. paternal allele) will give a quantitative signal of 50%.  Thus, 
genes whose imprinting is regulated by DNA methylation will show this kind of 
mosaic methylation pattern in an allelic-specific manner segregating from parents to 
their offspring. Alternatively, genes showing a composite pattern of methylation 
with consecutive CpG sites in the same amplicon being both, methylated and 
unmethylated will give also a 50% methylation value in direct PCR fragment 
sequencing.  
Hence, I further analyzed the distribution of the observed 50% methylation in 
SLC22A1 and PLG by sequencing the subcloned PCR products. Very strikingly, I 
observed that the 50% methylation in liver in both genes is distributed in a mosaic 
manner, with the CpG sites in the amplicon being either all methylated or all 
unmethylated in the same subcloned fragment. However, the observed mosaic 
methylation did not segregate with an annotated SNP neither for SLC22A1 
(rs1867351) nor for PLG (rs1950562). These results suggest that the observed tissue-
specific methylation in SLC22A1 and PLG is not allelic-specific and, if these genes are 
imprinted in human healthy liver, DNA methylation is not the responsible epigenetic 
mechanism. 
Figure 2.1.3 shows the allelic distribution of methylation in SLC22A1 and PLG. 
Moreover, this figure shows the allelic distribution in two regions used to control the 
selected experimental strategy. GNAS1 has been reported as imprinted in several 
tissues [183] [184]. I found that methylation in the T-DMR for this gene shows a 
mosaic distribution of DNA methylation in liver, with an annotated SNP (rs1800905) 
segregating with the methylated allele. Unlike, an intergenic region in Chromosome 
20p11.23 showed also 50% methylation in direct PCR product sequencing 
experiments but it is distributed in a composite pattern throughout the CpG sites and 
subcloned fragments.  
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Figure 2.1.3: DNA methylation in SLC22A1 and PLG is distributed in mosaic, but is not allelic-
specific in healthy liver. Bisulfite sequencing results of subcloned PCR fragments corresponding to 
the 5’-UTR of the SLC22A1, PLG and GNAS1 gene as well as an intergenic region on chromosome 
20p11.23. All PCR fragments displayed 50% methylation by direct bisulfite sequencing (not shown). 
SLC22A1, PLG and GNAS1 display a mosaic distribution while the intragenic region displays a 
composite pattern. Methylation in SLC22A1 and PLG does not segregate with annotated SNPs 
indicating that it is not allelic-specific. Unlike, methylation in GNAS1 segregates with the SNP, being 
the alleles G and A methylated and unmethylated, respectively. GNAS1 has been reported as 
imprinted in healthy liver [183]. 
 
To verify that SLC22A1 and PLG are effectively not imprinted in human liver, I 
analyzed the allelic profile of expression for these genes. I directly sequenced the 
amplified cDNA fragment in the RT-PCR. By analyzing the expressed genotype of 
two annotated SNPs contained in these fragments (rs2282143 for SLC22A1 and 
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rs1130656 for PLG, respectively), I determined that both genes are biallelical 
expressed in healthy human liver. Figure 2.1.4 shows the obtained trace files for 
SLC22A1 and PLG in one of the liver sample heterozygous for the studied SNPs at 
DNA level (genomic PCR fragment, upper panel) and in the expressed mRNA 
(cDNA fragment, lower panel). 
 
 
Figure 2.1.4: Biallelic expression of SLC22A1 and PLG in healthy adult liver. Sequencing traces 
showing the presence of an annotated SNP in genomic DNA (upper panel) and messenger RNA 
(lower panel). Healthy adult liver samples were heterozygous for the rs2282143 and rs1130656 SNPs 
in the SLC22A1 and PLG gene, respectively. Matched DNA/RNA samples from three individuals 
were used. 
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2.2. Determination of differential transcriptional and DNA methylation 
profiles in fetal and healthy adult lung 
 
2.2.1. Experimental design 
 
In the previous part, I have studied the extent of the correlation between DNA 
methylation and gene expression in healthy adult tissues in a candidate gene 
approach. Complementarily, genome-wide expression profiles using microarrays 
offer a different approach to this question, by selecting genes that are differentially 
expressed and subsequently studying the methylation status at their 5’ regions. 
First, I determined the expression profiles in 4 individual fetal lung and 4 individual 
healthy adult lung samples using Affymetrix microarrays. After strict upfront quality 
controls of the samples under study, as well as the produced raw data, I analyzed the 
produced profiles using the Robust Microarray Analysis (RMA) method. For a gene 
being considering as differentially expressed, I fixed a selection criterion of absolute 
log2 fold changes (Log2Fc) higher than 2. In that manner, genes at least 4-times 
highly expressed in the corresponding tissue were above the cutoff value. In total, 99 
genes were highly expressed in Fetal Lung and 354 were highly expressed in Healthy 
Adult Lung.  
Next, I determined the methylation status of 43 differentially expressed genes to 
study the putative role of DNA methylation in establishing the obtained 
transcriptional profiles. I selected the genes according to their measured differential 
expression either in fetal or healthy adult (Log2Fc>2, table 2.2.1) and high CG content 
of their 5’ UTR (>50%). I designed PCR fragments covering these CG rich regions and 
determined their methylation status in unrelated fetal (n=3) and healthy adult lung 
(n=3) samples by direct bisulfite sequencing. Highly methylated 5’-UTR regions 
correlated with decreased expression levels in 19% of the cases. 
The results presented in this section were submitted for publication and are currently 
under editorial review [Cortese R. et al, Correlative gene expression and DNA 
methylation profiling in lung development nominate new biomarkers in lung cancer, 
submitted to The International Journal of Biochemistry and Cell Biology] 
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Table 2.2.1. Expression and DNA methylation in 43 differentially expressed genes during lung 
development 
Gene 
Symbol Probeset Upregulation Log2Fc
1 Methylation FL2 
Methylation 
HAL2 
Wilcoxon 
test 3 
PLK2 201939_at Fetal 2,52 0% 0% p>0.05 
SOX11 204914_s_at Fetal 3,98 0% 0% p>0.05 
COL11A1 37892_at Fetal 3,37 0% 20% p<0.05 
GRB14 206204_at Fetal 2,53 10% 10% p>0.05 
MEOX2 206201_s_at Fetal 3,04 0% 20% p<0.05 
SERPINE2 212190_at Fetal 2,37 10% 30% p<0.05 
SOX9 202935_s_at Fetal 2,36 0% 20% p<0.05 
COL2A1 213492_at Fetal 2,59 10% 10% p>0.05 
TRO 211700_s_at Fetal 2,66 40% 30% p>0.05 
ROR1 211057_at Fetal 2,3 10% 10% p>0.05 
FBN2 203184_at Fetal 3,66 20% 50% p<0.05 
MEST 202016_at Fetal 3,08 40% 40% p>0.05 
MDK 209035_at Fetal 2,63 40% 70% p<0.05 
FGFR3 204379_s_at Fetal 2,2 90% 100% p>0.05 
GOLGIN67 208798_x_at Fetal 2,59 90% 90% p>0.05 
C5orf13 201310_s_at Fetal 3,83 0% 0% p>0.05 
IGF2BP3 203819_s_at Fetal 3,82 0% 0% p>0.05 
NID2 204114_at Fetal 3,28 10% 10% p>0.05 
RAMP 218585_s_at Fetal 4,04 10% 10% p>0.05 
SOX4 213668_s_at Fetal 2,47 10% 10% p>0.05 
TOP2A 201291_s_at Fetal 2,73 0% 0% p>0.05 
COL21A1 208096_s_at Fetal 2,39 20% 20% p>0.05 
FANCL 218397_at Fetal 2,41 10% 10% p>0.05 
GRP 206326_at Fetal 3,38 10% 10% p>0.05 
COL1A1 202311_s_at Fetal 3,6 20% 40% p<0.05 
IGF2 202409_at Fetal 2,86 90% 90% p>0.05 
CYP1A1 205749_at Healthy Adult 3,65 10% 10% p>0.05 
HCK 208018_s_at Healthy Adult 3,27 0% 0% p>0.05 
SLC39A8 209267_s_at Healthy Adult 4,47 0% 0% p>0.05 
FBP1 209696_at Healthy Adult 3,17 10% 10% p>0.05 
TU3A 209074_s_at Healthy Adult 3,76 20% 40% p<0.05 
WISP2 205792_at Healthy Adult 3,07 30% 30% p>0.05 
PRELP 204223_at Healthy Adult 2,94 60% 40% p>0.05 
SERPINA1 202833_s_at Healthy Adult 5,8 40% 40% p>0.05 
MARCO 205819_at Healthy Adult 3,44 80% 60% p<0.05 
PTGDS 211748_x_at Healthy Adult 3,39 60% 70% p>0.05 
SCNN1A 203453_at Healthy Adult 4,31 70% 90% p>0.05 
LAPTM5 201720_s_at Healthy Adult 3,28 90% 50% p<0.05 
SFTPD 214199_at Healthy Adult 4,78 50% 50% p>0.05 
BHLHLB3 221530_s_at Healthy Adult 2,81 0% 0% p>0.05 
MT1M 217546_at Healthy Adult 3,56 10% 10% p>0.05 
SLC15A3 219593_at Healthy Adult 2,2 30% 30% p>0.05 
MSR1 214770_at Healthy Adult 3,49 100% 100% p>0.05 
1: Results from one representative probeset corresponding to the detailed gene. 
2: Methylation values at the 5’ UTR. Methylation values represent the amplicon mean methylation. 
HAL: Healthy Adult Lung (n=3); FL: Fetal Lung (n=3) 
3: p-values obtained with Wilcoxon test comparing fetal and healthy adult lung samples 
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In an expression profiling experiment using Affymetrix GeneChip Arrays the sources 
of variability in descending order are: biological, sample preparation (total RNA 
isolation as well as labeling), and system (instrument and arrays) [185]. Quality of the 
total RNA prior to starting the experiment and of the products during the labeling 
procedure was thoroughly tested as explained in further sections. In the other hand, 
system noise is negligible when using GeneChip Array and there was no need for 
technical replicates [186] in the well-calibrated systems at Epigenomics.  
To address the biological variability, I have faced several constraints regarding the 
number of the available samples. Fetal human tissues are very difficult to obtain, 
especially in quality for RNA isolation; therefore, number of available samples was 
limited. All used fetal lung RNA samples were obtained from 20-25 weeks old 
fetuses. At this fetal age, lungs are in the Canicular and Saccular stages of 
development when pre-alveolar saccules expand and are subdivided in alveoli [187]. 
Both, female and male, individuals were included in both groups. 
In order to obtain statistical significant results, I used 4 independent samples for each 
group in the microarray experiment (biological replicates). I assumed that the intra-
group variation was lower than the inter-group variation, since both are non-
cancerous tissues expected to be homogeneous in terms of cellular composition. 
Retrospective unsupervised clustering analysis considering all the probesets in the 
array demonstrated that this assumption was correct (Figure 2.2.1). Furthermore, I 
validated the obtained results by single gene quantitative RT-PCR in 8 independent 
samples for each group, which gives universality to the discovered differences. 
 
 
Figure 2.2.1: Inter-group variation in the expression profiles is higher than intra-group variation. 
Unsupervised clustering of all normalized signals. Fetal and healthy adult samples clustered 
separately showing higher inter- than intra-group variation. Dendrogram was drawn using 
Manhattan distance and average linkage hierarchical clustering. The height measures represent the 
distance between individual samples and groups of samples. 
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2.2.2. Determination of expression profiles in Fetal and Healthy Adult Lung  
 
Upfront quality control of the samples under study 
 
As described in Material and Methods, I started the experiment by controlling the 
quality of the total RNA samples used for the microarray analysis and the gene 
candidate approach. Quality of the starting material is an essential feature in 
expression experiments and samples, which do not pass upfront quality controls, 
should be excluded from the analysis. Conservation of the biological material prior to 
RNA isolation, i.e. snap freezing or chemical treatments as RNA later TM, is crucial to 
preserve the integrity of the RNA, as well as the transcriptional status of the 
analyzed genes. Working with RNA samples isolated from tissues instead of 
cultured cells, make this point very challenging and therefore, I have followed very 
strict standards to evaluate the quality of the procured samples after receiving them. 
All 24 total RNA samples included in the analysis showed very good quality in terms 
of RNA integrity and purity.  
 
Target preparation, hybridization and scanning. First Order quality control 
 
After checking the quality of the included samples, I prepared cRNA from 4 fetal 
lung and 4 healthy adult lung samples according to the protocols stated in Material 
and Methods.  
After scanning, an image file (.dat file) was generated that allowed a first-hand 
estimation of the hybridization quality. First, arrays did not present image artifacts, 
i.e. High/low intensity spots, scratches, high regional, or overall background, etc., 
under ocular inspection of the image. Moreover, Oligo B2 spiked in the hybridization 
cocktail served as a positive hybridization control. Its hybridization was highlighted 
on the image by the pattern of intensities on the corners and edges, as well as the 
array name printed on the array.  
To further control the quality of the hybridization procedure, a Hybridization Report 
(.rpt file) was generated containing data regarding the efficiency of hybridization of 
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positive controls contained in the arrays as well as spiked controls added to the 
hybridization cocktail. 
Table 2.2.2 contains the more relevant values of the Hybridization Report for the 
analyzed samples. All samples showed very good performances for all the controls, 
indicating that produced microarray data was of very good quality and truly 
represent the biological status of the studied samples.  
 
Table 2.2.2: Hybridization report values 
 Fetal 1 Fetal 2 Fetal 3 Fetal 4 Adult 1 Adult 2 Adult 3 Adult 4 
Noise 
(RawQ) 2.59 2.04 2.44 1.87 2.52 1.87 2.33 2.21 
Background 61.68 58.22 55.34 57.16 63.01 56.84 57.21 55.54 
Present calls 13128 (58.9%) 
11831 
(53.1%) 
13231 
(59.4%) 
11616 
(52.13 %) 
12513 
(56.2%) 
11573 
(51.9%) 
12977 
(58.2 %) 
11831 
(53.1%) 
 
Housekeeping Controls1 
GAPDH 11450.2 (P) 
12762 
(P) 
9700.3 
(P) 
13175.3 
(P) 
16527.6 
(P) 
9815.1 
(P) 
8657.7 
(P) 
9138.8 
(P) 
ACTB1 
 
11523.9 
(P) 
18704.2 
(P) 
13368.4 
(P) 
14811.9 
(P) 
13513.7 
(P) 
18369.2 
(P) 
16354.5 
(P) 
12123.4 
(P) 
Ratios (3'/5') 
GAPDH 1.10 1.21 1.17 1.34 1.04 0.92 1.02 1.19 
ACTB 2.03 1.67 1.75 1.68 1.83 1.80 1.68 2.87 
 
Spiked Controls1 
Probe Set         
BIOB 581.9 (P) 727.2 (P) 480.5 (P) 676.9 (P) 504.9 (P) 440 (P) 482.7 (P) 738.9 (P) 
BIOC 2466.1 (P) 
2495.5 
(P) 
2063.2 
(P) 
2559.9 
(P) 
2016.2 
(P) 
2284 
(P) 
1803.6 
(P) 2571 (P) 
BIODN 5550.9 (P) 
6011.5 
(P) 
4181.5 
(P) 
5304.7 
(P) 
3853.0 
(P) 
4278 
(P) 
3431.2 
(P) 
5153.8 
(P) 
CREX 25258.8 (P) 
20528.3 
(P) 
17027.9 
(P) 
27224.2 
(P) 
17759.6 
(P) 
21835.6 
(P) 
12835.9 
(P) 
23833.6 
(P) 
1: Only data corresponding to 5’ probesets is shown. (P): Present signal 
 
Several values are relevant in the evaluation of the Hybridization Report and they 
must display values within accepted ranges [185]. Noise (RawQ) values represent the 
distribution of intensity of signal across the array. This value depends on particular 
factors for each scanner (i.e. electrical properties) and may vary from an instrument 
to the other, even in the same lab. Data used in the analysis should show comparable 
Noise values. Background values depend on the efficiency of washing and staining 
procedure and must range from 20 to 100 in expression arrays. Number of present 
calls will depend on the type of analyzed sample. However, very low values may 
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indicate poor sample quality and number of present calls must be comparable among 
the samples of the same biological group. Calls for all probesets corresponding to 
two housekeeping gene (GAPDH and ACTB) must be present in high intensity. 
Furthermore, the ratio between intensities corresponding to their 5’ and 3’ probesets 
must be lower than 3, otherwise indicating sample degradation. Finally, controls 
BIOB, BIOC, BIODN and CREX are spiked in increasing concentrations and must 
display therefore increasing signal intensities, indicating right sensitivity of 
hybridization and probe detection. 
Taken together, results of the first order quality control analysis demonstrated that 
the produced data was of very high quality, indicating that the analysis could be 
followed without discarding any microarray of the set. 
 
Quality controls of the produced raw data 
 
As a first step in the RMA procedure, raw data must be controlled in order to 
determine whether it fits to the assumptions of the model [188] [189]. All methods 
used were implemented in the affy, affyPLM and simpleaffy packages of the 
Bioconductor project (www.bioconductor.org) 
All analyzed arrays displayed very good results for all the quality controls and 
passed all the quality criteria, indicating that no array must be excluded from the 
analysis.  
First, I controlled that the produced data fits to the proposed “probe-level model”. 
This is a linear model in which probeset level parameters are usually factor variable 
for each probe. Chip level parameters could be factor variable grouping the arrays 
into treatment/status groups. In that manner, standard errors between the expected 
and observed values for each probeset are represented as box plots for each array 
(Figure 2.2.2, panel A). The distributions of the standard errors were comparable 
between all the arrays, indicating that the data set fits to the proposed model. 
Moreover, I represented the weights from the linear robust linear model fit as pseudo 
chip images (Figure 2.2.2, panel B). This graphical representation allows detecting 
spatial artifacts on the chip. As no microarray displayed poor quality areas bigger 
than 10% than the total surface, I continued the analysis including all the arrays. 
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Figure 2.2.2: Produced expression data fits to the “probe-level model”. A) Box plot of the model 
standard errors (standardized across probesets). The distributions are comparable between arrays. 
Narrow distributions suggest good quality of the produced data. B) Pseudo chip image of weights 
from the robust linear model fit. Areas of low weight are greener (poor quality), high weights are light 
gray. The absence of large green areas (more than 10% of the array surface) depicts good quality of the 
produced data. Only one representative array per group is shown. 
 
RMA analysis and determination of expression profiles 
 
After the quality control of the produced raw data, I determined the expression 
profiles of Fetal and Adult Lung. All method used were implemented in the affy, 
simpleaffy and multtest packages of the Bioconductor project. 
First, I normalized the obtained raw data, according to the RMA method [189]. After 
normalization, distribution of the data for each data set displayed a similar 
distribution of the standard errors (data not shown) and Fetal and Adult arrays 
cluster separately in the unsupervised hierarchical clustering (Figure 2.2.1). 
Plot of average intensity (A) versus estimated change (M), “MA-plot”, showed the 
majority of the probe sets scattering around zero (Figure 2.2.3). Several probesets 
located above or below a cutoff line with corresponding to 2 fold Log2Fc. These 
probesets represented the genes highly expressed in Fetal Lung (Log2Fc>2) or in 
Adult Lung (Log2Fc<-2), respectively.  
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Figure 2.2.3: Cutoff at Log2Fc separates differentially expressed genes. Average intensity A plotted 
vs. estimated log-fold change M (log (fetal) - log (Adult)). Grey dots represent probesets selected after 
fitting the cutoff at Log2Fc=2. 
 
In order to assign a statistical significance to the selected candidate genes, I applied 
multiple testing procedures, as assigned in the multtest package. Applied tests 
included Westfal &Yound maxT algorithm, Benjamini and Hochberg false discovery 
rates (FDR) and Bonferroni corrected two-sample Welch t-statistics for unequal 
variances, reviewed in [190].  
As selection criteria for the differentially expressed genes, I have chosen a minimum 
absolute Log2Fc of 2. According to these criteria, 99 genes were highly expressed in 
Fetal Lung (Log2Fc<-2) whereas 354 were highly expressed in Healthy Adult Lung 
(Log2Fc>2). 
Figure 2.2.4 graphically represents the differential expression profiles obtained for 
fetal and healthy adult lung. Hierarchical clustering of the differentially expressed 
458 probesets demonstrated that expression values clearly distinguish both groups. 
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Figure 2.2.4: Expression profiles of fetal and healthy adult lung. Hierarchical clustering of 458 
probesets found to be differentially expressed between fetal and healthy adult lung (Log2Fc >2 after 
multiple testing, see text for details). Columns represent each analyzed sample whereas probesets are 
arranged in rows. Expression values were obtained by RMA [189]. Expression values are represented 
in a color code ranging from orange (downregulation) to yellow (upregulation) 
 
2.2.3. Validation of expression profiles by qRT-PCR 
 
In order to validate the obtained profiles, I analyzed the expression of 21 
differentially expressed genes in 8 independent samples for each group by 
quantitative reverse-transcription PCR (qRT-PCR). 
Figure 2.2.5 summarizes the result of the validation experiment by showing the 
Log2Fc values obtained in the microarray and qRT-PCR experiments. 15 genes (71%) 
displayed coincident expression profiles in fetal and adult tissues with both methods. 
In no case, I found a gene that displayed significant higher expression in one tissue in 
the microarray experiment, while significant higher expression in the opposite tissue 
by qRT-PCR. Observed differences in the expression profiles might be due to 
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technical differences between the methods or different sensitivities of the statistical 
analysis used in each case. However, as samples used in each setup were 
independent, these results might also indicate differences in the expression of a 
particular gene in each included individual. 
 
 
Figure 2.2.5: Validation of expression profiles by qRT-PCR. Comparison of expression values for 
single gene measurement as obtained by microarray (black bars) and quantitative reverse 
transcription analysis (qRT-PCR) (white bars). 15 out of 21 genes (71%) displayed coincident 
expression profiles in fetal and adult tissues with both methods. No gene displayed significantly 
higher expression in opposite groups when both measurements are compared.  Microarray results 
correspond to one representative probeset per gene. qRT-PCR values were calculated in 8 
independent samples per group and processed with the Q-Gene algorithm [191]. 
 
Taken together these results indicate that the determined expression profiles in the 
microarray experiment are representative of the expression status of more than the 
half of the analyzed genes in fetal and adult lung in general. Furthermore, the fact 
that no gene displayed significant upregulation in opposite tissues when using two 
different methods in independent samples, suggests that the determined patterns in 
the microarray experiment are consistent with the biological expression profiles of 
these tissues in general. 
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The chosen method for qRT-PCR involves the relative quantification of transcribed 
mRNA for a particular gene in two biological groups. In order to normalize 
expression differences between tissues, expression results of the target gene must be 
calibrated against the expression of a reference gene, which is equally expressed in 
both tissues. To identify a gene that does not display significant differences in 
expression between fetal and adult lung, I screened a panel of 7 putative 
housekeeping genes, GAPDH, ACTB, UBC, RPL13A, PSMB6, ATP50 and POLR2F, 
with the BestKeeper algorithm proposed by Pfaffl and colleagues [191]. Although all 
seven genes displayed equivalent variances in the analyzed samples (data not 
shown), I decided to use GAPDH as a calibrator. This gene displayed the most robust 
results in the real time PCR amplification, in terms of standard variation between 
replicates and shape of the dissociation curves. 
 
2.2.4. Pathway analysis 
 
To gain further insight into the biological function of the expression profiles, I 
analyzed the data with the MAPPFinder software [192] thereby relating the 
expressed genes to each term of the Gene Ontology hierarchy. Table 2.2.3 shows the 
MAPPFinder results for 10 most over-represented groups ranked by their 
corresponding Z- score groups. Groups over-represented in genes upregulated in 
fetal lung were related to extracellular matrix components: “fibrillar collagen” group 
(GO ID: 5583, 6/9 changed genes, Z-score: 25.735); “collagen type I” (GO ID: 5584, 
3/3 changed genes; Z-score: 22.348); “collagen” (GO ID: 5581, 8/27 changed genes, 
Z-score: 19.603); “extracellular matrix structural constituent” group (GO ID: 5201, 
11/69 changed genes Z- score: 15.942). Groups identified as highly over-represented 
in genes upregulated in adult lung were related to immunological processes: the 
“Complement activation, classical pathway” (GO ID: 6958, 6/23 changed genes, Z-
score: 8.125), the “antigen processing\, exogenous antigen via MHC class II” (GO ID: 
19886, 10/13 changed genes, Z-score: 19.023) and “antimicrobial humoral response” 
(GO ID: 19735, 8/82 changed genes, Z-score: 6.275). 
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Table 2.2.3: Over-represented GO groups in genes upregulated in fetal and healthy adult lung 
GO Name GOID GO Type1 
Number 
Changed 
Number 
Measured 
Number 
in GO 
Percent 
Changed 
Percent 
Present 
Z 
Score 
 
Groups over-represented in genes upregulated in fetal lung 
fibrillar collagen 5583 C 6 9 9 66.67 100.00 25.74 
collagen 5581 C 8 27 32 29.63 84.38 19.60 
extracellular 
matrix structural 
constituent 
5201 F 11 69 85 15.94 81.18 16.60 
phosphate 
transport 6817 P 9 61 89 14.75 68.54 14.39 
inorganic anion 
transport 15698 P 9 114 146 7.89 78.08 10.17 
anion transport 6820 P 9 139 175 6.47 79.43 9.05 
extracellular 
matrix (sensu 
Metazoa) 
5578 C 13 307 377 4.23 81.43 8.39 
extracellular 
matrix 31012 C 13 311 383 4.18 81.20 8.32 
sensory 
perception of 
mechanical 
stimulus 
50954 P 6 83 97 7.23 85.57 7.87 
sensory 
perception of 
sound 
7605 P 6 83 97 7.23 85.57 7.87 
 
Groups over-represented in genes upregulated in healthy adult lung 
response to biotic 
stimulus 9607 P 98 764 912 12.83 83.77 21.74 
defense response 6952 P 94 730 870 12.88 83.91 21.32 
immune response 6955 P 87 657 769 13.24 85.44 20.83 
Antigen 
processing\. 
exogenous 
antigen via MHC 
class II 
19886 P 10 13 22 76.92 59.09 19.02 
MHC class II 
receptor activity 45012 F 9 12 21 75.00 57.14 17.81 
Antigen 
presentation\. 
exogenous 
antigen 
19884 P 9 12 21 75.00 57.14 17.81 
response to 
external biotic 
stimulus 
43207 P 61 468 544 13.03 86.03 17.10 
Response to 
pest\. pathogen 
or parasite 
9613 P 60 458 512 13.10 89.45 17.01 
response to 
external stimulus 9605 P 66 617 713 10.70 86.54 15.56 
response to 
stimulus 50896 P 110 1552 2053 7.09 75.60 15.07 
1: GO group type according to GO nomenclature: C= cellular location;  F= molecular function; P= 
biological process 
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2.2.5. Correlation between DNA methylation and gene silencing in fetal and 
adult lung 
 
To study a possible epigenetic regulation of the identified differentially expressed 
genes, I obtained methylation profiles of the 5’- UTR for 43 genes using direct 
bisulfite sequencing. I have selected these genes according to their measured 
differential expression either in fetal or healthy adult (Log2Fc>2, table 2.2.1) and high 
CG content of their 5’ UTR (>50%). Figure 2.2.6 displays examples of the 5’-UTR 
methylation for several genes while table 2.2.1 displays the obtained methylation 
values in combination with the calculated Log2Fc for each gene. Out of the 43 
analyzed genes, 8 (19%) exhibited a correlation between DNA methylation of the 5’ 
UTR and downregulation of the cognate gene. Among these genes, 6 (COL11A1, 
MEOX2, SERPINE2, SOX9, SERPINE2, FBN2 and MDK) were highly expressed and 
hypomethylated in fetal lung and 2 (LAPTM5 and MARCO) highly expressed and 
hypomethylated in adult lung (figure 2.2.6 and table 2.2.1).  
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Figure 2.2.6: DNA methylation profiles in fetal and healthy adult lung. 8 out 43 (19%) exhibited a 
correlation between DNA methylation of the 5’ UTR and downregulation of the gene. Representative 
results for three genes are shown. LAPTM5 is highly expressed (Log2Fc=3.28) and displayed 
significantly lower methylation in adult lung (p<0.05). TU3A showed higher expression 
(Log2Fc=3.76) and significantly higher methylation in some CpG positions in adult lung (p<0.05 
compare to figure). TOP2A is highly expressed in fetal lung (Log2Fc=2.73) and is unmethylated in 
healthy fetal and adult lung (p>0.05). Statistical differences were assessed using the Kruskal-Wallis 
test [194]. 
 
 
For example, the lysosome-associated protein, transmembrane-5 gene (LAPTM5) is 
highly expressed (Log2Fc=3.28) in adult lung and displayed lower methylation in 
adult lung (90% and 50% amplicon mean methylation in fetal and adult lung 
respectively, figure 2.2.6). Interestingly, 2 genes (5%) (SCNN1A and TU3A, figure 
2.2.6 and table 2.2.1) showed higher methylation in their respective 5’-UTRs in tissues 
where the cognate genes were also highly expressed. This finding may point to a 
positive regulation of expression by DNA methylation. The majority of the genes (33 
genes (76%), table 2.2.1) displayed no changes in their methylation profiles, being 
hypermethylated or unmethylated in fetal and healthy adult lung. 
 
2.2.6. DNA methylation and expression profiling of bi-directional promoters 
 
The distribution of the genes throughout the genome might influence their 
transcriptional profiles. By aligning full length cDNA sequences, Trinklein and 
colleagues [193] identified a class of divergently transcribed pairs, whose TSSs are 
separated by less than 1000 bp. The authors also reported that these “head-to-head” 
genes represent more than 10% of the transcriptome, thus any phenomena affecting 
their regulation might influence the phenotype. Authors showed that some of these 
genes are co-regulated, whereas others exhibit complementary expression profiles.  
In order to study a putative role for DNA methylation in the regulation of bi-
directional promoters, I selected 20 pairs of reported “head-to-head” genes, studied 
their co-expression out of the results of the genome-wide expression profiles from 
fetal and healthy adult lung and analyzed the methylation profiles of the shared 
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regions at their 5’-UTRs by direct bisulfite sequencing. Out of the 20 regions, 17 
contained an annotated CpG island (Ensembl v41) and 3 did not, although they 
exhibited a high CG content. Table 2.2.4 summarizes the results obtained for DNA 
methylation analysis of these regions in fetal and adult lung samples and the 
expression values for the annotated “head-to-head” genes.  
 
Table 2.2.4: DNA methylation and expression in 20 pairs of “head-to-head” genes 
Gene Symbol 
(- strand) Log2Fc
1 Gene Symbol     (+ strand) Log2Fc
1 CpG island 
Methylation 
Adult Lung2 
Methylation 
Fetal Lung2 
ARFRP1 0.19 ZGPAT 0,37 Yes 25% 25% 
NTHL1 0.39 TSC2 0,5 Yes 0% 0% 
THYN1 0.01 ACAD8 0,16 Yes 0% 0% 
DERL2 0.01 MIS12 0,09 Yes 0% 0% 
MATN4 0.08 RBPSUHL 0,04 No 100% 100% 
TAX1BP3 0.23 TMEM93 0,02 Yes 0% 0% 
CEBPA 0.54 FLJ12355 0,01 Yes 0% 0% 
ZCWPW1 0.16 BCDIN3 0,18 Yes 0% 0% 
CXorf2 0.06 TKTL1 0,21 No 100% 100% 
LSM1 0 BAG4 0,11 Yes 0% 0% 
THAP10 0.18 LRRC49 0,8 No 0% 0% 
MOAP1 0.29 C14orf130 0,5 Yes 0% 0% 
PSMA7 0.27 SS18L1 0,67 Yes 0% 0% 
SLC25A11 0.17 RNF167 0,08 Yes 0% 0% 
SUPT7L 0.44 SLC4A1AP 0,02 Yes 0% 0% 
EME2 0.28 NUBP2 0,01 Yes 0% 0% 
RECQL 0.53 GOLT1B 0,33 Yes 0% 0% 
CABP7 0 UCRC 0,13 Yes 0% 0% 
ARFIP2 0.51 FXC1 0,28 Yes 0% 0% 
GGA3 0.29 MRPS7 0,12 Yes 0% 0% 
1 Only the results for one representative probeset per gene are shown  
2 Results are binned in four groups (0, 25, 50 and 100%) 
 
Most regions were unmethylated (0-25%) and only two pairs, pair 5 (MATN4-
RBPSUHL genes) and pair 9 (CXORF2-TKTL1 genes), were hypermethylated. 
Noteworthy these two pairs did not contain a CpG island. The third pair not 
containing a CpG island, pair 11 (THAP10- LRRC49 genes), displayed unmethylation 
(0%) similarly to CpG island- contained regions. I did not find any differential 
methylation between fetal and adult lung samples in these regions. Figure 2.2.7 
illustrates the obtained results showing the position of the studied regions and their 
methylation status in fetal and adult lung tissues for regions containing (panel A) or 
not containing (panel B) a CpG island. 
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Figure 2.2.7: DNA methylation of bi-directional promoters in fetal and healthy adult lung. A) Bi-
directional promoters containing an annotated CpG island are unmethylated (<25%) in fetal and 
healthy adult lung. Representative result for a “head-to-head” gene pair is shown (RN167 and M2OM 
in the + and – strands, respectively). B) 2 out of 3 bi-directional promoters not containing a CpG 
island are hypermethylated (>90%) in fetal and healthy adult lung. Representative result for a “head-
to-head” gene pair is shown (RBPSL and MATN4 in the + and – strands, respectively).  
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To look for trends suggesting co-expression of the selected “head to head” genes, I 
analyzed their expression using the microarray expression profiles obtained from 
fetal and healthy adult lung samples in the previous part of this work. Paired genes 
were similarly expressed in both tissue groups showing Log2Fc values between 0 
and 0.8. Genes in “head-to-head” gene pairs did not show major variances between 
their expression values when compared individually.  Figure 2.2.8 A illustrates the 
comparison in fetal and healthy adult lung by showing 4 “head-to-head” pairs. 
Expression values were similar for genes in opposite strands, despite differences 
attributable to differences in hybridization efficiencies for individual probesets, 
indicating that “head-to-head” genes may co-express in fetal and healthy adult lung. 
To address this possibility, I calculated the Pearson correlation coefficient for the 20 
“head-to-head” genes contained in table 2.2.4 and compared to randomly generated 
pairs of genes in different chromosomes (n=100,000). Figure 2.2.8 B shows that 
expression in studied pairs (blue line, median = 0.4) is more correlated than in 
random pairs (black line, median = 0). In addition, I calculated the Pearson 
correlation coefficients for all bi-directional genes listed by Trinklein and colleagues 
[193] included in the HG-U133A microarray (red line, median= 0.38, n=57 pairs). 
Similarities in distribution of correlation coefficients between the selected 20 pairs 
and those from Trinklein and colleagues suggested that studied pairs are 
representative of the overall expression of “head-to-head” genes. 
Comparing the expression values for each “head-to-head” gene pair with the 
methylation of the respective 5’-UTR, I found that genes containing a 
hypermethylated putative promoter exhibited the lowest expression values in both 
strands (Figure 2.2.8 C). Genes corresponding to hypermethylated promoters were 
downregulated, regardless the strand where they were located (left panel) and the 
tissue type (right panel). This last observation constitutes a strong evidence for role 
of DNA methylation controlling the co-expression of “head-to-head” genes. 
Taken together the results of my experiments suggest that “head-to-head” genes are 
co-expressed in fetal and healthy adult lung and that methylation of the bi-
directional promoter may influence this co-expression. 
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Figure 2.2.8: Methylation and expression data suggest co-expression of “head-to-head” genes in 
healthy adult and fetal lung. A) “Head-to-head” genes are equally expressed in fetal and healthy 
adult lung. Representative results for four pairs are shown. Black triangles represent individual 
expression values for genes in the – strand and white circles those for genes in the + strand. As lines 
run parallel across individual sample measurements, no evidence against co-regulation is detected. B) 
Expression values in lung are correlated in genes in opposite strand for “head-to-head” gene pairs but 
not in randomly paired genes. Pearson coefficients higher than 0 indicate positive correlation while 
coefficients equal to 0 indicate no correlation. Blue line represent “head-to-head” gene pairs listed on 
table 2.2.4 (n=20), red line correspond to other head-to-head genes reported by Trinklein and 
colleagues [193] also present in the HG-U133A array (n=57) and black line represents randomly paired 
genes in opposite strand and different chromosomes (n=100,000).  C) “Head-to-head” genes 
corresponding to hypermethylated bi-directional promoters are downregulated, regardless coding 
strand and tissue type.  Expression values for hypermethylated and unmethylated bi-directional 
promoters are shown. Genes in + and – strand are highlighted in left-side plot (black triangles and 
white circles, respectively). Values for genes in fetal (gray triangles) and healthy adult lung (black 
circles) are shown in the right-side plot. 
 
 
2.2.7. Differentially expressed genes in lung development as methylation 
marker in lung cancer  
 
Current knowledge suggests that lung cancer cell ontogeny is determined by the 
consequences of gene transcriptional activation and/or repression events that 
recapitulate events important in embryonic lung development [157]. However, 
nothing is known about the role of the epigenetic control of gene expression on this 
regulation. 
I studied the DNA methylation status of the 43 candidate genes, already studied in 
fetal lung, in lung cancer. I profiled a panel of non-related 15 lung small cell lung 
carcinoma samples (12 adenocarcinomas and 3 squamous cell carcinomas) and 5 
healthy adult lung DNA samples. Table 2.2.5 summarizes the results of the DNA 
methylation analysis obtained in this analysis together with the methylation data 
obtained for fetal samples (section 2.2.5) 
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Table 2.2.5: DNA methylation values for candidate genes in healthy adult and tumor lung samples 
Gene Symbol Methylation 
HAL1 
Methylation 
MDT1 
Methylation 
PDT1 
Methylation 
FL1 
Kruskal-
Wallis test 2 
PLK2 0% 0% 0% 0% p>0.05 
SOX11 0% 0% 0% 0% p>0.05 
COL11A1 20% 20% 20% 0% p>0.05 
GRB14 10% 0% 0% 10% p>0.05 
SERPINE2 30% 50% 50% 10% p>0.05 
SOX9 20% 50% 50% 0% p>0.05 
COL2A1 10% 0% 0% 10% p>0.05 
TRO 30% 0% 0% 40% p>0.05 
ROR1 10% 20% 20% 10% p>0.05 
FBN2 50% 50% 50% 20% p>0.05 
MEST 40% 50% 50% 40% p>0.05 
MDK 70% 80% 50% 40% p<0.05 
FGFR3 100% 100% 100% 90% p>0.05 
GOLGIN67 90% 100% 100% 90% p>0.05 
C5orf13 0% 0% 0% 0% p>0.05 
IGF2BP3 0% 0% 0% 0% p>0.05 
NID2 10% 0% 0% 10% p>0.05 
RAMP 10% 0% 0% 10% p>0.05 
SOX4 10% 0% 0% 10% p>0.05 
TOP2A 0% 0% 0% 0% p>0.05 
COL21A1 20% 20% 20% 20% p>0.05 
FANCL 10% 20% 20% 10% p>0.05 
GRP 10% 20% 20% 10% p>0.05 
COL1A1 40% 50% 50% 20% p>0.05 
IGF2 90% 100% 100% 90% p>0.05 
CYP1A1 10% 0% 0% 10% p>0.05 
HCK 0% 0% 0% 0% p>0.05 
SLC39A8 0% 0% 0% 0% p>0.05 
FBP1 10% 20% 20% 10% p>0.05 
TU3A 40% 50% 50% 20% p>0.05 
WISP2 30% 30% 30% 30% p>0.05 
PRELP 40% 50% 50% 60% p>0.05 
SERPINA1 40% 50% 50% 40% p>0.05 
MARCO 60% 50% 50% 80% p>0.05 
PTGDS 70% 70% 70% 60% p>0.05 
SCNN1A 90% 100% 100% 70% p>0.05 
LAPTM5 50% 50% 80% 90% p<0.05 
SFTPD 50% 50% 50% 50% p>0.05 
BHLHLB3 0% 0% 0% 0% p>0.05 
MT1M 10% 0% 0% 10% p>0.05 
SLC15A3 30% 30% 30% 30% p>0.05 
MSR1 100% 100% 100% 100% p>0.05 
1: Methylation values at the 5’ UTR. Methylation values represent the amplicon mean methylation. HAL: Healthy 
Adult Lung (n=5); MDT: Moderately differentiated tumor (n=6); PDT: Poorly differentiated tumor (n=4); FL: 
Fetal Lung (n=3) 
2: p-values obtained with Kruskal-Wallis test comparing healthy adult and differentially differentiated tumor 
samples 
 
In general, all tumor and healthy lung samples displayed low methylation values at 
their 5’-UTR, ranging from 0 to 50 % methylation and only for 5 genes (IGF2, MDK, 
GOLGIN67, FGFR3 and MARCO), I found hypermethylation (>70%) of the analyzed 
region. Methylation profiles were, in general, unchanged between fetal, healthy adult 
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and tumor samples. Noteworthy, 4 genes displayed patterns of differential 
methylation among those samples, arising as possible biomarkers for lung cancer: 
MEOX2, MDK, LAPTM5, and FGF3R. 
When comparing all lung cancer samples to either healthy fetal or adult lung, 
MEOX2 displayed statistically significant differential methylation (p<0.002, Kruskal-
Wallis test [194]) in lung cancer (Figure 2.2.9). Specifically, MEOX2 gene displayed 
mean methylation values of approximately 50%, 20% and 0% for tumor, healthy 
adult and fetal lung, respectively (Figure 2.2.9).  
 
 
Figure 2.2.9: MEOX2 is differentially methylated in lung cancer. MEOX2 displayed higher 
methylation (mean methylation 40%) in lung cancer samples when compared to healthy fetal and 
adult lung (amplicon mean methylation 20% and 0%, for healthy fetal and adult lung, respectively) 
(p<0.002). Statistical differences were assessed using the Kruskal-Wallis test [194] 
 
Although several genes were not aberrantly methylated in all lung tumor samples, I 
observed statistical significant methylation patterns when analyzing the differential 
methylation in respect to tumor differentiation and tumor type (as assessed by 
pathological review). For two genes (MDK and LAPTM5, Figure 2.2.10), less 
differentiated lung tumors displayed methylation values similar to those observed in 
fetal samples (p<0.005, Kruskal-Wallis test) and differentiated tumors were more 
similar in their methylation to healthy adult lung tissues. MDK exhibited mean 
methylation values of 40% and 50% in fetal lung and poorly differentiated tumors, 
respectively, while being 70% and 80% methylated in healthy adult lung and 
moderately differentiated tumors respectively (Figure 2.2.10, upper panel). LAPTM5 
exhibited mean methylation values of 90% and 80% in fetal lung and poorly 
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differentiated tumors, respectively, and displayed 50% methylation in both healthy 
adult lung and moderately differentiated tumors (Figure 2.2.10, lower panel). 
The region of differential methylation in MDK was located outside of a CpG island at 
the 5’-UTR (950 bp upstream from TSS). Differentially methylated region in LAPTM5 
was located surrounding the TSS. For MDK and LAPTM5 patterns of differential 
methylation in lung cancer resemble those observed in fetal lung. The differential 
methylation observed in less differentiated tumors has a putative application in lung 
cancer diagnosis, as lack of cellular differentiation is indicative of increased tumor 
aggressiveness [195]. 
 
Figure 2.2.10: DNA methylation profiles of MDK and LAPTM5 in poorly differentiated lung 
tumors resemble those observed in fetal lung. MDK (upper panel) displays higher methylation in 
healthy adult lung similar to moderately differentiated tumors (amplicon mean methylation 70% and 
80%, respectively), whereas lower methylation in poorly differentiated tumors and fetal lung 
(amplicon mean methylation 50% and 40%, respectively). LAPTM5 (lower panel) displays lower 
methylation in healthy adult lung and moderately differentiated tumors (amplicon mean methylation 
50% for both groups) while being higher methylated in poorly differentiated tumors and fetal lung 
(amplicon mean methylation 80% and 90%, respectively). Fetal lung profiles in both genes are similar 
to those in poorly differentiated tumors and significantly different to those in moderately 
differentiated tumors (p=0.00499, and p=0.00536 in MDK and LAPTM5, respectively). Statistical 
differences were assessed using the Kruskal-Wallis test [194] 
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The FGFR3 gene was hypermethylated in fetal, healthy adult and most lung cancer 
samples (Figure 2.2.11 and table 2.2.5). However, when comparing the methylation 
between different tumor types, I observed that squamous cell carcinoma samples 
were significantly hypomethylated (mean methylation value 70%; p<0.015, Kruskal-
Wallis test) compared to the rest of the analyzed samples (mean methylation values 
100%, 90% and 100% for healthy adult lung, fetal lung and adenocarcinoma, 
respectively). 
 
 
Figure 2.2.11: FGFR3 is less methylated in squamous cell carcinoma than in healthy adult and fetal 
lung, as well as adenocarcinoma. FGFR3 is significantly (p<0.015, Kruskal-Wallis test) 
hypomethylated in squamous cell carcinoma (SqCC) compared to healthy fetal and adult lung, as well 
as adenocarcinoma (Adc). The examined region displayed a mean methylation of approximately 70% 
in SqCC and a mean methylation of 100%, 90% and 100% in healthy adult lung, fetal lung and Adc 
tumors, respectively. 
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2.3.  Conservation of tissue-specific DNA methylation profiles throughout the 
evolution 
 
2.3.1. Conservation of tissue-specific DNA methylation patterns  in human / 
mouse orthologues 
 
Syntenic regions between human and mouse chromosomes are mapped in genome 
browsers such Ensembl (www.ensembl.org). Syntenic blocks display strong 
conservation of sequence, however little is known about the conservation of tissue-
specific DNA methylation profiles. To study their conservation, I have studied the 
methylation status in 61 human/mouse orthologue regions. By direct sequencing of 
bisulfite-treated DNA, I determined the methylation profiles in four adult mouse 
tissues and compared these values with those retrieved from the Human Epigenome 
Project [67]. Consequently, the results of my experiments presented in this section 
were published as part of the first phase of HEP [67] 
I found that the majority (69.4%) of the studied regions differed by less than 20% 
methylation. This result suggests a significant conservation of DNA methylation 
between human genes and their murine orthologues. 
Table 2.3.1 shows the studied genes and their methylation values in human and 
mouse. I included in the study 61 regions with different sequence homology (55-
100%) and designed PCR fragments for bisulfite-converted DNA. Among the 
selected regions, 24 corresponded to 5’-UTR of annotated genes, while 37 
corresponded to Conserved Non-Genic regions (CNGs). I determined the 
methylation status of those regions in four tissues in human and mouse, heart 
muscle, liver, skeletal muscle and skin. In general, regions that showed 
hypermethylation and no methylation in all four tissues, displayed similar patterns 
in human and mouse. Unlike, tissue-specific methylation was conserved only in four 
orthologous regions.  
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Table 2.3.1: Conservation of DNA methylation profiles in human and murine orthologues 
Position Gene Human Heart Liver 
Sk. 
Muscle Skin Gene Mouse Heart Liver 
Sk. 
Muscle Skin 
Sequence 
homology 
5'-UTR MYO18B 50 100 25 100 Q8C3H0 100 100 75 100 62.5% 
5'-UTR GP1BB 0 0 100 0 Gp1bb 25 25 25 25 69.6% 
5'-UTR HIRA 25 25 25 25 Hira 0 0 0 0 56.7% 
5'-UTR TOMM22 0 0 0 0 Tomm22 0 0 0 ND 69.4% 
5'-UTR HORMAD2 75 75 75 75 Hormad2 75 75 75 75 66.7% 
5'-UTR TIMP3 100 100 100 100 Timp3 100 100 100 100 77.3% 
5'-UTR CSDC2 50 75 50 50 Csdc2 100 50 50 ND 73.0% 
5'-UTR OSM 100 100 10 50 Osm 50 75 75 75 61.8% 
5'-UTR PSCD4 50 50 50 50 Pscd4 50 75 75 75 74.1% 
5'-UTR CRYBB1 100 100 100 100 Crybb1 100 100 75 75 63.8% 
5'-UTR SUSD2 50 25 25 50 Susd2 25 25 25 25 69.6% 
5'-UTR Q6ZRW2 50 100 25 50 Zc3h12d 0 0 0 25 71.8% 
5'-UTR CCDC28A 0 0 0 0 Ccdc28a 0 0 0 0 63.2% 
5'-UTR LACE1 0 0 0 0 Lace1 0 0 0 0 65.7% 
5'-UTR PKHD1 50 50 50 50 Pkhd1 100 50 100 100 65.7% 
5'-UTR GRIK2 25 25 25 50 Grik2 0 0 25 0 73.2% 
5'-UTR WISP3 100 100 100 100 Unannotated 100 100 75 75 59.8% 
5'-UTR VNN1 100 50 50 100 Vnn1 50 50 50 50 67.9% 
5'-UTR SLC22A1 100 50 100 100 Slc22a1 100 50 100 100 82.7% 
5'-UTR TBX18 25 0 50 25 Tbx18 25 25 50 25 59.4% 
5'-UTR TFAP2A 25 25 25 25 Tcfap2a 25 25 25 25 53.1% 
5'-UTR TGM3 75 100 50 100 Tgm3 75 50 50 25 81.7% 
5'-UTR RIN2 0 100 0 0 Rin2 0 100 0 0 82.3% 
5'-UTR NCOA5 0 0 0 0 Ncoa5 0 0 0 0 57.9% 
Intergenic CNG 75 100 25 75 CNG 100 100 75 75 83.2% 
Intergenic CNG 100 100 50 75 CNG 75 100 50 50 72.9% 
Intergenic CNG 100 50 50 100 CNG 100 50 50 100 93.6% 
Intergenic CNG 100 100 100 100 CNG 100 100 100 100 88.6% 
Intergenic CNG 100 75 50 50 CNG 100 100 50 50 86.1% 
Intergenic CNG 100 75 50 50 CNG 100 100 75 50 83.9% 
Intergenic CNG 100 50 100 75 CNG 100 100 100 100 86.1% 
Intergenic CNG 100 100 100 100 CNG 75 75 75 75 81.1% 
Intergenic CNG 0 100 0 0 CNG 100 0 25 0 66.8% 
Intergenic CNG 100 100 100 100 CNG 50 50 50 50 63.3% 
Intergenic CNG 75 75 50 75 CNG 75 75 75 75 76.0% 
Intergenic CNG 0 0 0 0 CNG 100 100 100 100 87.4% 
Intergenic CNG 0 0 0 0 CNG 0 0 0 0 77.2% 
Intergenic CNG 0 0 0 0 CNG 0 0 0 0 69.2% 
Intergenic CNG 75 100 50 100 CNG 75 75 50 75 74.5% 
Intergenic CNG 75 100 50 100 CNG 75 75 50 100 77.2% 
Intergenic CNG 25 100 25 25 CNG 50 50 50 50 71.5% 
Intergenic CNG 25 75 0 25 CNG 50 100 25 50 84.3% 
Intergenic CNG 100 100 100 100 CNG 100 100 100 100 68.5% 
Intergenic CNG 100 100 100 100 CNG 100 100 100 50 83.7% 
Intergenic CNG 100 100 100 100 CNG 100 100 100 100 88.3% 
Intergenic CNG 100 100 100 100 CNG 75 75 75 75 81.8% 
Intergenic CNG 100 100 100 100 CNG 75 75 75 75 84.0% 
Intergenic CNG 100 100 100 100 CNG 100 100 100 100 79.9% 
Intergenic CNG 100 100 100 100 CNG 100 100 100 100 92.6% 
Intergenic CNG 100 100 100 100 CNG 100 100 100 100 95.1% 
Intergenic CNG 75 75 75 75 CNG 75 75 75 75 92.7% 
Intergenic CNG 100 100 100 100 CNG 100 100 75 100 90.7% 
Intergenic CNG 100 100 100 100 CNG 100 100 100 100 94.0% 
Intergenic CNG 100 100 50 75 CNG 100 100 100 100 89.5% 
Intergenic CNG 50 100 50 50 CNG 100 75 50 75 88.9% 
Intergenic CNG 100 100 100 100 CNG 100 100 100 100 72.2% 
Intergenic CNG 100 100 100 100 CNG 100 100 100 100 65.9% 
Intergenic CNG 75 100 50 50 CNG 75 100 50 50 79.6% 
Intergenic CNG 0 0 0 0 CNG 0 0 0 0 67.8% 
Intergenic CNG 25 0 25 25 CNG 0 0 0 0 74.3% 
Intergenic CNG 0 0 0 0 CNG 0 0 0 0 71.0% 
Methylation values were binned in four groups (0, 25, 50 and 100%). ND: Not determined. CNG: Conserved non-genic region.  
Paired regions displaying conserved tissue-specific methylation are in bold. 
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I found conservation of the tissue-specific DNA methylation in the 5’ UTR of 
RIN2/Rin2 genes and in 3 CNGs (Figure 2.3.1). Remarkably, regions displaying 
conservation of methylation between mouse and human also showed high 
conservation of sequence (homology higher than 75%).  
 
 
Figure 2.3.1: Conservation of tissue-specific DNA methylation profiles in human and mouse. 
Conservation of tissue-specific methylation profiles was observed in some gene-associated 5’-UTR 
and conserved non-genic regions. Two examples are shown: RIN2/Rin2 and Chr20p12.3/Chr2F3 
display 82.3% and 93.6% sequence homology, respectively.  Samples are displayed column wise with 
rows representing individual CpGs of the PCR fragment. Quantitative methylation analysis results 
are shown in a color scale ranging from yellow (~0% methylation), green (~50% methylation) to dark 
blue (~100% methylation). 
 
Next, I analyzed the data altogether to detect common trends that might apply to the 
conserved regions. Three different clusters were clearly distinguishable in the 
correlation plots (Figure 2.3.2). Regions showing hypermethylation and no 
methylation are clustered and clearly differentiable, however regions of intermediate 
methylation are much more dispersed (Panel A), suggesting a poorer conservation 
rate in regions of heterogeneous methylation. In addition, human-mouse pairs with 
high sequence homology displayed low methylation differences (Panel B). I did not 
find any difference in conservation neither between the different tissues analyzed 
(Panel A) nor between regions located in the 5’-UTR and CNGs (Panel B), as they are 
dispersed similarly in the plot. 1000X resampling with randomization of the human-
Differential DNA methylation profiles modulating phenotypes 
________________________________________________________________ 
 70 
mouse pairs demonstrated that the observed trends are not stochastic (Panel C). 
Furthermore, histogram of frequencies for the differences in methylation showed 
that low differences in methylation between human and mouse are the most 
frequently observed (Panel D) 
 
 
Figure 2.3.2: DNA methylation is highly conserved between human and mouse.  Correlation of 
methylation of CpGs in mouse and human matched by local alignment of conserved regions. A) High 
and low methylated regions were more conserved than regions with heterogeneous methylation. All 
studied tissues displayed similar rates of conservation, as they were equally dispersed in the plot  
Color code: heart muscle (red), liver (green), skeletal muscle (yellow), skin (blue). B) Human-mouse 
pairs with high sequence homology displayed low methylation differences, with no differences 
regarding to amplicon location Color code: 5’-UTR (green), CNG (red). (C) Data was resampled 1000 
x with replacement randomizing pairs from mouse and human, showing that observed distributions 
were not stochastic. (D) Histogram of frequencies shows that lower methylation differences are the 
most frequent in all studied tissues.  
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2.3.2. Case of study: Methylation and expression in the IGF2R locus in human 
and murine orthologous loci 
 
IGF2R locus is highly conserved between human and mouse. Genes are arranged in 
identical manner (Figure 2.3.2) and share a high sequence homology. In a previous 
section, I have determined that two genes in the human locus (SLC22A1 and PLG) 
displaying novel T-DMRs are not imprinted in healthy adult human tissues (section 
2.1.2).  To gain more knowledge about the methylation status of genes within this 
locus and its conservation in their murine orthologues, I analyzed their methylation 
profiles by direct sequencing of bisulfite-treated DNA in human and mouse tissue 
samples. 
I found that DNA methylation is highly conserved between human and mouse in 
SLC22A1, PLG, SLC22A2, SLC22A3 in agreement with the observed high homology 
of DNA sequence. Unlike, methylation and DNA sequence are low conserved in an 
imprinting controlling region (ICR) of the IGF2R gene. Very interestingly indeed, the 
tissue-specific differential methylation observed in PLG and SLC22A1 in section 2.1.2 
was conserved in mouse. 
Figure 2.3.3 is a schematic view of the IGF2R locus in human (upper panel) and the 
Igf2r locus in mouse (lower panel) and the location of the designed bisulfite-
converted DNA PCR fragments for each gene. 
Genes in the IGF2R locus in human are arranged in the same manner than in the 
murine orthologous locus Igf2r on chromosome 17A2. I designed bisulfite-converted 
DNA PCR fragments for a reported ICR on intron 2 of the IGF2R gene in human, as 
well as the 5’ regions of the SLC22A1, SLC22A2, SLC22A3 and PLG. Moreover, I 
designed PCR fragments for bisulfite-converted DNA in their murine orthologues. 
The examined regions displayed a sequence homology of 57.5% for IGF2R/Igf2r, 
77.9% for SLC22A1/Slc22a1, 80.4% for SLC22A2/Slc22a2, 72.9% for SLC22A3/Slc22a3 
and 65.5% for PLG/Plg.  
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Figure 2.3.3: Genomic structure of the human and mouse IGF2R locus. Schematic representation of 
the IGF2R locus in human (upper panel) and mouse (lower panel). Red Boxes within the IGF2R and 
Igf2r genes represent the annotated imprinted control region (ICR) in intron 2. Purple boxes represent 
the annotated CpG islands (Ensembl v.40) and the orthologous regions analyzed for DNA 
methylation are shown as green boxes. The examined regions displayed a sequence homology of 
57.5% for IGF2R/Igf2r, 77.9% for SLC22A1/Slc22a1, 80.4% for SLC22A2/Slc22a2, 72.9% for 
SLC22A3/Slc22a3 and 65.5% for PLG/Plg. 
 
Figure 2.3.4 shows the methylation status of the studied genes in human (panel A) 
and mouse (panel B) in heart muscle, liver and skeletal muscle. Observed tissue-
specific methylation in SLC22A1 and PLG in human tissues is conserved in mouse. In 
the same manner, both human and mouse tissues showed hypermethylation in the 5´ 
regions of SLC22A2 and no methylation in the 5’ regions of SLC22A3, respectively. 
Unlike, ICR in intron 2 of the human IGF2R gene was hypermethylated in all the 
studied tissues, while the murine orthologue, Igf2r, displayed 50% methylation in all 
the studied tissues. 
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Figure 2.3.4: DNA methylation analysis for genes in the IGF2R locus in human (A) and mouse (B). 
Tissue specific methylation was only observed in PLG and SLC22A1. The observed methylation 
profiles in human are conserved in mouse for Plg, Slc22a1, Slc22a2 and Slc22a3 but not for Igf2r. 
Samples are displayed column wise with rows representing individual CpGs of the PCR fragment. 
Quantitative methylation analysis results are shown in a color scale ranging from yellow (~0% 
methylation), green (~50% methylation) to dark blue (~100% methylation). 
 
Moreover, I studied the expression of IGF2R, SLC22A2 and SLC22A3 genes in human 
skeletal muscle, liver and heart muscle. While IGF2R displayed a highly methylated 
ICR2 and high expression, SLC22A2 displayed high methylation at the 5’-UTR in all 
three tissues and low expression only in skeletal muscle.  In turn, SLC22A3 was 
highly expressed and displayed unmethylation at the 5’-UTR in all studied tissues 
(Figure 2.3.5, panel A). In addition, I confirmed the lack of imprinting of these genes 
by detecting biallelic expression, similarly to that observed in SLC22A1 and PLG. 
(Figure 2.3.5, panel B) 
 
Differential DNA methylation profiles modulating phenotypes 
________________________________________________________________ 
 74 
 
 
Figure 2.3.5: Biallelical expression of IGF2R, SLC22A2 and SLC22A3 in healthy adult tissues. A)  
Results of RT-PCR showing the expression of IGF2R, SLC22A2 and SLC22A3 genes. Similar amounts 
of cDNA were used as indicated by control amplification of actin ß (ACTB). Representative results for 
3 independent samples are shown. Pooled total RNAs derived from tissues and cell lines were used 
as positive control. Colored bars above each gel represent the methylation status, as indicated in 
figure 2.3.4. B) Biallelic expression was analyzed by sequencing of the amplified cDNA and 
identification of heterozygous annotated SNPs. Red arrows mark the position of the annotated SNP 
in each gene. Annotated SNPs (Ensembl v.40) were rs1570070, rs624249 and rs2292334 for IGF2R, 
SLC22A2 and SLC22A3 respectively. Presence of both alleles in the sequenced cDNA indicates 
biallelical expression 
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2.3.3. Conservation of DNA methylation upon gene duplications 
 
The results presented in this section have been sent for publication and are currently 
under editorial review [Cortese R. et al, DNA Methylation in gene duplications leading to 
gene families and pseudogenes, sent to Genomics] 
 
2.3.3.1.  Conservation of DNA methylation in the PLG and TBX gene 
families 
 
PLG gene is a member of a gene family. In order to study whether the observed 
tissue-specific methylation is conserved in the other members of the family, I 
analyzed the methylation status of PLGLA and PLGLB. I found that the 50% 
methylation in liver and its mosaic-like distribution are conserved in both PLGLA 
and PLGLB genes. 
Comparative sequence analysis of PLG in humans showed high homology to three 
variants of the PLG gene family. The PLGLA gene (ENSG00000169659) is located on 
chromosome 2q12.2 and shows 95.8% homology with the PLG gene in its 5’ region 
and exon 1. In turn, two variants of the PLGLB1 gene (ENSG00000125551 and 
ENSG00000183281) are located on chromosome 2p11.2 with a homology of 95% and 
96%, respectively. Figure 2.3.6 shows the alignment of the 5’ regions of the PLG gene 
and the mentioned variants. Primers for the designed bisulfite-converted DNA PCR 
fragment bound to the regions showing no mismatches between the variants. 
However, the fragment contained several mismatches that allowed the identification 
of the variants by sequencing the subcloned PCR fragment (Figure 2.3.6). 
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Figure 2.3.6: High sequence conservation among members of the PLG family. PLG and its 
paralogous genes display high sequence homology as evidenced by genomic sequence alignment of 
the PLG, PLGLA and PLGLB 5’ regions. Sequences analyzed by bisulfite sequencing are underlined. 
Red rectangles highlight the mismatches between the aligned sequences. 
 
Figure 2.3.7 shows the distribution of DNA methylation for PLG, PLGLA and PLGLB 
in subcloned PCR products from liver samples.  As observed in the parental gene, 
methylation in PLGLA and PLGB was distributed in a mosaic manner. Methylation in 
PLG family clones did not correlate with an annotated SNP in this region (rs4252059), 
indicating that these genes are not allele-specifically methylated. 
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Figure 2.3.7: Mosaic distribution of DNA methylation in PLG, PLGLA and PLGLB in liver. CpG 
sites in the subcloned PCR products were either all methylated or all unmethylated. Numbers indicate 
the position of each CpG relative to the corresponding transcription start site (TSS) (Ensembl NCBI 
40). Filled and empty circles represent methylated and unmethylated CpGs, respectively. Dashed 
circles indicate CpG positions lost due either to sequence polymorphism (in PLG gene) or sequence 
mismatches with PLG (PLGLA and PLGLB genes). Alleles were identified by an annotated SNP 
(rs4252059) within the amplified sequence for PLG or the equivalent polymorphism in PLGLA and 
PLGLB. 
 
Expression analysis in matched RNA samples by RT-PCR and further sequencing of 
the cDNA fragments  (Figure 2.3.8) revealed that, like PLG, PLGLA and PLGLB are 
expressed in liver (showing 50% methylation) but silenced in skeletal muscle and 
heart muscle (showing 100% methylation). The high sequence homology of the 
transcribed mRNAs made impossible to distinguish between them simply by 
designing different RT-PCR fragments. To approach this issue, I first designed a 
fragment, which allowed the amplification of all three variants (Figure2.2.8, panel A). 
This fragment amplified only in liver samples, suggesting that all three variants were 
expressed only in liver. The presence of 12 mismatches between the PLG, PLGLA and 
PLGLB transcripts allowed the verification of the expression of all variants by 
sequencing the amplified cDNA. Figure 2.2.8 panel B, shows the possible 
polymorphisms for each studied mismatch. In addition, it shows an example of the 
obtained trace file. Two mismatches, MM6 (A/G) and MM7 (A/C), confirming the 
expression of PLG and, at least, PLGLA or PLGLB. Combinatorial analysis with other 
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mismatches (data not shown) demonstrated that all three variants are expressed in 
liver. 
 
 
 
Figure 2.3.8: PLG and its paralogous genes are expressed only in liver. A) A fragment allowing the 
amplification of all three variants (PLG, PLGLA and PLGLB) display the same expression than a 
fragment specific for PLG. B) The combinatorial analysis of 12 mismatches between PLG, PLGLA and 
PLGLB allowed the verification of the expression of all three variants.  Example of only two proximal 
mismatches (MM6 and MM7, red square and arrows) is shown. Amplified RT-PCR fragment were 
directly sequenced as detailed in materials and methods. 
 
Hence, all variants displayed a correlation between hypermethylation of the 5’ region 
and the silencing of the gene. The presence of several mismatches in the alignment of 
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the studied sequences allowed inferring the methylation and expression status of the 
three variants as well as the identity of the expressed transcript (Figures 2.3.7 and 
2.3.8). However, because the two PLGLB1 variants differ by only one mismatch in the 
coding region with no homology to PLG (data not shown), I could not assess whether 
there are differences in methylation and expression between both PLGLB1 variants, 
ENSG00000125551 and ENSG00000183281. 
In contrast to the PLG gene duplicates that arose recently in the hominoid lineage, 
the TBX family arose early during evolution and is present in vertebrates, 
invertebrates and protostomes (e.g. Drosophila melanogaster and Caenorhabditis 
elegans). To further examine the methylation profiles in this large gene family I 
selected 15 genes from four subfamilies (Tbr1 subfamily: TBX21, EOMES and TBR1; 
Tbx1 subfamily: TBX1, TBX10, TBX22, TBX18, TBX15 and TBX20; Tbx2 subfamily: 
TBX2, TBX3, TBX4 and TBX5; Tbx 6 subfamily: MGA and TBX6) and performed 
DNA methylation profiling of their 5’-UTR in 8 different tissues and primary cells 
(Figure 2.3.9). Most of the genes and tissues were unmethylated with TBX10 being 
the most prominent exception. Out of these genes, 7 (TBX10, TBX1, TBX18, TBX15, 
TBX4, TBX5 and TBX21) were differentially methylated in at least one of the tissues, 
but none of the genes showed an identical methylation pattern. In particular, 
differential methylation was evident in genes displaying a shorter evolutionary 
distance. For example, TBX1 was hypermethylated in melanocytes, fibroblasts and 
skeletal muscle while being unmethylated in the remaining tissues. The closely 
related TBX10 gene was hypermethylated in most of the tissues but four CpGs (93, 
104, 119 and 139 bp upstream from the TSS) were unmethylated. Similarly, genes of 
the Tbx 2 subfamily were differentially methylated as well. Genes such as MGA and 
TBR1 that are more distant from other family members displayed no differential 
methylation. 
 
Differential DNA methylation profiles modulating phenotypes 
________________________________________________________________ 
 80 
 
Figure 2.3.9: Methylation profiling of TBX gene family members. Methylation profiles of 15 genes 
of the TBX transcription factor family and their evolutionary relation are shown. The 15 genes are 
from four subfamilies (Tbr1 subfamily: TBX21, EOMES and TBR1; Tbx1 subfamily: TBX1, TBX10, 
TBX15, TBX18, TBX20 and TBX22; Tbx2 subfamily: TBX2, TBX3, TBX4 and TBX5; Tbx 6 subfamily: 
MGA and TBX6). Closely related TBX genes display complementary methylation profiles (e.g. 
TBX1/TBX10 and TBX2/TBX3). The evolutionary more distant MGA and TBR1 are not differentially 
methylated in the tissues examined.  Phylogenetic relations within the TBX family were previously 
described in [196]. 
2. Results 
_____________________________________ 
 81
2.3.3.2.  Conservation of DNA methylation in pseudogenes 
 
To further study the conservation of DNA methylation upon gene duplication, I 
examined the methylation profiles of processed and unprocessed pseudogenes. In 
agreement with the observed in the PLG gene family, I found that tissue-specific 
DNA methylation observed in the parental genes is conserved in some unprocessed 
pseudogenes, which derive from gene duplications. Unlike, I did not find such 
conservation in processed pseudogenes, which derive from the insertion of 
retrotransposons in the genome.  
Table 2.3.2 summarizes the observed values for DNA methylation in processed and 
unprocessed pseudogenes and their respective parental genes, as well as the 
sequence homology in the studied regions.  
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Table 2.3.2: Methylation values for pseudogenes and their respective parental genes. 
 
Pseudogene 
Name 
Sample 1 
Methylation1 
Sample 2 
Methylation 
Parental 
Gene 
Sample 1 
Methylation 
Sample 2 
Methylation 
Sequence 
Homology 
Distance 
Ψ−ΙΝ 
 
Type 
Pseudogene 
AP000357.2 100% 0% ACTR2 100% 100% 57.10% 0.61995 Processed 
AP000357.3 100% 25% ARL5A 0% 0% 92.30% 0.0279 Processed 
RP11-758C21.1 100% 50% BDH2 100% 100% 96.60% 0.0285 Processed 
RP1-181C9.1 100% 25% ANP32B 0% 0% 71.40% 0.2568 Processed 
AP000358.2 100% 25% FN3K 100% 50% 87.70% 0.0525 Processed 
CTA-229A8.2 100% 50% GAPDH 50% 50% 62.50% 0.11345 Processed 
AC007050.7 100% 100% POM121L3 100% 100% 96.80% 0.0693 Processed 
RP3-412A9.4 100% 50% SNRPN 100% 100% 88.10% 0.1189 Processed 
KB-1269D1.3 100% 25% MAD1L1 100% 75% 95.10% 0.021 Processed 
AC000078.2 100% 25% RPL8 100% 75% 65.90% 1.17195 Processed 
AC004019.3 100% 50% LOC376522 75% 50% 84.00% 0.2314 Processed 
CTA-373H7.4 100% 0% HBLD1 0% 0% 99.50% 0.0375 Processed 
CTA-373H7.4 100% 0% HBLD1 75% 75% 75.80% 0.16795 Processed 
RP1-47A17.8 100% 25% ADAMTS7 100% 100% 84.50% 0.13465 Processed 
RP1-106I20.2 100% 100% NDUFA9 100% 100% 94.10% 0.07255 Processed 
AC004471.4 100% 100% NM_032028.2 100% 100% 82.80% 0.15665 Processed 
RP3-405J24.1 100% 100% RPL12 100% 50% 92.20% 0.06145 Processed 
CTA-150C2.8 100% 50% APOBEC3G 100% 100% 64.30% 0.27425 Unprocessed 
CTA-246H3.2 0% 0% LRP5 0% 0% 89.10% 0.13055 Unprocessed 
RP4-539M6.7 100% 25% SLC39A1 100% 25% 84.80% 0.1258 Unprocessed 
KB-1592A4.6 100% 100% BCR 100% 100% 97.20% 0.0212 Unprocessed 
KB-1995A5.12 100% 50% Q6UW61 100% 50% 94.40% 0.0183 Unprocessed 
RP11-34P13.1 100% 100% DDX11 75% 75% 71.30% 0.192 Unprocessed 
RP11-223J15.2 100% 100% EEF1A2 50% 50% 64.30% 0.5787 Unprocessed 
RP4-732G19.2 100% 100% CYP4Z1 100% 100% 88.80% 0.147 Unprocessed 
RP11-552J9.1 100% 100% XAGE2 100% 100% 72.60% 0.307 Unprocessed 
BMS1LP6 100% 100% BMS1L 100% 100% 89.10% 0.12695 Unprocessed 
CTSLL3 75% 75% CTSL 75% 75% 89.30% 0.11065 Unprocessed 
RP11-432I13.3 75% 100% CUBN 100% 75% 89.40% 0.0983 Unprocessed 
RP11-453N3.6 75% 75% ABCD1 75% 75% 95.40% 0.04085 Unprocessed 
RP11-392A23.3 50% 50% GSTA1 100% 100% 83.70% 0.1901 Unprocessed 
NM_002688.4 0% 100% SEPT5 0% 0% 53.50% 0.6047 Unprocessed 
 
 
 
                                                 
1 DNA methylation values corresponding to two paired samples being tissues (liver, skeletal muscle and heart muscle) or 
primary cells (keratinocytes, fibroblasts, melanocytes and CD4+ lymphocytes) per parental gene-pseudogene pair. The selection 
was based on pseudogenes, for which our group had previously detected tissue specific methylation [67]. The values shown are 
the median of all CpGs position within the PCR fragment rounded to 0, 25%, 50%, 75% and 100%, respectively 
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Pseudogenes are distributed through the genome and, in many cases, the paralogous 
parental gene have been described. I selected 32 pseudogenes displaying differential 
methylation in human healthy adult tissues from a large scale study [67]. Next, I 
selected the corresponding parental genes according to its annotation in the 
Vertebrate Annotation Database (VEGA) [197] and determined their methylation 
status by direct sequencing of bisulfite-converted DNA in regions of high sequence 
homology. In total, I have included the in the analysis 15 unprocessed pseudogenes 
and 17 processed pseudogenes and their parental genes. To search for conservation 
of tissue specific methylation, I have analyzed the methylation status of each pair in 
two healthy adult human tissue (skeletal muscle, liver and heart muscle) or primary 
cells (fibroblasts, melanocytes, keratinocytes and CD4+ lymphocytes). 
 
Unprocessed Pseudogenes 
 
Unprocessed pseudogenes derive from the parental gene after genome duplication 
and further rearrangements and mutations [75]. Among the 15 unprocessed 
pseudogenes analyzed, five (33%) showed tissue-specific methylation in at least one 
examined tissue. For two pseudogenes, RP4-539M6.7 and KB-1995A5.12, this 
differential methylation was conserved in the respective parental genes, SLC39A1 
and Q6UW61_HUMAN. Six (40%) unprocessed pseudogenes and their respective 
parental genes were hypermethylated in both tissues, while one (7%) pseudogene-
parental gene pair was unmethylated in the analyzed tissues. The remaining 3 
unprocessed pseudogenes (20%) and their respective parental genes displayed 
heterogeneous methylation values ranging from 25% to 75%. In no case, I found a 
parental gene displaying tissue-specific methylation, while the respective 
unprocessed pseudogene had lost the differential methylation. 
 
Pairs displaying tissue specific methylation 
 
The parental gene SLC39A1 and its unprocessed pseudogene RP4-539M6.7 showed 
100 % and 25 % methylation in liver and keratinocytes, respectively. Alike, the gene 
Differential DNA methylation profiles modulating phenotypes 
________________________________________________________________ 
 84 
coding for the Q6UW61_HUMAN protein and its unprocessed pseudogene KB-
1995A5.12 showed 100 % methylation in liver while 50 % methylation in skeletal 
muscle. 
Figure 2.3.10 illustrates the conservation of T-DMRs in parental genes and 
unprocessed pseudogenes, taking as an example the Q6UW61_HUMAN/KB-
1995A5.12 pair, for the unprocessed pseudogene (panel A) and the parental gene 
(panel B). In addition, the figure also shows the position of both analyzed fragments. 
Despite the very high sequence homology (> 94 %), the fragment corresponding to 
the parental gene is located in the intron 2, while the corresponding to the 
unprocessed pseudogenes is located in its 5’-UTR. Further analysis of the sequences 
surrounding the studied regions in both, parental gene and pseudogene, revealed 
that they were highly homologous (>95 %). Moreover, the parental exon 3 is highly 
similar to the exon 1 of the pseudogene, and the exon-intron architecture of the 
unprocessed pseudogene resembles that observed in the parental gene. These 
observations suggest that the accumulated mutations after duplication might have 
affected critical sequence motifs within the coding region (i.e. splicing signals) 
leading to the generation of new transcripts, despite the high sequence homology in 
general. 
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Figure 2.3.10:  Conservation of tissue specific methylation in an unprocessed pseudogene / parental gene 
pair. A and B) The T-DMR of the unprocessed pseudogene KB-1995A5.12 (A) is conserved in its parental gene 
Q6UW61_HUMAN (B). The positions of the analyzed regions are shown. Liver samples are hypermethylated in 
both regions, while skeletal muscle samples display 50% methylation.  Rows represent individual samples with 
columns representing individual CpGs positions along the PCR fragment. Quantitative methylation analysis 
results are shown in a color scale ranging from yellow (~0% methylation), green (~50% methylation) to dark 
blue (~100% methylation). The position of each analyzed fragment is depicted according Ensembl v40 
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SLC39A1 and its unprocessed pseudogene displayed also conservation of the tissue 
specific methylation. Similarly to the observed in Q6UW61_HUMAN, regions of high 
sequence homology are located in the 5’-UTR in the unprocessed pseudogene and in 
the coding region in the parental gene. However, in this case there were not a 
relation between analyzed fragment and the architecture of both transcripts.  
The unprocessed pseudogene CTA-150C2.8 displayed tissue specific methylation 
(hypermethylation in liver, 50 % methylation in skeletal muscle), but its parental 
gene, APOBEC3G, was hypermethylated. Studied regions were located in the 5’-UTR 
for the unprocessed pseudogene and in the coding region for the parental gene. 
These regions showed relatively low sequence homology (57%). In the same manner, 
the unprocessed pseudogene NM_002688.4 displayed tissue specific methylation 
(unmethylation in liver, hypermethylation in skeletal muscle) in its 5’-UTR, while its 
parental gene, SEPT5, was unmethylated in intron 1 in both analyzed tissues. 
Analyzed regions also showed low sequence homology (54%). Very interestingly, 
parental gene and pseudogene are located consecutively on chromosome 22 and both 
analyzed regions are within the same CpG island. 
The RP11-432I12.3 unprocessed pseudogene displayed tissue specific methylation, 
75% in liver and 100% in skeletal muscle. Noteworthy, its parental gene, CUBN, 
displayed also specific methylation in the studied tissues, but in an inverted manner 
(100% in liver and 75% in skeletal muscle). Studied regions showed high sequence 
homology (89%) and were located in the last intron of both genes (intron 6 and intron 
66, for the unprocessed pseudogene and parental gene, respectively).  
 
Pairs displaying hypermethylation 
 
In all cases, studied regions were located in the coding region of both, unprocessed 
pseudogene and parental gene. Out of 6 studied pairs, 4 displayed conservation of 
the hypermethylation in both tissues for the unprocessed pseudogene and the 
parental gene. These 4 pairs showed also high sequence homology (>72 %). Unlike, 2 
pairs not showing conservation of the hypermethylation were those with the lowest 
sequence homology (71% and 64%). 
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The studied region in the RP11-34P12.1 pseudogene contained a part of intron 2, the 
whole exon 3 and a part of the intron 4. It showed hypermethylation in both studied 
tissues, liver and skeletal muscle. In turn, the studied region on its parental gene, 
DDX11, contained a part of intron 23, the whole exon 24 and a part of the intron 24. 
The registered methylation values were lower (75%) than in the unprocessed 
pseudogene and no tissue-specific methylation was found. 
Differences were still more pronounced between the unprocessed pseudogene RP11-
223J15.2 and its parental gene, EEF1A2. Studied region in the unprocessed 
pseudogene consisted of the whole exon 2 and part of the intron 2, while that for the 
parental gene contained part of intron 1 and exon 2.  Both regions shared relatively 
low sequence homology (64 %) 
 
Pairs displaying unmethylation  
 
In only one pair both, unprocessed pseudogene and parental gene, showed 
unmethylation. The studied region in the unprocessed pseudogene CTA-246H2.2 
was located in an annotated CpG island in the 5’ end of the transcript. For its 
parental gene, LRP5, I studied also a CpG island located in the 5’ end of the 
respective transcript. Both regions showed high sequence homology (89 %) and were 
unmethylated in liver and skeletal muscle. 
 
Pairs displaying heterogeneous methylation  
 
Among the remaining 3 analyzed pairs, CTSL and its unprocessed pseudogene, 
CTSLL3, showed 75% methylation in both analyzed tissues (liver and skeletal 
muscle). Both studied regions were located in the coding region (exon 2-3 and exon 
3-4, respectively) and shared high sequence homology (89%)  
Likewise, the parental gene ABCD1 and its unprocessed pseudogene, RP11-453N.6, 
showed 75% methylation in liver and skeletal muscle. In this case, studied regions 
were located also in coding regions for both genes, exons 2-3 for the pseudogene and 
exons 7-8 for the parental gene and shared high sequence homology (95%) 
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Unlike, the unprocessed pseudogene RP11-392A22.3 displayed 50% methylation in 
liver and skeletal muscle, but its parental gene, GSTA1, was hypermethylated in 
these tissues. For this pair, studied regions were also located in the coding regions, 
part of intron 5 and exon 6 for both genes, and were highly homologous (83 %). 
 
Processed Pseudogenes 
 
Processed pseudogenes derive from retrotransposition of the parental gene and 
incorporation into the genome [75]. Among the 17 analyzed processed pseudogenes, 
13 (76%) displayed tissue- specific methylation, while 4 (24%) were hypermethylated. 
I did not found conservation of the tissue- specific methylation between the 
processed pseudogenes and their respective parental gene.  
 
Pairs displaying tissue- specific methylation 
 
Despite the high number of pairs analyzed, I did not find any pair where the 
differential methylation found in the processed pseudogene was conserved in the 
respective parental gene.  
Figure 2.3.11 shows an example of the lack of conservation of the tissue- specific 
methylation observed in processed pseudogenes. Panel A shows the position of the 
analyzed region in the processed pseudogene AP000357.3 and the observed 
methylation. The analyzed fragment was located at the 5’ end of the transcript and 
tissue-specific methylation was observed between fibroblasts (0-25%) and 
keratinocytes (75-100%). Such differential methylation was not observed in the 
respective parental gene, ARL5, amid the high homology of both analyzed sequences 
(92%). Panel B shows the position of the analyzed region in the parental gene and the 
observed unmethylation in both cell types, fibroblasts and keratinocytes. 
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Figure 2.3.11: Tissue-specific methylation is not conserved in processed pseudogene / parental gene 
pairs. A and B) The T-DMR located within the processed pseudogene AP000357.3 (A) is not conserved 
in its parental gene ARL5A (B). The processed pseudogene is unmethylated (<20%) in fibroblasts and 
hypermethylated (>80%) in keratinocytes. In contrast, the parental gene is unmethylated in both cell 
types. Methylation values and fragment positions are shown as in figure 2.3.10. 
 
The studied region in the CTA-373H7.4 processed pseudogene surrounded the TSS. I 
found differential methylation between CD4+ lymphocytes (hypermethylated) and 
fibroblasts (unmethylated). Besides the very high sequence homology (99%), the 
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studied region in the parental gene, HBLD1, was located within an annotated CpG 
island. The parental gene did not display differential methylation being both cell 
types unmethylated.  
CTA-229A8 displayed hypermethylation in CD4+ lymphocytes and 50% methylation 
in skeletal muscle. Very interestingly, its annotated parental gene was the 
housekeeping gene GAPDH, which showed 50% methylation in both tissues. 
Sequences of the studied regions were 62 % homologous.   
AP000357.2 displayed hypermethylation in liver while unmethylated in sperm at the 
5’ end of the transcript. The studied region displayed low sequence homology (57%) 
with the respective parental gene, ACTR2, which showed hypermethylation in both 
tissues. 
Similarly, the processed pseudogene RP11-758C21.1 showed tissue specific 
methylation at the 5’ end of the transcript (100% methylation in CD4+ lymphocytes 
and 50% methylation in fibroblasts). However, the region of high homology (96%) of 
sequence in its parental gene, BDH2, displayed hypermethylation in both analyzed 
tissues. 
A region comprising the exon 1 and part of the 5’ UTR of the processed pseudogene 
RP1-181C9.1 displayed hypermethylation in liver and 25 % methylation in 
keratinocytes. The region 5’ region of its parental gene, ANP32B, displayed high 
sequence homology (71%), however was unmethylated in both tissues. 
The whole transcript and a part of the 5’UTR of the AP000358.2 pseudogene showed 
differential methylation between melanocytes (25%) and CD4+ lymphocytes 
(hypermethylation). Its parental gene, FN3K, shared high sequence homology within 
the coding region (88%). CD4+ lymphocytes showed also hypermethylation of this 
region, but melanocytes displayed 50% methylation. 
RP3-412A9.4 processed pseudogene displayed hypermethylation in its 5’ region in 
CD4+ lymphocytes, while 50% in skeletal muscle. The 5´ region in its annotated 
parental gene, SNRPN, was highly homologous (88%), but displayed 
hypermethylation in both samples. 
KB-1269D1.3 displayed tissue specific methylation in the 5’-UTR. Studied region was 
hypermethylated in CD4+ lymphocytes and 50% methylated in keratinocytes. The 
annotated parental gene for this processed pseudogene was MAD1L1. Both studied 
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regions displayed 95% sequence homology. The parental gene showed 
hypermethylation in lymphocytes but 75% methylation in keratinocytes. 
Similarly, AC000078.2 displayed differential methylation in its 5’-UTR that was lost 
in its parental gene, RPL8. Studied regions were 66% identical. Although both genes 
displayed hypermethylation in liver, the processed pseudogene showed 25% 
methylation in fibroblasts and the parental gene 75 %in same samples. 
Regions surrounding the TSS were highly homologous (84%) between the processed 
pseudogene AC004019.3 and its annotated parental gene LOC376522. The 
pseudogene displayed differential methylation in liver (100%) and fibroblasts (50%). 
The parental gene showed 75% methylation in liver and 50% in fibroblasts in the 
studied region. 
RP1-47A17.8 showed hypermethylation in liver and 25 % methylation in fibroblasts 
at the 5’end. Region of high homology (84%) in the parental gene was located in the 
coding region of its parental gene NP_055087.2. This region lost the differential 
methylation being hypermethylated in both studied tissues. 
 
Pairs displaying hypermethylation 
 
4 processed pseudogenes showed hypermethylation in both analyzed tissues. In 3 of 
them, I also observed hypermethylation in the respective parental gene. Very 
interestingly however, RP3-405J24 showed hypermethylation in liver and 
keratinocytes, but its parental gene, RPL12, showed tissue specific methylation (100% 
in liver and 50% in keratinocytes, respectively). Studied regions were highly 
homologous (92%) 
Studied regions in AC007050.7 and its parental gene, POM121L3, were 
hypermethylated in liver and fibroblasts. They were 96% homologous. 
Similarly, an intragenic region showing high sequence homology (94%) in RP1-
106I20.2 pseudogene and its parental gene NDUFA9 was hypermethylated in liver 
and skeletal muscle. 
AC004471.4 was hypermethylated in CD4+ lymphocytes and fibroblasts. Alike, its 
parental gene NM_032028.2 was hypermethylated in both tissues. Studied regions 
shared an 82% homology in their sequences. 
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2.3.3.3.  DNA methylation profiles in duplicated genomic sequences and 
their relation to evolutionary distances 
 
To investigate the relation of the DNA methylation in duplicated sequences and the 
time of duplication, I determined the evolutionary distance between the 
pseudogenes and they respective parental genes.  
Figure 2.3.12 shows examples of the obtained radial trees and the calculated DNA 
distances for PLG and TBX families, as well as pairs of parental gene with processed 
or unprocessed pseudogenes. 
 
 
Figure 2.3.12 Examples of DNA distances between gene variants and pseudogene / parental gene 
pairs. DNA distances were calculated using the PHYLIP software and results are represented as a 
radial tree for each gene pair. The distance between the internal node and the duplicated gene or 
pseudogene is indicative for the evolutionary distance to the parental gene. Examples of distances 
from the internal node are shown for the PLG variants (0.0313 and 0.0209, for PLGLA and PLGLB, 
respectively, upper panel), the TBX1/TBX10 (0.2346) pair and unprocessed (0.0183) and processed 
pseudogenes (0.0856, lower panel). The DNA distance observed for TBX1/TBX10 (0.2346) is about 10 
times larger than those observed in the PLG family. 
 
Processed and unprocessed pseudogenes displayed a wide range of distances, 
regardless their type (Table 2.3.2). I did not find any differences in distribution of 
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DNA distance values between processed and unprocessed pseudogene (p=0.86532 
One-way ANOVA Test – Bonferroni Corrected) (Figure 2.3.13) 
 
 
Figure 2.3.13: DNA distances to the parental gene are similar in processed and unprocessed 
pseudogenes. Box plots comparing the calculated DNA distances obtained using the PHYLIP 
algorithm. Both populations are not significantly different (p=0.86532, One-way ANOVA Test – 
Bonferroni Corrected) 
 
DNA distances for the variants of the PLG gene showed similar distances, 0.0313 and 
0.0209 for PLGLA and PLGLB, respectively. As PLGLB orthologues exist in 
Chimpanzee (Pan troglodytes) but not in old world monkey (Maccaca mulatta) and 
within the Eutheria infraclass, it can be estimated that the PLG duplication occurred 
after the hominid-cercopithecoid divergence, some 29-35 million years ago [198]. In 
contrast, the evolutionary distance of the TBX1 and TBX10 pair (0.2346) is about 10 
times larger than the one observed for PLG and these genes are present as well in 
other mammals such as mice indicating that this duplication occurred at least 80-130 
million years ago [199]. 
I have calculated the DNA distances according to the Jukes-Cantor model [200]. This 
model assumes that all substitutions, transitions and transversions, are equally likely 
to happen. Therefore, the calculated distance is an estimate of the divergence time 
between both sequences. In the Jukes-Cantor model the obtained estimate is a 
maximum likelihood estimate.  
To calculate the distances between the analyzed sequences, I computed DNA 
distance matrices for each pair using the chimpanzee orthologue of the parental gene 
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as an “outgroup”. Human and chimpanzee genomes have a very close evolutionary 
relationship, with an average nucleotide divergence of 1.2% [201]. Although the 
chimpanzee genome is not as well annotated as the human genome, it offered the 
chance to control whether the studied pairs had similar mutation rates. 
Consequently, pairs included in the study were only those from confirmed 
orthologues (as retrieved from Ensembl Database v40) and showing similar distances 
between the human and chimpanzee genes.  
I have chosen to use unrooted phylogenetic trees to represent the results. Since only 
three sequences are under study, a triangular configuration with a determined 
internal node (IN) is the only one possible. Hence, distances from each sequence to 
the IN can be easily calculated (see details in Materials and Methods). This 
configuration allows comparing the distances to the internal node between trios of 
human/chimpanzee/duplicated sequence. Due to this simple configuration and the 
high homology of the analyzed sequences, e.g. PGL human/PLG 
chimpanzee/PLGLA human trio displayed 20 mismatches in 289 nucleotides, 
resampling controls were not necessary. In such controls, e.g. bootstrapping, random 
dataset are created out of the original dataset and the entire possible configuration 
tested [202]. 
Next, I analyzed the conservation of DNA methylation in each tissue in its 
dependency to the evolutionary distance of the PLG variants, the TBX1/TBX10 pair 
and the pseudogene - parental gene pairs (Figure 2.3.14). In this analysis, conserved 
methylation was assigned if the methylation values from the respective gene pair 
differed by less than 20% between measurements in the same tissues. For both, 
unprocessed and processed pseudogenes, I observed a lack of methylation 
conservation for most of the tissues and pseudogenes examined. This lack of 
conserved methylation was evident as well for pseudogene - parental gene pairs that 
arose fairly recently as evidenced by a short evolutionary distance (Figure 2.3.14, 
panel A). Conserved T-DMRs were only observed for two unprocessed 
pseudogenes/parental gene pairs (see above) and for the PLG variants. Notably, 
these pseudogenes displayed a rather short evolutionary distance to their parental 
genes (0.1258 and 0.0183 for the RP4-539M6.7/SLC39A1 and LL22NC03-31F3.7/ 
Q6UW61_HUMAN pairs, respectively). In addition, I analyzed if pseudogenes are 
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preferentially hypermethylated or hypomethylated compared to their parental genes 
finding no evidence that the analyzed pseudogenes became persistently 
hypermethylated (Figure 2.3.14, panel B). I found pseudogenes that were both 
hypomethylated and hypermethylated when compared to the cognate parental gene. 
Although the analyzed number of gene pairs is too small to generalize this 
observation, I observed a trend indicating that hypermethylated processed 
pseudogenes were evolutionarily more distant to their parental genes than 
unmethylated processed pseudogenes. 
 
 
Figure 2.3.14: Relations between the conservation of DNA methylation and evolutionary distances. 
A) Relation between tissue-specific DNA methylation conservation and DNA distance in gene families 
and unprocessed and processed pseudogenes. Pairs displaying conservation of methylation are 
among those showing the shorter distances. B) DNA methylation transitions in gene duplications. The 
methylation profiles from the parental genes were compared to the respective gene variants and 
pseudogenes. Many of the parental genes displayed the same methylation values compared to their 
respective pseudogenes in each individual tissue. Hypermethylated processed pseudogenes exhibit 
larger DNA distances to the parental genes than unmethylated processed genes. Black rhombuses, 
white circles, gray triangles and black squares represent unprocessed pseudogenes, processed 
pseudogenes, PLG gene variants and the TBX1/TBX10 pair, respectively. Y- Axis: DNA distances to 
the internal node calculated by PHYLIP algorithm. 
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2.4. Interaction of Genetic and Epigenetic variations in disease  
 
2.4.1. Case of study: DNA Methylation profiles in Progeria and FPLD 
patients 
 
Although it represents an inherent idea of epigenetic regulation, little is known about 
how the epigenetic layer of control interacts with the genetic background in the 
development of a diseased phenotype, discussed in [173] [174]. In this regard, 
progeroid syndromes represent an excellent model to study such interaction.  
As described in the introduction, mutations in the LMNA (lamin A/C) gene are 
recognized as an etiological factor for several laminopathies displaying progeroid 
features [175]. However, the underlying mechanisms are not clear. Moreover, 
patients displaying distinct phenotypes, as different as to be considered different 
syndromes, bear the very same mutation.  Thus, I studied the methylation profiles of 
10 genes selected from the literature to investigate whether they are connected to the 
distinct phenotypes observed in Familial Partial Lipodystrophy (FPLD) and 
Hutchinson-Gilford syndrome (Progeria). The results of my experiments presented 
in this section have been published in a peer-reviewed scientific journal [266]. 
Progeroid syndromes are characterized by a premature ageing of the affected 
patients (OMIM ID: 176670). Interestingly, variations in DNA methylation have been 
widely reported as correlating with age [180]. In this regard, I selected from the 
literature a panel of 9 age-related candidate genes plus the LMNA gene itself, to look 
for methylation variations on them. 
The panel of analyzed genes consisted of the following genes:  Chondroitin Sulfate 
Proteoglycan 2 (Versican) (CSPG2), Estrogen Receptor 1 (ESR1), Insulin-like Growth 
Factor 1 Receptor (IGF1R), Insulin-like Growth Factor 2 Receptor (IGF2R), Lamin 
A/C (LMNA),  MutL Homologue 1 (MLH1), RAN binding protein 1 (RANBP1), 
Retinoic Acid Receptor, Beta (RARB), Zinc Metallopeptidase (STE24 homologue, 
yeast) (ZMPSTE24), and Transforming Growth Factor, Beta Receptor I (activin A 
receptor type II-like kinase, 53kDa) (TGFBR1).  
Individuals included in the study belonged to three groups, as described in Material 
and Methods, the “FPLD group”, the “Progeria group” and the “Control group”. 
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DNAs were isolated from cultured B- Lymphoblastoid cells from these individuals 
(see culture description in Material and Methods). Table 4.1.1 in Materials and 
Methods section summarizes the phenotypes and genotypes of the included 
individuals. 
The ten investigated genes showed low methylation in all samples, regardless of the 
group they belong, with methylation rates ranging between 0 and 30 % (Figure 2.4.1). 
However, two results were remarkable. The RARB gene showed a significantly 
higher methylation in all 6 patients of the “FPLD group” when compared to the 
patients of the “Progeria group” as well as the “Control group”. In addition, LMNA 
was clearly but not significantly lower methylated in patients 1 – 3 (Family A) than in 
patients 4 – 6 (Family B) within the “FLDP group”.   
 
Differential DNA methylation profiles modulating phenotypes 
________________________________________________________________ 
 98 
 
Figure 2.4.1: DNA methylation profiles for 10 candidate genes in all included individuals. In 
general genes displayed low DNA methylation values. RARB1 was highly methylated in FPLD 
patients than in Progeria patients or healthy individuals. LMNA was differentially methylated in 
FPLD patients members of two families bearing different mutations. Color code for methylation 
values ranges from yellow (~0%) to dark blue (~100%). p-values represent the results of Wilcoxon test 
and are shown in a color code. Green cells corresponds to p<0.05 meaning significant differences and 
black cells corresponds to p>0.05, meaning non-significant differences.  
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Figure 2.4.2 shows the methylation profiles for the RARB gene in more detail. The 
RARB gene encodes 2 different protein isoforms that arise by alternative usage of two 
promoters: RARB1 and RARB2. Three transcripts for this gene are annotated in the 
Ensembl Database, a long transcript (ENST00000264330) and two shorter transcripts 
(ENST00000330688 and ENST00000383772), probably regulated by promoter 1 (P1) 
and promoter 2 (P2), respectively. Differential methylation of P2 correlates with gene 
silencing of the RARB2 isoform in several cancer cell lines [203] and represents one of 
the best studied T-DMRs in epigenetic studies.The region I have studied was located 
in P2, upstream to the short transcript and in intron 1 of the long transcript.  
Patients in the FPLD group displayed 50% methylation, while those in the “Progeria 
goup” and the “Control goup” displayed unmethylation of the studied region. 13 out 
of 16 investigated CpG dinucleotides showed significantly higher methylation values 
in FPLD patients than in Progeria patients (p<0.05, Wilcoxon Test). Similarly, 15 out 
of 16 investigated CpG dinucleotides displayed higher methylation values in FPLD 
patients compared to healthy individuals.  
 
 
Figure 2.4.2:  RARB is highly methylated in FPLD patients compared to progeria patients and 
healthy individuals. FPLD patiens displayed 50% methylation in P2 promoter of the RARB gene, 
whereas this region was unmethylated in progeria patients and healthy individuals.  
 
Although sharing the same clinical signs, affected members of both families in the 
“FPLD group” beared different mutations. Interestingly, I found also methylation 
differences when I compared the members of both FPLD families. Studied region in 
the LMNA gene displayed 50 % methylation in the affected members of the Family B 
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(carrying the R471G mutation) and unmethylation in affected members in Family A 
(carrying the R482L mutation)  (Figure 2.4.3). The studied region was a CpG island 
comprising the exon 1 and part of the 5’ upstream region of the LMNA gene. Though 
clearly visible, this difference was not statistically significant (p>0.05, Wilcoxon test), 
probably due to the low number patients in each group.  
 
 
Figure 2.4.3: FPLD patients bearing different mutations in the LMNA gene show differential DNA 
methylation in the 5’-UTR of this gene. Studied region in the LMNA gene displayed 50% 
methylation in the affected members of the Family B (carrying the R471G mutation) and 
unmethylation in affected members in Family A (carrying the R482L mutation). Although differences 
were clearly visible, they were not statistically significant (p>0.05, Wilcoxon test) 
 
Noteworthy,  I detected all methylation changes in B-lymphoblastoid cells isolated 
from whole blood samples. This fact enables the study with minimal intervention, 
which is a very desirable feature in a diagnostic procedure. In order to control 
possible changes in the methylation patterns introduced during immortalization, 
culture and thawing of the cells, I compared DNA from freshly prepared 
lymphocytes and the corresponding imortalized lymphocytes of three healthy 
probands (Figure 2.4.4). 
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Figure 2.4.4: Immortalization and culture procedures did not affect the methylation profiles of 
RARB1 and LMNA1. Observed unmethylation in healthy controls in RARB1 and LMNA remained 
unchanged after immortalization, culture and thawing of the lymphoblastoid cells. p-values 
represents results of Wilcoxon test and are shown in a color code. Green cells corresponds to p<0.05 
meaning significant differences and black cells correspond to p>0.05, meaning non-significant 
differences. 
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3. Discussion 
 
3.1. General considerations 
 
Epigenetic phenomena in general and DNA methylation in particular play a major 
role in the regulation of gene expression, contributing to the modeling of cellular 
phenotypes. Differences in DNA methylation can be observed at very different 
levels, such tissue- and developmental stage- specific variations in healthy tissues but 
also related to oncogenic transformation or in other non-cancer diseases as well. 
In this work, I have studied the functional aspects of the differential DNA 
methylation. I have focused the study on its correlation with RNA expression in 
healthy tissues, the evolutionary conservation of tissue-specific DNA methylation 
profiles and the putative influence of DNA methylation in modifying phenotypes 
despite the same genetic background.  
 
3.2. Relations between DNA methylation and gene expression – Theory and 
experimental approaches 
 
It is widely accepted that methylation of the promoter region is related to gene 
silencing. However, experimental evidence on this topic tends to be ambiguous. 
Pioneer works in this area by A.D. Riggs [88] and Holliday and Pough [89] proposed 
theoretical models based on DNA methylation to explain chromosome X inactivation 
and other events in cell differentiation during development. Since then, several 
models have been drawn to explain the epigenetic regulation of gene expression, not 
only by DNA methylation but also by histone modifications and RNA interference 
(as detailed in Introduction). Current knowledge supports the idea that there is no 
such universal mechanism. Instead, different mechanisms might regulate particular 
genes in determined physiological states and they might have a synergic action, as 
demonstrated in the maintenance of the X-chromosome inactivation [35]. 
Methylation patterns are established during development and tissue- and cell- 
specific patterns. Nevertheless, whether this differential methylation is related to 
tissue-specific gene expression still remains as an open question. Changes of 
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methylation patterns in cancer cells are a frequent feature, reviewed in [204] [106]. 
After the discovery of methylation differences, researchers attempt to establish 
correlations with the expression profiles in the involved genes in order to understand 
the functional consequences of the findings. 
The use of analogous of deoxycytidine allows the pharmacological inhibition of the 
enzymes responsible for DNA methylation in eukaryote cells, DNA 
methyltransferases (DNMTs). Among these analogous, 5-azacytidine (azacytidine) 
and 5-aza-2'-deoxycytidine (decitabine) are the most used. Cells treated with these 
agents display expression profiles different to those observed in untreated cells and 
therefore, a reactivation of genes potentially silenced by DNA methylation is 
concluded. These agents are widely employed to discover genes regulated by DNA 
methylation and they were also tested clinically as potential anti-cancer drugs, 
reviewed in [145]. Recently, microarray-based expression profiles of cells treated 
with methylation inhibitors were employed to detect differentially methylated genes 
in different human cell lines [205] [206] [207] [208].  
Pharmacological inhibition of DNMTs represented a huge advance in the 
understanding of epigenetic regulation of gene expression. However, some authors 
discussed its fundamentals and applications. By using a microarray-based approach, 
Gius and colleagues [206] reported that the effects of decitabine in expression profiles 
were more similar to those of an inhibitor of histone acetylation, Trichostatin A 
(TSA), than to single or double knockouts of DNMTs. In addition, the same study 
reported as many genes up- as downregulated after demethylation. These 
observations, though controversial, raise questions about the mechanisms of action 
and effects of deoxycytidine analogous. The vast variety of epigenetic mechanisms 
thought to regulate gene expression and a complementary functionality among 
DNMTs might explain these observed differences. In addition, a myriad of different 
laboratory protocols are available for the treatment of cultured cells with DNA 
methylation inhibitors. Doses and exposure times that have no effect in some 
experiments are highly cytotoxic in others. Response differences related to cell type 
and culture conditions explain these differences and protocols must be adjusted 
accordingly.  
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Its inapplicability when tissues samples are used instead of cell lines, e.g. patient 
samples, represents another drawback for this approach. Not surprisingly, the 
inverse correlation between DNA methylation and gene expression become more 
diffuse when tissue-based studies are conducted [90] [209]. Very few clear examples 
of tissue-specific control of gene expression by hypermethylation of the promoter 
region were known prior to the results of my experiments, i.e. the maspin gene, 
SERPINB5 [31].  
 
3.3. RNA expression related to tissue- specific differentially methylated regions 
 
Methylation profiles produced by direct sequencing of bisulfite converted DNA have 
the highest possible resolution (single-base pair) and allow the simultaneous analysis 
of several CpGs in the regions of interest. In addition, the use of tissue samples adds 
valuable experimental evidence. It gives in vivo evidence for functionally relevant 
tissue-specific differentially methylated regions (T-DMRs) and opens the possibility 
to directly study their involvement in human pathologies. I made use of these 
advantages to approach a long-standing question: do tissue-specific DNA 
methylation patterns determine gene expression profiles that define tissue 
phenotypes? 
Among genes displaying T-DMRs in healthy tissues and primary cells, I found a 37% 
correlation rate between decreased expression levels and methylation of the 5’-UTR 
(16 out of 43 genes).  
I have defined the 5’-UTR as the region ranging between 2 kb upstream and 1 kb 
downstream of the TSS. Despite the fact that I have not confirmed the presence of 
annotated regulatory features in each of the investigated areas, CpG-rich regions 
surrounding the TSS are expected to have functional consequences in the expression 
of the gene. Kim and colleagues defined a high-resolution map of active promoters in 
the human genome by analyzing the in vivo binding of the RNApol II preinitiation 
complex (PIC). The authors reported that 87% of the TFIID-binding sites were within 
2.5 kb of annotated 5’ ends of known messenger RNA and suggested that binding 
sites beyond these limits correspond to unannotated transcriptional units [210]. 
Accordingly, hypermethylation of the 5’-UTR correlates with silencing of the 
SERPINB5 gene in human tissues [31]. The results presented here extend the list of 
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genes, which rely on methylation as a mean to restrict gene expression to different 
tissues and cell-types, and constitute baseline information for further 
experimentation in this area. When compared to the germ line data, where the 
majority of 5’-UTR appears as unmethylated [211], tissue-specific methylation 
profiles suggest that DNA methylation is acquired throughout the development 
silencing particular genes and modeling tissue phenotypes. Mouse models, in which 
lack of DNA methyltransferases causes embryonic lethality, have highlighted the 
importance of DNA methylation in normal development [10] [86].  
In addition, I did not find any correlation when the T-DMRs were located in the 
coding region or downstream to an annotated transcript. Few examples in the 
literature locate functional promoters within the coding regions of the genes [212] 
[213] [214] [215] and probably they represent alternative promoters for unannotated 
transcripts. In addition, a molecular function has been described for intragenic DNA 
methylation: it may decrease gene expression by altering the chromatin structure and 
reducing the efficiency of Pol II elongation [216]. In turn, intergenic regions may 
regulate the expression of neighboring genes either directly through the folding of 
the coding DNA strand during transcription [217] or indirectly by creating open 
/close chromatin structures that enable the access of the transcriptional machinery, 
reviewed in [218]. Alternatively, these T-DMRs can actually be promoters of non-
coding RNA transcripts that regulate in trans the expression of related genes, as 
observed in the Air transcript in murine Igf2r [100] and other imprinted genes. 
Taken together, the data presented here support the idea of several layers of 
epigenetic controls regulating gene expression in different tissues. These data also 
suggest that DNA methylation could not only avoid expression by blocking the 
assembly and action of the transcription machinery, but also by blocking enhancers 
and insulators located outside of the promoter and coding regions. The lack of 
correlation with expression in several T-DMRs supports the interplay with other 
molecular mechanisms, such histone modifications and non-coding RNAs. 
 
3.4. DNA methylation and transcriptional profiles in lung development 
 
3. Discussion 
_____________________________________ 
 107
It is widely accepted that DNA methylation has an important impact during 
mammalian development, for recent reviews see [219] [220]. However, little is known 
about stage-specific differential methylation and its functional consequences in lung 
morphogenesis.  To study the role of the epigenetic phenomena in the establishment 
of transcriptional profiles during lung development, I investigated DNA methylation 
status of differentially expressed genes between fetal and healthy adult lung.  
 
Genome-wide expression profiles and their biological interpretation 
 
First, I have determined the expression profiles of human fetal lung tissue samples 
during the canalicular and saccular stage (20-25 weeks) of development. 
Differentially expressed genes allowed the unsupervised molecular classification of 
the samples according to their tissue type (Figure 2.2.1). In addition, I have validated 
the expression of 15 out of 21 studied genes (71%) in independent samples by a 
different method (qRT-PCR).  
Analysis of gene ontology (GO groups) showed that groups related to components of 
the extracellular matrix (ECM) are over-represented in fetal lung. During canalicular 
and saccular stages in lung development, tissular structures suffer dramatic 
morphologic changes where ECM plays a key role [221]. As part of the ECM, 
collagen proteins play a key role in morphogenesis and epithelial differentiation 
[222]. Unlike, in healthy adult lung tissular structures are less dynamic and lower 
turnover of ECM components is expected. The results presented in this work suggest 
that the increased requirements of ECM components, especially collagen proteins, in 
these developmental stages are fulfilled, at least in part, by transcriptional activation 
of the corresponding genes.  
In turn, groups over-represented in adult lung are related to immunological 
processes. The postnatal immune system is a product of regulated events towards the 
acquisition of definitive functional properties, reviewed in [223]. The results of this 
work support a role for an increased transcriptional activity for the effector 
molecules (e.g. complement components and major histocompatibility complex 
(MHC) antigens) either by infiltrated cells into the lung tissues or by lung cells 
themselves. In this regard, NF-kappa B pathway activation in epithelial airway cells 
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was reported in inflammation [224]. Activation of NF-kappa B causes enhanced 
expression of genes encoding inflammatory cytokines, acute phase proteins, 
immunoreceptors, and chemokines, suggesting that mature pulmonary cells are able 
to express effectors molecules upon proinflammatory stimuli.  
 
Correlation between methylation and expression in fetal lung 
 
I studied the methylation status of 43 genes differentially expressed genes and found 
that 19% of them displayed a correlation between decreased expression and 
methylation of the 5’ UTR.  I selected the genes according to their differential 
expression (Log2Fc>2) and a high CpG content at the 5’ region. Notably, most of the 
studied regions were unmethylated in both, fetal and healthy adult samples 
according with the notion of extensive hypomethylation (<20%) in 5’ CpG islands 
and regions of high CpG content [67]. As I focused the study on 5’ regions, obtained 
results may underestimate the regulatory features located along the coding region or 
downstream to the encoded transcript that might also regulate expression by DNA 
methylation at this developmental stage. 
 
3.5. DNA methylation and regulation of bi-directional promoters 
 
Recently, Trinklein and colleagues reported a relative abundance of bi-directional 
promoters in the human genome. They constitute a common, though poorly 
understood, feature in mammalian genomes [193]. I analyzed the methylation status 
of 20 bi-directional promoters in fetal and healthy adult lung and did not found 
differential methylation in any of them. Promoters located within an annotated CpG 
island (Ensembl v41) exhibited unmethylation in both groups, while two out of three 
promoters, which were not located within a CpG island, were hypermethylated. By 
comparing the expression profiles of “head-to-head” genes located in opposite 
strands, I found that they were more frequently co-expressed than randomly paired 
genes located in different chromosomes. Noteworthy, genes corresponding to the 
hypermethylated promoters were downregulated suggesting that DNA methylation 
play a role in the regulation by bi-directional promoters.  Other groups reported 
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differential methylation of particular bi-directional promoters in colorectal cancer 
[93] and in several cell lines [94]. Here, I present experimental evidence showing that 
DNA methylation might also control co-expression of “head-to-head” genes during 
lung development. 
 
3.6. DNA methylation profiles in lung development and lung tumorigenesis 
 
It has been suggested that the transcriptome of non-small cell carcinomas resemble 
those of lung fetal cells [157]. Bonner and colleagues [160] identified 62 genes as 
being involved in lung development, for which the expression was markedly 
increased in mouse lung carcinoma samples. However, such relation for DNA 
methylation profiles has not been determined yet. Using differentially expressed 
genes in healthy fetal and adult lung as a guidepost, I have identified four genes 
(MEOX2, MDK, LAPTM5 and FGFR3) that are differentially methylated in lung 
cancer. I found that MEOX2 was uniformly hypermethylated in lung cancer 
compared to healthy adult and fetal lung. Furthermore I have provided evidence that 
the methylation is not uniform in lung cancer but is rather correlated with either the 
differentiation state (MDK, LAPTM5) or the lung cancer type (FGFR3). 
MEOX2 (also known as growth arrest specific homeobox gene, GAX) was uniformly 
hypermethylated in lung cancer tissues compared to healthy adult and fetal lung 
specimens. Besides its role in somite formation and patterning [225] MEOX2 is 
expressed in vascular endothelial cells and inhibits angiogenesis [226]. Hence, the 
observed hypermethylation of the MEOX2 5’-UTR, combined with the inverse 
correlation of gene expression and 5’-UTR methylation in healthy fetal and adult 
lung might indicate that MEOX2 is silenced in tumors via DNA methylation and 
thus allows for neo-vascularization required for tumor growth and spread. 
The methylation status of MDK and LAPTM5 in poorly differentiated lung tumors 
was significantly altered when compared to moderately differentiated lung tumors. 
For MDK, I observed hypomethylation in poorly differentiated tumors. MDK exerts 
pleiotropic biological activities related to tumorigenesis (i.e. fibrinolytic, anti-
apoptotic, mitogenic, transforming, angiogenic, and chemotactic activities) [227] and 
it has been proposed as a prognostic marker in gastrointestinal stromal tumors 
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(GISTs) where expression of MDK was correlated with a worse outcome compared to 
MDK-negative GISTs [228]. In contrast, LAPTM5 was hypermethylated in poorly 
differentiated lung tumors compared to moderately differentiated lung tumors. This 
gene is located on chromosome 1p34, a region frequently involved in chromosomal 
rearrangements in lung cancer [229]. Similar to multiple myeloma cell lines, where 
LAPTM5 is often silenced by hypermethylation [230], silencing of this gene by DNA 
methylation may therefore contribute to the development of more aggressive cancer 
phenotypes as reflected by the poorly differentiated histology. As histological grade 
represents an independent prognostic factor for survival in non-small cell lung 
cancer [195], it is conceivable that both MDK and LAPTM5 methylation profiles can 
be used as marker for tissue differentiation and might represent prognostic markers 
for lung cancer. Further studies using more samples will help to elucidate the 
prognostic power of these markers. 
Differential methylation in FGFR3 allows the differentiation of squamous cell 
carcinoma samples from adenocarcinoma. Squamous cell carcinoma tumors are 
usually slow growing, with late metastasis predominately to the liver, adrenal 
glands, kidneys, and bones [231]. Recently developed therapies based on 
antiangiogenic anti-VEGF antibodies, i.e. bevacizumab (Avastin, Roche), are 
associated to adverse effects in the circulatory system (hemorrhage, hypertension, 
tromboembolic events and proteinuria) in squamous cell carcinoma patients, and 
only patients without predominant squamous cell histology are eligible to receive 
bevacizumab [232].  Currently, classification of non-small cell lung carcinomas 
(NSCLC) is based on histopathological review, but lung tumor heterogeneity hinders 
the precise classification in many cases [149]. For that reason, molecular markers that 
allow the precise classification of NSCLC are highly desired. In this regard, Dosaka-
Akita and colleagues reported a low expression of GnT-V gene significantly 
associated to squamous cell carcinomas [233]. My finding of differential methylation 
in FGFR3 nominates this new biomarker for classifying squamous cell carcinoma at 
DNA level. 
 
3.7. Conservation of DNA methylation between human and mouse 
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The use of animal models is a driving force in biological research. Particularly in 
epigenetic studies, methylation status of murine genes is determined and frequently, 
these results are extrapolated to human orthologues [157] [159] [160]. However, no 
systematic analyses have been performed so far to determine the degree of 
conservation of DNA methylation profiles in these two species. In this study, I have 
determined that the majority of studied regions (69.4%) differed by less than 20% in 
their methylation profiles in mouse and human. This finding suggests that DNA 
methylation is evolutionary conserved between human and mouse in the studied 
tissues. Bernstein and colleagues showed that histone modifications are strongly 
conserved, even though many of the corresponding sites are not conserved at DNA 
level [234]. Unlike, I found that syntenic regions displaying conservation of 
methylation between mouse and human showed high conservation of sequence 
(homology higher than 75%).  
Additionally, I did not find differences in conservation rates neither between 5’-UTR 
and conserved non-genic regions (CNGs) nor between tissue types. The global 
conservation of methylation patterns despite its location supports the possibility of 
other physiological functions for DNA methylation rather than only controlling gene 
expression in cis. Conserved non-genic regions might represent indeed controlling 
elements for the expression of currently undiscovered non-coding RNAs, which 
regulate in turn expression of coding genes in trans. Antisense transcripts are a 
common regulatory element in imprinting, as described for mouse Igf2r [100] and 
Kcnq1  [101], as well as GNAS1  [235] in human. Alternatively, they might also 
represent relics of silenced retrotransposons incorporated in a common ancestor, as 
shown in genome-wide analysis in Arabidopsis [236].  
 
3.8. Methylation of the IGF2R cluster but not imprinting status is conserved in 
mouse and human orthologues 
 
Imprinting of the IGF2R gene has been thoroughly studied in human and mouse. 
However, the polymorphic occurrence of this phenomenon in healthy adult human 
tissues and the absence of an orthologue for the antisense Air transcript in human 
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make it still an unresolved issue. Moreover, little is known about the imprinting 
status of other genes in the cluster and the role of DNA methylation remains unclear. 
I have found that the methylation profiles of the 5’ UTRs of genes located in the 
IGF2R locus are conserved between human and mouse. I have shown that SLC22A2 
and SLC22A3, for which the imprinting status in adult tissues was previously not 
known, are not imprinted in healthy human tissues. In addition, I have not found 
imprinting of human IGF2R in these tissues, which is consistent with previous 
reports showing that human IGF2R is only imprinted in some individuals and in 
some fetal tissues [237]. In mice, Igf2r, Slc22a2 and Slc22a3 are maternally imprinted 
[182] [238] and silencing of the paternal allele depends on the expression of the 
antisense transcript Air [100]. In turn, the expression of Air is regulated in part by 
DNA methylation of the Air promoter with the maternal allele being 
hypermethylated and the paternal allele being unmethylated. Therefore, absence of 
imprinting for all genes within the human IGF2R locus is further supported by the 
lack of an allele-specifically methylated putative Air promoter. The comparative 
methylation profiling presented in this work revealed that the murine Air promoter 
is about 50% methylated but the orthologous region in human is homogenously 
hypermethylated. Of all regions profiled within this locus, the Air promoter and its 
homologous region in human were the only regions for which the DNA methylation 
was not conserved.  
 
3.9. Conservation of DNA methylation upon genome duplications 
 
The mechanisms and signals that lead to tissue-specific methylation are currently not 
known. Here, I have analyzed the fate of T-DMRs in gene duplication events. For the 
functional PLG gene family, T-DMRs are conserved in all known members 
independent of the genomic location of each variant. For all three variants, the 
methylation status of the T-DMRs is inversely correlated with the respective gene 
expression suggesting that the function of these T-DMRs is conserved as well. 
Similarly, I found conserved T-DMRs in two pairs of parental/unprocessed 
pseudogenes, SLC39A1/RP4-539M6.7 and Q6UW61_HUMAN/KB-1995A5.12. These 
results suggest that the sequence itself might contain the signal conferring tissue 
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specific methylation independent of the genomic location. A possibility I currently 
cannot rule out is that the differential methylation of e.g. PLGA and PLGB arose 
independently and re-occurred after gene duplication.  
The T-DMRs observed in the TBX family and the vast majority of T-DMRs found in 
both unprocessed and processed pseudogenes are not conserved suggesting that 
other mechanisms leading to T-DMRs must exist as well. Possibly, once the gene 
duplication is transmitted through the germ line, DNA methylation associated with 
e.g. tissue development may override the existing methylation mark of the 
duplicated gene and thereby generate a new methylation profile for this gene. I have 
observed a bias for recently evolved processed pseudogenes being rather 
unmethylated compared to more distant processed pseudogenes. This finding, if 
confirmed by a larger gene panel, may indicate that new processed pseudogenes 
become preferentially integrated into open chromatin structures that are generally 
associated with unmethylated DNA. A similar bias has been reported for 
retroviruses such as the human immunodeficiency virus (HIV) that preferentially 
integrate in open chromatin structures [239]. 
The function of T-DMRs located within pseudogenes is not known. They could be 
non-functional evolutionary relics of abortive gene duplications but may as well 
confer stage- and tissue- specific expression of pseudogenes. Some pseudogenes, 
although not coding for a functional protein, are transcribed and have a regulatory 
function [240]. For example, the NOS [241] and the Markorin [242] pseudogenes 
regulate expression of the respective parental genes, although others have disputed 
these results [243] [31]. 
Rodin and Riggs [70] proposed an epigenetic complementation model (ECM) to 
predict the fate of gene duplicates. In this model, stage and tissue-specific epigenetic 
silencing/activation help to maintain negative selection on both copies of the 
duplicated gene. This epigenetic complementation would thus lead to a 
complementary expression of the original gene and its twin copy and consequently, 
complementary gene expression would expose both copies to a purifying selection 
and may prevent degradation into a pseudogene. In this aspect, it is of interest to 
note that the methylation profiles observed for the functional TBX gene family were 
very gene-specific and each gene had a distinct methylation profile. In this study, I 
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have analyzed a limited number of different tissues and cells and it is likely that a 
more comprehensive analysis would reveal further specific T-DMR profiles. For 
example, our group has recently shown that TBX21 is specifically unmethylated in 
CD4+ Th1 and CD8+ memory lymphocytes but not in CD4+ and CD8+ naïve 
lymphocytes [244]. In contrast, the very recently evolved PLG family members 
displayed similar expression and methylation profiles that may indicate that some 
PLG genes are destined to pseudogenization. Thus, my findings provide 
experimental evidence supporting an epigenetic complementation in gene family 
evolution and point to a prominent role of DNA methylation in shaping the plasticity 
of the human genome. 
 
3.10. DNA methylation in non-cancer diseases. Modulating the phenotypic 
features upon similar genetic backgrounds 
 
Variations in DNA methylation profiles between affected and healthy individuals are 
a hallmark in cancer [204] [106]. Nevertheless, although a role for CpG methylation 
has been proposed (as detailed in introduction), experimental evidence in other 
human pathologies is far from conclusive. Because the epigenetic status is more 
dynamic than changes at DNA sequence level, it has been hypothesized a 
coordinated role of genetic and epigenetic factors in the etiology of complex disease 
and suggested that they should be investigated in parallel [173]. Beyond mutations in 
coding genes for proteins involved in DNA methylation mechanisms that may 
impair their functions, e.g. mutation in MECP2 gene in Rett syndrome [245], very few 
examples are known for phenotypic modeling at epigenetic level upon a common 
genetic background. In this regard, preliminary evidence supports a model that 
incorporates both genetic and epigenetic contributions in the causation of autism 
[246]. 
Lipodystrophies are familial or acquired disorders characterized by variable loss of 
fat tissue. In familial partial lipodystrophy (FPLD) loss of fat occurs at puberty. In a 
FPLD subgroup, Dunnigan type or FPLD2, subcutaneous fat is lost from the limbs 
and partially from the trunk. Later on, the patients may show acanthosis nigricans, 
hirsutism, polycystic ovaries, insulin-resistant diabetes, dyslipidemia and liver 
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steatosis. Although, FPDL2 is caused by mutations in the LMNA gene located in 
chromosome 1 [177], its manifestation is markedly dependent on sex with female 
carriers being more severely affected [247]. Mutations in the LMNA gene are 
proposed to cause many other diseases including muscular dystrophies [248], 
progeroid syndromes [249], mandibuloacral dysplasia [250], dilated cardiomyopathy 
[251] and restrictive dermopathy [252]. The mechanisms by which the different 
mutations in the LMNA gene lead to the very different tissue-specific disease 
phenotypes are still unclear, but they might be attributable to epigenetic variation of 
affected patients.  
In the present study, I have investigated the relation of DNA methylation and the 
underlying mutation as a reason for the development of the differential phenotypes 
in patients bearing LMNA mutations. For this purpose, I analyzed the methylation 
patterns of 10 candidate genes in patients with FPLD2, with other laminopathies and 
controls. One gene, RARB, is significantly highly methylated in patients with FPLD2 
compared to other laminopathies. In addition, LMNA is highly methylated in FLDP2 
patients carrying the LMNA R471G mutation.                  . 
The RARB gene encodes the retinoic acid receptor beta and mediates retinoid effects 
in controlling cell growth, differentiation, apoptosis, and carcinogenesis. RARB has 
been shown to be differentially methylated in several cancers, such as malignant 
melanoma [253], testicular tumors [254] and carcinoma of cervix [122].  Nevertheless, 
the function of RARB in the etiology of FLPD2 is currently not known. 
Protease inhibitor therapy of HIV is frequently associated with a FPLD-like condition 
characterized by lipoatrophy of the limbs, fat accumulation of abdomen, breasts and 
cervical region ("buffalo hump"), hyperlipidemia, and insulin resistance. This 
HAART (Highly Active Anti-Retroviral Therapy) related lipodystrophy syndrome 
may be a result of the inhibition of two proteins involved in lipid metabolism that 
have significant homology to the catalytic site of HIV protease, namely cytoplasmic 
retinoic acid binding protein type 1 and low density lipoprotein-receptor-related 
protein [255]. The cellular retinoic acid binding protein II, CRABP2, is an intracellular 
protein involved in the transmission of the vitamin A-derived signal, which regulates 
genes responsible for lipid metabolism and adipocyte differentiation [256]. This data 
suggest a close link between the retinoic acid pathway and the development to 
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lipodystrophy and support a role for changes in the methylation of the retinoic acid 
receptor gene in the development of lipodystrophic phenotypes in the investigated 
patients.  
The differential DNA methylation of the LMNA gene between both FPLD families 
may play a role synergic to the different mutation in development of the different 
FPLD phenotype. Although the difference is visible in the methylation plot, p-values 
after Wilcoxon test do not show statistical significance. As only three patients per 
group were available for comparison, marginal p-values are expected. Thus, these 
results would suggest a trend towards differential methylation of LMNA gene 
between both families carrying different mutations.  
The results of my experiments suggest a relation between LMNA mutations 
phenotypes and DNA methylation. The combined effects of LMNA mutations and 
DNA methylation of functionally related genes might explain therefore the variety of 
phenotypes observed in the different laminopathies. 
 
3.11. DNA methylation markers found in blood. A feature enabling low-
invasive diagnostic procedures and screening 
 
Biomarkers at DNA levels, i.e. mutations and SNPs, are generally present in a mosaic 
manner in affected individuals. Unlike, functional biomarkers such differentially 
expressed genes, proteins and DNA methylation markers are mainly associated to a 
tissue or cellular type. Because of this fact, diagnostic procedures based on these 
markers require invasive procedures (e.g. biopsies) for sampling or the use of related 
remote samples (e.g. sputum or bronchial lavage in lung cancer). Although they 
allow screening in general population, biomarkers in remote samples are not always 
as sensitive and specific as those found in the tissue of origin. Thus, sensitive and 
specific biomarkers based on easily accessible samples are preferred. 
To investigate the methylation status of candidate genes in lipodystrophies, I based 
the study on cultured lymphocytes isolated from patients’ blood samples. However, 
cell culturing may induce changes in methylation values [181]. To confirm that the 
discovered markers were not an artifact of culturing procedures, I proved that their 
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methylation profiles did not change through passages in lymphocytes of three 
healthy controls (Figure 2.7.4) 
The fact that I found methylation differences in cultured lymphocytes from 
peripheral blood makes them very valuable. Next steps would require the study of 
their sensitivity and specificity in larger sample sets. 
 
 
3.12. Concluding remarks 
 
The relation between hypermethylation and the silencing of the associated gene 
represent one of the most accepted concepts in tissue-specific gene regulation, 
despite the lack of experimental evidence supporting it. Here, I have approached this 
issue in two directions. First, using a semiquantitative RT-PCR approach I studied 
the expression of associated genes to 55 regions discovered as tissue-specifically 
methylated in healthy human tissues and primary cell lines. The obtained correlation 
rate (39% of the studied regions at the 5’-UTR) is quite different to that usually 
reported in the literature obtained by treating cell lines with de-methylating agents 
and subsequent gene reactivation. The observed differences support the idea of a co-
existence of epigenetic mechanisms regulating expression, which might be masked 
by the overwhelming action of the de-methylating drugs.  
On the other hand, I have determined expression profiles for healthy adult and fetal 
lung identifying the differentially expressed genes. By looking at the methylation 
status of the 5’-UTR of 43 differentially expressed genes, I have determined a 
correlation rate of 19%. Besides variations introduced by the different technologies 
applied, differences in the observed rates (obtained by looking at distinct genes) give 
support to the idea of several regulation mechanisms acting rather in a gene-specific 
manner.  
As tumor ontogeny often recapitulates transcriptional profiles of embryonic 
development, it is conceivable to use fetal expression and DNA methylation profiles 
to guide a biomarker discovery in tumor samples. Here, I have made use of the 
comparative expression profile and DNA methylation profile analysis obtained from 
fetal and adult lung tissues to identify novel biomarker candidates for lung tumors. I 
have identified four genes (MEOX2, MDK, LAPTM5 and FGFR3) that are 
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differentially methylated in lung cancer. Whereas I found that MEOX2 was 
uniformly hypermethylated in lung cancer compared to healthy adult and fetal lung, 
I have provided evidence that the methylation is not uniform in lung cancer but is 
rather correlated with either the differentiation state (MDK, LAPTM5) or the lung 
cancer type (FGFR3). If confirmed in a larger sample panel, differential methylation 
on MEOX2, MDK, LAPTM5 and FGFR3 will turn to biomarkers with an application 
in lung cancer molecular characterization. 
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4. Materials and methods 
 
4.1. Samples and Patients 
 
4.1.1. Tissue samples and primary cells from healthy human individuals  
 
Healthy human tissues samples for DNA isolation 
 
Healthy human tissue samples were obtained from one of the following sources: 
Asterand, (Detroit, US), Pathlore Plc. (Nottingham, UK), Tissue Transformation 
Technologies (T-cubed, Edison, US), Northwest Andrology (Missoula, US), NDRI 
(Philadelphia, US) and Biocat GmBH (Heidelberg, Germany). Only anonymized 
samples were used and ethical approval was obtained for the study.  The approving 
institutions were the Ethical Commission of the Medical Association in Berlin 
(Ärtztekammer Berlin, Friedrichstrasse 16, 10969 Berlin, Germany) and the 
Cambridge Local Research Ethics Committee (Box 148, Addenbrooke’s NHS Trust, 
Hills Road, Cambridge CB2 2QQ, UK, approval ID: LREC-03/094). Contamination 
by blood cells is estimated to be low as blood specific methylation profiles were not 
detected in the tissues. 
 
Human primary cells for DNA and RNA isolation 
 
Human primary cells were obtained from Cascade Biologics (Mansfield, UK), Cell 
Applications Inc. (San Diego, US), Analytical Biological Services Inc. (Wilmington, 
US), Cambrex Bio Science (Verviers, Belgium) and from the DIGZ (Berlin, Germany). 
Dermal fibroblasts, keratinocytes and melanocytes were cultured according to the 
supplier’s recommendations up to a maximum of 3 passages reducing the risk of 
aberrant methylation due to extended culturing. As an additional control, the 
average methylation of selected amplicons obtained from dermal fibroblasts, 
keratinocytes and melanocytes was compared with the methylation of the same loci 
in human skin samples. No significant deviation between the methylation of the 
primary cells and tissues was detected, indicating that cell culturing for a limited 
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number of passages does not change DNA methylation (data not shown). CD4+ T-
lymphocytes were isolated from fresh whole blood by depletion of CD4+ monocytes 
followed by a negative selection. CD8+ cells were isolated from fresh whole blood by 
positive selection. Subsequent FACS analysis confirmed a purity of CD4+/CD8+ T-
lymphocytes greater than 90%. 
Aliquots of the same samples of the human melanocytes, keratinocytes, fibroblasts, 
CD4+ and CD8+ cells that were used for methylation analysis were used for RNA 
analysis. Primary cell cultures were harvested and kept at -80 °C until RNA isolation.  
 
Matched DNA/ RNA samples 
 
For correlation studies, matched total RNA/DNA samples (heart muscle, skeletal 
muscle and liver) were purchased from BioCat GmbH (Heidelberg, Germany).  
 
Isolated RNA samples from human tissues 
 
Isolated total RNA samples from healthy human tissues (heart muscle, skeletal 
muscle and liver) were purchased from Ambion (Austin, US). Samples were kept at -
80°C until used for reverse transcription or microarray analysis. 
 
4.1.2. Tissue samples from mouse 
 
Mouse DNA samples from liver, heart, skin and skeletal muscle were acquired from 
BioCat GmbH (Heidelberg, Germany).    
 
4.1.3. Patients and controls for the study of DNA methylation profiles in 
Progeria and FPLD syndromes 
 
Dr. Thomas Brune (University of Magdeburg, Germany) coordinated the recruitment 
and diagnosis of patients and controls for this study. 
 
Patients and controls group:  
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Ten patients from two independent families bearing different mutations in the 
LMNA gene were enrolled in the study. Five healthy adults and one healthy member 
of the one FPLD2 family served as controls. The patients and the controls were 
evaluated according the following groups (Table 4.1.1): 
FPLD Group:  Patients 1-3 belong to the same family (Family A) and exhibit the 
typical phenotype of familial partial lipodystrophy type 2 (FPLD2) including 
acanthosis nigricans, partial lipodystrophy with sparing of the face, severe 
hypertriglyceridemia, insulin-resistant diabetes, and severe hypertriglyceridemia. All 
three carry the mutation R482L in the LMNA gene. One healthy member of the 
family with no mutation serves as family intern control.  Patients 4-6 belong to the 
same family (Family B) and carry the R471G mutation in the LMNA gene. Patient 4 is 
a 14 years old girl affected by an overlapping syndrome including partial 
lipodystrophy, insulin-resistant diabetes, acanthosis nigricans, liver steatosis, muscle 
weakness and contractures.  Patient 5 is her 18-year-old sister and exhibits only a 
partial lipodystrophy. Patient 6 is their father carrying the same mutation but does 
not show a lipodystrophy phenotype.  Their healthy mother does not carry any 
mutation in the LMNA gene and serves as a family intern control.  
Progeria Group:  Patients 7 and 8 are a 1-year-old girl and a 5-years-old boy, 
respectively. They are affected by Hutchinson-Gilford syndrome (Progeria) reported 
by De Busk and colleagues [257]. Both patients carry the progeria-typical Cl960T 
mutation in the LMNA gene [179]. Patient 9 is a 5 years old girl with an overlapping 
syndrome including early-onset myopathy with progeroid features. She carries a de 
novo heterozygous mutation (S143F) in the LMNA gene. Patient 10 is a 3.5-years-old 
boy suffering from scleroderma-like lesions of the skin occurred at 3 months of age. 
Poor weight gain with loss of subcutaneous fat, prominent scalp veins, progressive 
hair loss and lentigo senilis were noted shortly after. X-rays revealed the absence of 
the lateral regions of clavicles as well as acroosteolysis of the fingers and myopathy 
and cardiomyopathy were absent. Sequencing of LMNA gene revealed a 
heterozygous stop mutation leading to a protein that is elongated by 7 additional 
aminoacids at the C-terminal. The mother and a healthy brother of the patient carry 
the same mutation. Sequencing of the ZMPSTE24 gene showed a homozygous 
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deletion of an acceptor splice site (IVS9-Ex10) leading to the complete loss-of-
function of the mutated ZMPSTE24 [258]. 
 
Control group: 5 healthy females (24- 33 years old) individuals served as controls.  
 
Table 4.1.1. Phenotypes and genotypes of the enrolled patients 
 Patient number Sex 
Age 
(years) Phenotype 
Lamin-
Mutation 
Additional 
Mutation 
Patient 1   Familial Partial Lipodystrophy LMNA A/C 
R482L 
none 
Patient 2   Familial Partial Lipodystrophy LMNA A/C 
R482L 
none 
Patient 3   Familial Partial Lipodystrophy LMNA A/C 
R482L 
none 
Patient 4 Female 14 Familial Partial Lipodystrophy LMNA A/C 
R471G 
none 
Patient 5 Female 18 Familial Partial Lipodystrophy, 
mild phenotype 
LMNA A/C 
R471G 
none 
FPLD-Group 
Patient 6 Male  No phenotype LMNA A/C 
R471G 
none 
Patient 7 Female 1 Hutchinson-Gilford-Syndrome LMNA A/C 
Cl960T 
none 
Patient 8 Male 7 Hutchinson-Gilford-Syndrome LMNA A/C 
Cl960T 
none 
Patient 9 female 5 Early onset myopathy with 
progeria like symptoms 
LMNA A/C 
S143F 
none Laminopathies-Group 
Patient 10 Male 3 Progeria like Symptoms, 
myopathy and cardiomyopathy 
were absent 
LMNA A/C 
c1960 CT 
ZMPSTE24 
IVS9-Ex10 
Patient 11 female 30 Healthy Control none none 
Patient 12 female 32 Healthy Control none none 
Patient 13 female 29 Healthy Control none none 
Patient 14 female  Healthy Control none none 
Healthy Control 
group 
Patient 15 female  Healthy Control none none 
 
Cell culture and DNA isolation from patients and controls: 
 
10 ml venous blood was drawn from each patient and controls into a heparin blood 
collection tube. The blood samples were fractionated by standard Ficoll-Hypaque 
method (Ficoll, 1,077 g/ml Nycomed Pharma AS, Oslo, Norway). After 3 times 
washing with phosphate buffered saline (PBS) the cells were cultured in tissue 
culture medium RPMI 1640 supplemented with 10% fetal bovine serum and essential 
aminoacids. The culture was infected with EBV supernatant. After 30 min. 
incubation, further tissue culture medium (RPMI 1640 supplemented with 12% fetal 
calf serum (FCS) containing Cyclosporin-A was added. The cells usually started to 
show morphological changes after 3 to 4 days when dividing cells can be seen as 
dumbbell shaped structures under an inverted microscope. Six to eight weeks after 
4. Materials and Methods 
_________________________________________ 
 123
showing typical manifestation of big cellular masses an aliquot of the cells was used 
for further investigation. To exclude an impact of the immortalization process on the 
methylation pattern of the investigated genes I compared DNA from freshly 
prepared lymphocytes (A) and the corresponding immortalized lymphocytes (B) of 
three healthy probands (Figure 2.4.4)  
To isolate DNA from B-lymphoblastoid cells, they were pelleted by centrifugation, 
washed two times in 1 x PBS and resuspended in 2 ml OLD-T buffer (40 mM 
Tris/HCl, 150 mM NaCl, 25 mM EDTA, pH 7.5). After addition of 50 µl proteinase K 
and 100 µl 20 % SDS, incubation was carried out at room temperature over night, 
followed by phenol/chloroform extraction. The DNA was precipitated using 2 
volumes of absolute ethanol. 
 
4.1.4. Fetal and Healthy Adult Lung tissue samples 
 
Total RNA samples from fetal and healthy adult lung were acquired from Biocat 
GmbH (Heidelberg, Germany). Sample set consisted of 24 unrelated samples (12 fetal 
lung and 12 healthy adult lung samples) including male and female individuals. All 
fetal lung samples were derived from 20-25 week all fetuses.  Samples were kept at –
80 °C until they were used.  
Before proceeding with microarray analysis and qRT-PCR, RNA samples passed a 
very strict upfront quality control in terms of RNA integrity and purity. Integrity of 
the total RNA was confirmed by running the samples on denaturing urea-agarose 
gels. Before loading, 1 µg total RNA was mixed with 3 volumes of loading buffer (8 
M Urea, 10 mM Tris-HCl, 1 mM EDTA, 1% NP 40, 0.05% Bromophenolblue) and 
denatured by heating 2 minutes at 95°C. Samples were run on a 2% agarose-1M Urea 
gel and stained with Ethidium Bromide prior to UV- visualization.  Non-degraded 
total RNAs display two characteristic bands on the gel, corresponding to 18S and 28S 
ribosomal RNAs. Degraded RNAs would show smears instead of clearly visible 
band on the denaturing agarose electrophoresis. Moreover, all 24 samples showed 
A260/280 ratios within the 1.8-2.0 range when diluted in RNAse-free TE buffer, 
indicating than they were not contaminated with an excess of proteins, which will 
impair the cDNA synthesis and in vitro transcription. 
Differential DNA methylation profiles modulating phenotypes 
________________________________________________________________ 
 124
 
4.1.5. Patients and controls for the study of DNA methylation profiles in 
Lung Cancer 
 
DNA samples from fetal lung were purchased from Biocat GmbH (Heidelberg, 
Germany).  Tissue samples for DNA isolation from healthy adult and tumor lung 
were acquired from Integrated Laboratory Services (Bethesda, US) and Asterand 
(Detroit, US). Lung cancer sample panel consisted of 15 non- small cell lung 
carcinoma samples (12 adenocarcinomas and 3 squamous cell carcinomas). Samples 
were pathologically reviewed before DNA isolation and clinical information about 
the patients was available from the supplier. In all cases, only anonymized samples 
were used. 
 
4.2. DNA isolation 
 
DNA was extracted using the DNeasy kit (Qiagen, Hilden, Germany) according to 
the manufacturer’s recommendation. Briefly, up to 25 mg of tissue or 1 x 106 cells 
were incubated with Proteinase K (Qiagen, Hilden, Germany) at 37 °C until total 
disintegration. Next, lysis solution was loaded into silica columns and washed with 
buffers included in the kit. DNA was finally eluted with the corresponding buffer 
(AE buffer, included in the kit). 
Isolated DNA was quantified spectrophotometrically and purity was determined 
calculating A260/A280 ratios. Integrity of the DNA was confirmed by running the 
samples in a 1% agarose gel.  
 
4.3. RNA isolation 
 
Total RNA was isolated using the RNeasy kit (Qiagen, Hilden, Germany) according 
to supplier’s recommendations. Briefly, up to 25 mg of tissue or 1 x 106 cells were 
mechanically disrupted with a rotor-stator device (DIAX100) in a lysis buffer 
included in the kit, which contained ß-mercaptoethanol. Lysis solution was loaded 
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into silica columns and washed with buffers included in the kit. Total RNA was 
eluted with RNAse free water. 
Isolated total RNA was quantified spectrophotometrically. Isolated samples also had 
to pass the same strict quality controls described for the purchased samples. Samples 
were stored at -80°C until they were used in expression profiling experiments. 
 
4.4. PCR amplification 
 
4.4.1. Amplification of bisulfite-treated DNA 
 
DNA was bisulfite converted and PCR amplified following Epigenomics’ proprietary 
protocols [259]. Bisulfite-specific primers with a minimum length of 18bp were 
designed using a modified Primer3 program. The target sequence of the designed 
primers contained no CpGs allowing an unbiased amplification of both 
hypomethylated and hypermethylated DNAs.  Primers that gave rise to an amplicon 
of the expected size using non-bisulfite treated DNA as a template were discarded, 
thus ensuring the specificity for bisulfite-converted DNAs. Primers were also tested 
for specificity by electronic PCR (ePCR). 
 
4.4.2. Amplification of genomic DNA 
 
Genomic DNA amplification was carried out using the HotStartTaq DNA 
polymerase kit (Qiagen, Hilden, Germany) with 10 ng of genomic DNA and gene-
specific primers. Primers for genomic DNA amplification were designed using the 
Primer3 software [260]. Amplification conditions for the genomic DNA were: 15’, 
95°C followed by 40 cycles of 92°C for 60 sec., 72°C for 60 sec., 72°C for 60 sec. and a 
final extension step of 10 minutes at 72°C. Genomic PCR fragments used for the 
genotyping of the matched DNA/RNA samples contained at least one reported SNP. 
 
4.5. Reverse transcription PCR 
 
4.5.1. Semiquantitative reverse transcription PCR 
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cDNA was synthesized from total RNA using the Omniscript RT kit (Qiagen, Hilden, 
Germany) and random hexamers. PCR (92°C for 1 minute, 60°C for 1 minute, 72°C 
for 1 minute for 40 cycles) was performed using the HotStartTaq DNA polymerase 
kit (Qiagen) with 3 µl of the prepared cDNA and gene-specific primers. All kits were 
used according to the manufacturer’s recommendations. PCR products were 
analyzed by electrophoresis on 2.5 % agarose gels. All RT-PCR fragments were 
designed spanning at least one intron to avoid amplification of contaminating 
genomic DNA. Universal RNA (BioCat, Heidelberg, Germany) was used as positive 
control. RT-PCR fragments used to determine allelic expression contained at least 
one reported SNP. 
 
4.5.2. Quantitative reverse transcription PCR 
 
cDNA was synthesized using the Omniscript RT kit (Qiagen, Hilden, Germany) and 
a mixture of poly T primer (1 µM) and random hexamers (10 µM). This feature 
allowed the transcription of long transcripts avoiding at the same time the 
overestimation of mRNA copy number produced by random hexamers [261]. PCR 
was performed using the SYBR Green PCR Master Mix (Applied Biosystems, Foster 
City, US) with 2 µl of a 1:100 dilution of the prepared cDNA and gene-specific 
primers. All kits were used according to the manufacturer’s recommendations.  All 
qRT-PCR fragments had a maximum length of 150 bp and were designed spanning 
at least one intron to avoid amplification of contaminating genomic DNA. Universal 
RNA (BioCat, Heidelberg, Germany) was used as positive control. 
 
4.6. Bisulfite sequencing 
 
4.6.1. Direct sequencing strategy 
 
Direct sequencing was carried out as previously described [262] [66] [67]. PCR 
amplicons from bisulfite treated DNA, genomic DNA and semiquantitative RT- PCR 
products were quality controlled by agarose gel electrophoresis. Amplicons showing 
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single and intense bands were purified with ExoSAP-IT (USB Corporation, 
Cleveland, US) to remove any excess nucleotides and primers, and sequenced 
directly in forward and reverse directions. 
Sequencing was performed on an ABI 3730 capillary sequencer using 1/20th dilution 
of ABI Prism BigDye terminator V3.1 sequencing chemistry after hotstart (96°C for 30 
seconds) thermocycling (92°C for 5 seconds, 50°C for 5 seconds, 60°C for 120 seconds 
x 44 cycles). Before injection, products were purified on DyeEx plates (Qiagen, 
Hilden, Germany). PCR and RT-PCR fragments were directly sequenced with the 
same primers as in the PCR reaction.  The obtained sequencing chromatograms were 
used to quantify the methylation at a given CpG as described below. Samples and 
expressed alleles were genotyped by identification of annotated SNPs in the trace 
files.  
 
4.6.2. Sequencing of subcloned fragments 
 
For the analysis of allele specific methylation, PCR products from bisulfite-treated 
DNA were cloned into a TA-cloning plasmid according to the manufacturer’s 
instruction (pGEM- T-Easy cloning kit, Promega) and DNA was isolated using a 
Qiaprep Spin Plasmid Miniprep kit (Qiagen, Hilden, Germany) according to 
manufacturer’s instructions. Cloned PCR products were sequenced in forward and 
reverse direction using M13 primers (M13-F: TGTAAAACGACGGCCAGT, M13-R: 
CAGGAAACAGCTATGACC). Sequencing was performed using the same 
conditions described for direct sequencing. Methylation in particular CpG positions 
was determined by visual inspection of the trace files. 
 
4.7. Expression profiling using Affymetrix GeneChipTM microarrays  
 
Figure 4.7.1 illustrates the workflow followed for the target preparation and 
hybridization using Affymetrix GeneChip system. All steps were performed using 
kits and chemicals acquired from Affymetrix (Santa Clara, USA) according to 
manufacturer’s instructions.  
 
Differential DNA methylation profiles modulating phenotypes 
________________________________________________________________ 
 128
 
Figure 4.7.1: Experimental workflow for genome wide expression profiling. Double-stranded 
cDNA is produced by reverse transcription. Amplification of double stranded DNA with biotin 
labeled nucleotides produces labeled antisense copy RNA (cRNA). cRNA is purified, fragmented and 
hybridized to microarrays. After hybridization, microarrays are washed and stained with 
streptoavidin-phycoerithrin conjugated and scanned. Reproduced from www.affymetrix.com 
 
Briefly, double-stranded cDNA was prepared from 5 µg of Total RNA in a One-Cycle 
cDNA synthesis reaction. After clean-up, biotin-labeled cRNA was produced by in 
vitro transcription, purified and fragmented prior to hybridization. The quality of all 
the steps was controlled by electrophoresis on agarose gels or by 
spectrophotometrical measurement, accordingly. Fragmented cRNA was hybridized 
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to HG-U133A GeneChip microarrays (Affymetrix, Santa Clara, USA) according to 
manufacturer’s recommendations.  After hybridization, microarrays were washed 
and stained with Streptoavidin Phycoerythrin (SAPE) conjugate. Microarrays were 
scanned and raw data produced for further analysis, as described below. 
 
4.8. Analysis and statistical methods 
 
4.8.1. DNA methylation studies 
 
Sequencing results were analyzed using the ESME program as previously described 
[262] [66] [67]. This program allows quantifying methylation rates from 
electropherogram curves.   
Figure 4.8.1 shows the rationale of the ESME analysis method. DNA samples are 
mainly heterogeneous in terms of methylation. Among the genome copies particular 
CpG positions are either methylated (mC) or unmethylated (C). Bisulfite treatment of 
genomic DNA converts unmethylated cytosine (C) nucleotides into uracil (U) [48]. 
Thus, differences in methylation after bisulfite treatment produce single nucleotide 
polymorphisms, which can be detected by sequencing of PCR products. During the 
amplification step, uracil nucleotides are replaced by thymine (T). In a direct 
sequencing strategy, obtained trace files of heterogeneously methylated CpG 
positions will show both, C signals for methylated copies and T signals for 
unmethylated copies. Analysis method in ESME software includes the normalization 
of the obtained peaks and further quantification of methylation by comparing the 
areas below the curves in the corresponding peaks.  Furthermore, conversion rates 
for unmethylated Cs are determined as a control of the performance of the bisulfite 
treatment. Only sequences that display a conversion rate higher than 98% were used 
for analysis. Methylation values for individual Cs within each amplicon and sample 
are calculated and visualized by color coding ranging from dark blue (100% 
methylation) to yellow (0% methylation).  Differential methylation between the 
studied groups was tested for statistical significance using Wilcoxon’s rank sum test 
[263] and Kruskal-Wallis test [194].  
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Figure 4.8.1: The sodium bisulfite treatment and direct bisulfite sequencing strategy. Genomic 
DNA containing unmethylated (blue spheres) and methylated (gray lollypops) cytosines is treated 
with sodium bisulfite as indicated [259]. Unmethylated cytosines are converted to uracils (orange 
spheres) whereas methylated cytosines remain unchanged. Converted DNA is amplified by PCR. 
Produced uracils are replaced by thymines. PCR products are directly sequenced and raw trace files 
are analyzed using the ESME software [262]. Analysis method includes the normalization of the 
obtained peaks and further quantification of methylation by comparing the areas below the curves in 
the corresponding peaks. Quantitative methylation results are displayed as color-coded matrices 
ranging from yellow (~0% methylation) to green (~50% methylation) and dark blue (~100% 
methylation) 
 
 
4.8.2. DNA distance matrices and radial trees 
 
DNA distance matrices and radial trees were constructed with the PHYLIP software 
package [264]. Distances between the internal node and the pseudogene sequence 
d(HΨ,IN) were computed according to the following equation: d(HΨ,IN)= [d(H,HΨ) 
+ d(HΨ,C) – d(H,C)] /2, where d(H,HΨ) is the distance between the parental gene 
and pseudogene sequences, d(HΨ,C) the distance between the pseudogene and 
chimpanzee gene sequences and d(H,C) the distance between the parental human 
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and chimpanzee gene sequences, as obtained in the DNA distance matrix for each 
gene group. To determine whether methylation values were conserved between 
parental and derivative sequences, I assigned the methylation values in two tissues 
per pair. I binned the obtained methylation values to 0%, 25%, 50%, 75% and 100%, 
as shown in Table 2.3.2. Pairs displaying methylation differences lower than 25% 
were considered unchanged. 
 
4.8.3. Microarray expression profiling 
 
After microarray scanning, probeset intensities were calculated from the raw data 
according to the Robust Multiarray Analysis (RMA) method [189]. All used methods 
are implemented in the affy, affyPLM and simpleaffy packages of the Bioconductor 
project (www.bioconductor.org). Applied tests for statistical analysis and 
determination of differentially expressed genes included Westfal &Yound maxT 
algorithm, Benjamini and Hochberg false discovery rates (FDR), Bonferroni corrected 
two-sample Welch t-statistics for unequal variances, reviewed in [190]. All methods 
used are implemented in the multtest package of the Bioconductor project. As a 
selection criterion in this experiment, I have chosen a minimum absolute (log)-fold 
change of 2, Log2Fc>2. This cutoff allows selecting genes that are, at least, four-times 
highly expressed in the corresponding tissues. 
 
4.8.4. q-RT-PCR expression analysis 
 
Expression data produced by single gene qRT-PCR was processed using the qGene 
application [265]. Normalized gene expressions were calculated using Mean 
Normalized Expressions.  Target gene expression was standardized against the 
expression of the GAPDH gene. This gene was chosen as a calibrator after evaluating 
six genes in the model system (GAPDH, ACTB, UBC, RPL13A, PSMB6 and ATP50) 
using Repeated Pair-Wise Correlation Analysis implemented in the BestKeeper 
algorithm [191]. Differential expression in fetal and healthy adult groups was 
determined by two-tailed unpaired t-Test, implemented in the qGene application. 
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4.8.5. Pathway analysis 
 
MAPPFinder software relates microarray data from differentially expressed genes 
and annotated pathways in GenMAPP as well as the annotations from the Gene 
Ontology (GO) Consortium [192]. This software calculates a cumulative total of 
genes changed for a pathway or GO group and assign a statistical value, the Z-score.  
This score represents the standard statistical test under the hypergeometrical 
distribution and is calculated by subtracting the expected number of genes meeting 
the criterion from the observed number of genes, and then dividing by the standard 
deviation of the observed number of genes. 
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